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Abstract 
 
Widespread changes in gene expression accompany vascular smooth muscle cell (VSMC) phenotypic 
switching, a hallmark of vascular disease. Upon insult, VSMCs downregulate contractile proteins and 
upregulate genes linked to vascular remodelling, such as matrix metalloproteinases (MMPs) and pro-
inflammatory cytokines. However, the epigenetic mechanisms which regulate VSMC phenotypic 
switching remain unclear. This thesis explores the role of histone 3 lysine 9 dimethylation 
(H3K9me2), a repressive epigenetic mark, in regulating the expression of disease-associated VSMC 
genes. 
 
Intriguingly, murine models of VSMC phenotypic switching revealed reduced levels of H3K9me2 upon 
loss of the contractile state while chromatin immunoprecipitation (ChIP) identified a subset of IL-
1α/injury-responsive VSMC gene promoters enriched for H3K9me2. To test the functional 
importance of H3K9me2 for VSMC gene regulation the methyltransferase G9A/GLP was 
pharmacologically inhibited in vitro and in vivo. The resulting loss of H3K9me2 attenuated the 
expression of contractile VSMC markers and significantly potentiated IL-1α/injury-induced expression 
of MMP and pro-inflammatory genes.  
 
H3K9me2-mediated regulation of contractile and IL-1α-responsive VSMC gene expression was 
confirmed in cultured human VSMCs (hVSMCs). This prompted the use of hVSMCs to investigate the 
mechanism underlying H3K9me2-dependent regulation of IL-1α-mediated VSMC genes. Interestingly, 
G9A/GLP inhibition did not influence the level of IL-1α-induced nuclear localisation of the NFkB 
transcription factor p65 but significantly increased IL-1α-induced p65 binding to the IL6 promoter, 
correlating with reduced H3K9me2 levels. In contrast, enrichment of p65 was not observed at 
reported NFkB sites within the MMP3 promoter after IL-1α stimulation. Rather, IL-1α-induced MMP3 
expression was dependent on JNK activity and G9A/GLP inhibition potentiated IL-1α-induced binding 
of the AP-1 transcription factor cJUN to the MMP3 promoter. 
 
Collectively, these findings suggest that H3K9me2 plays a role in maintaining the contractile VSMC 
state and prevents binding of both NFkB and AP-1 transcription factors at specific IL-1α-regulated 
genes to possibly block spurious induction of a pro-inflammatory state.  
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1.1 Cardiovascular function and disease 
 
Cardiovascular disease (CVD) is a major financial and health concern worldwide. Across Europe, 
approximately 47% of all deaths are attributed to CVD, costing the EU economy almost €196 billion a 
year (ESC, 2012). Moreover, the CVD burden is predicted to rise due to an aging population with 
increasing rates of obesity and diabetes (WHO, 2015). Therefore, it is important to understand the 
mechanisms underlying CVD to both prevent and improve therapies against such diseases.  
 
CVDs are predominately the clinical manifestation of atherosclerosis, a chronic and progressive 
disease of large and medium sized blood vessels. Atherosclerosis is characterised by vascular 
inflammation, fibrosis, necrosis and calcification, which leads to the formation of plaques. 
Subsequent narrowing of the blood vessels and plaque rupture can trigger a range of complications 
affecting multiple organ systems. Atherosclerosis is a multi-factorial disease and normally develops 
many years before clinical symptoms manifest. Proposed risk factors include high cholesterol, 
hypertension, smoking and diabetes (Libby 2013). 
 
1.1.1 Vascular structure and function 
 
Most blood vessels consist of three layers: an intima, media and adventitia (Figure 1.1). Each layer is 
distinct in its composition and functionality but all participate in vascular growth, homeostasis, repair 
and disease (Stenmark et al., 2013). The inner most layer, the intima, is a single endothelial cell layer, 
mediating the passage of material into and out of the bloodstream. Endothelial cells respond to 
environmental stimuli and can signal surrounding tissue to react and remodel (Pugsley and Tabrizchi, 
2000; Ross and Pawlina, 2011). 
 
The muscular middle layer, the media, predominantly contains vascular smooth muscle cells (VSMCs) 
and extra cellular matrix (ECM). In the healthy blood vessel, VSMCs align in concentric layers, 
separated by elastic fibers, to form a highly ordered structure. VSMCs are heterogeneous but 
primarily function to regulate blood flow and pressure through contraction (Pugsley and Tabrizchi, 
2000; Ross and Pawlina, 2011). Unlike their cardiac and skeletal smooth muscle relatives, VSMCs can 
reversibly alter their quiescent "contractile" phenotype to a more active "synthetic" state in response 
to changing environmental cues. Such phenotypic switching is essential for vascular growth, 
homeostasis and repair but can become dysregulated in disease (Alexander and Owens, 2012). 
The adventitia forms the protective outermost connective tissue layer of the blood vessel. The 
adventitia is mainly composed of fibroblasts and ECM but also contains a variety of other cell types, 
including dendritic cells, macrophages and vascular progenitor cells. Within large arteries, the 
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adventitia contains smaller vessels, important for the trafficking of material such as leukocytes, into 
and out of the vessel wall. Recent studies have shown that adventitial cells mediate communication 
between vascular endothelial cells and VSMCs with their surrounding tissues (Ross and Pawlina, 
2011; Stenmark et al., 2013). 
 
 
 
Figure 1.1: Vascular wall structure. The three structural layers of an elastic blood vessel wall (intima, media 
and adventitia), including cellular and extra cellular components (adapted from Ross and Pawlina, 2011). 
 
1.1.2 Atherogenesis  
 
Atherogenesis is complex but can typically be classified into four main stages (Figure 1.2): 1) Firstly, 
endothelial cell damage and dysfunction stimulates the accumulation and oxidation of low-density 
lipoprotein (LDL) within the vessel wall. Oxidised LDL attracts monocytes from the blood into the 
subendothelial intima where they transform into macrophages which ingest lipoproteins to become 
foam cells. 2) The subsequent production of inflammatory mediators and cytokines stimulates 
VSMCs to migrate from the media to the intima where they proliferate and secrete ECM proteins. 3) 
In progressing plaques, macrophages and VSMCs die, releasing lipids which accumulate within the 
centre of the plaque to form the necrotic core. VSMCs are thought to migrate and proliferate to 
create the fibrous cap and encage the necrotic core to stabilise the plaque. 4) In advanced plaques, 
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the fibrous cap can rupture and trigger thrombus, which can lead to a number of complications 
including heart attack and stroke (Libby et al., 2011). 
 
 
 
Figure 1.2: Atherogenesis. A) The healthy vasculature. B) Initiation of atherogenesis. Blood leukocytes adhere 
to endothelial cells and infiltrate the intima. In the intima, monocytes mature to macrophages and uptake lipid 
to form foam cells. C) VSMCs migrate into the intima and proliferate. A proportion of VSMCs uptake lipid to 
form foam cells. Extracellular lipid released from dead and dying VSMCs and macrophages accumulate at the 
centre of the plaque to form the necrotic core. VSMCs on the luminal side of the vessel wall secrete strength 
giving ECM components, forming the fibrous cap which helps to stabilise the plaque. D) Plaque rupture and 
subsequent thrombosis can block blood flow and lead to numerous complications including heart attack and 
stroke (from Libby et al., 2011). 
 
1.2 VSMC function and phenotype 
 
In the healthy blood vessel, VSMCs primarily function to regulate blood flow and pressure. These 
VSMCs exhibit a low rate of proliferation, low synthetic activity and express a unique set of 
contractile proteins, essential for the contraction and relaxation of the vascular wall. These proteins 
either act as structural components of the contractile apparatus or as regulators of contraction and 
include: transgelin (TAGLN), smooth muscle ꭤ actin (ACTA2), calponin (CNN1), smoothelin (SMTN) 
and smooth muscle myosin heavy chain (MYH11) (Rensen et al., 2007). These contractile VSMCs are 
also marked by myocardin (MYOCD) expression, a myogenic transcriptional co-activator specifically 
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expressed in cardiac and contractile smooth muscle (Rensen et al., 2007). However, despite being a 
highly differentiated and specialised cell type, VSMCs retain remarkable plasticity and can alter their 
quiescent "contractile" phenotype to a more active "synthetic" state (Alexander and Owens, 2012). 
Synthetic VSMCs can re-acquire many characteristics of the contractile phenotype, suggesting the 
phenotypic switch is reversible (Aikawa et al., 1997; Christen et al., 2001; Manderson et al., 1989; 
Sottiurai et al., 1989; Thyberg et al., 1995; Thyberg et al., 1997). Such phenotypic switching is 
required to maintain vascular homeostasis and regulate vascular response to injury and 
inflammation. "Synthetic" VSMCs are characterised by the loss of contractile marker expression and 
the upregulation of selective gene sets, including pro-inflammatory cytokines and matrix 
metalloproteinases (MMPs), leading to increased cell migration, proliferation and secretion of pro-
inflammatory cytokines (Alexander and Owens, 2012; Clarke et al., 2010; Owens et al., 2004). 
 
1.2.1 VSMC phenotypic switching in vascular disease  
 
VSMC phenotypic switching can become dysregulated in vascular disease. Injury, inflammation, 
endothelial cell dysfunction and the accumulation of lipids within the vessel wall are known to induce 
VSMCs to phenotypically switch (Alexander and Owens, 2012). Initially, VSMC-derived cells were 
difficult to identify due to the down regulation of contractile VSMC genes. Furthermore, although the 
expression of contractile genes marks contractile VSMCs, many of these genes are also expressed by 
other cell types (Gomez and Owens, 2012). However, recent genetic fate mapping studies using 
transgenic mice with tamoxifen regulated smooth muscle specific cre recombinase and fluorescent 
cre-dependent reporter genes, have definitively shown the neointimal cells that arise following 
vascular injury are largely derived from medial "contractile" VSMCs (Herring et al., 2014; Nemenoff 
et al., 2011). Moreover, immunofluorescent quantification has revealed that these fluorescent 
VSMC/VSMC-derived cells comprise approximately 80% of the cellular component of the neointima 
formed following carotid artery ligation (Herring et al., 2014). Such genetic fate mapping studies have 
shown that VSMCs can modulate their gene expression profile to resemble various cell types. For 
example, VSMC-derived cells have been reported to express macrophage (Lgals3), mesenchymal 
stem cell (Sca1) and myofibroblast (Acta2 and Pdgfrb) markers (Shankman et al., 2015). A number of 
studies also suggest VSMCs can acquire a osteo-chondrocytic transcriptional repertoire (Alp, Bglap, 
Opn, Runx2 and Bmp2) (Briot et al., 2014; Rong et al., 2014; Speer et al., 2009; Steitz et al., 2001). 
Combined, these findings suggest VSMCs can switch to a number of distinct phenotypes (Figure 1.3). 
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Figure 1.3: Schematic of VSMC phenotypic switching in atherosclerosis. VSMCs undergo phenotypic switching 
to multiple distinct phenotypes within advanced atherosclerotic lesions. VSMCs within the core of the plaque 
can acquire myofibroblast, mesenchymal stem cell (MSC), macrophage and osteo-chondrocyte markers, while 
VSMCs forming the cap resemble the contractile VSMC state (adapted from Bennett et al., 2016). 
 
 Another widely held view is that contractile and synthetic VSMCs represent two ends of a diverse 
phenotypic spectrum, with VSMCs also existing in a range of intermediate phenotypes (Figure 1.4) 
(Rensen et al., 2007). 
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Figure 1.4: Hypothetical VSMC phenotypic spectrum. (A) Distinct VSMC populations (represented a to f) have 
different potentials to phenotypically switch (from Rensen et al., 2007). (B) Schematic representation of 
expression levels of genes associated with a particular SMC phenotype (from Rensen et al, 2007). 
 
1.2.2 Cytokines in vascular function and disease 
 
The vascular inflammatory response requires complex interaction between resident vascular cells 
and inflammatory cells which is governed, in part, by cytokines. Cytokines describe a diverse group of 
small soluble proteins (~5-30 kDa) involved in cell-to-cell communication and can act to both 
promote and/or inhibit inflammation and atherogenesis (Figure 1.5). Cytokines are clustered into 
several categories such as interleukins (e.g. IL-1α), tumor necrosis factors (e.g. TNFα), growth factors 
(e.g. PDGF and TGFβ), lymphokines (e.g. LPS) and interferons. Bone marrow derived, adventitial, 
endothelial and VSMCs are all known to produce and respond to cytokines via cell surface receptors 
which stimulate NFκB, AP-1, JAK-STAT and Smad signalling pathways. Activation of such signalling 
pathways influence VSMC adhesion, migration, growth, proliferation, apoptosis and the composition 
of the ECM (Schober, 2008; Sprague and Khalil, 2009).  
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Figure 1.5: Pro- and anti-atherogenic cytokines. Cytokines can be classified broadly into two groups depending 
on whether they promote or suppress atherogenesis (adapted from Tousoulis et al., 2016). 
 
Several cytokines affect VSMC phenotype and are associated with vascular dysfunction. For example, 
activation of the platelet-derived growth factor (PDGF) signalling pathway is known to promote the 
synthetic VSMC phenotype (Chen et al., 2015a; Chen et al., 2015b; Nurminskaya et al., 2014) 
whereas transforming growth factor beta (TGFβ) signalling promotes the contractile state (Hao et al., 
2002; Hautmann et al., 1997; Liu et al., 2003). The pro-inflammatory cytokines interleukin 1 alpha (IL-
1α) and tumor necrosis factor alpha (TNFα) also induce VSMCs to switch to a more synthetic 
phenotype. Both cytokines stimulate the VSMC inflammatory response and activate NFκB and AP-1-
dependent transcription of cytokines (e.g. Il6 and Ccl2) and matrix metalloproteinases (MMPs) (Lim 
and Park, 2014). Interleukin 6 (IL6) has been observed to upregulate VSMC migration, proliferation 
and vascular calcification whilst attenuating VSMC contraction (Kurozumi et al., 2016; Lee et al., 
2016; Watanabe et al., 2004). Also, IL6 treatment of VSMCs activates the JAK-STAT pathway which 
induces the expression of monocyte chemoattractant protein-1 (Ccl2) (Watanabe et al., 2004). CCL2 
plays a major role in the recruitment of monocytes and T cells to the vessel wall and has been shown 
to stimulate VSMC migration and proliferation (Schober, 2008; Selzman et al., 2002). Together, these 
findings suggest IL6 and CCL2 promote the progression of vascular disease.  
 
However, the role of many cytokines in vascular disease is often not clear cut. For example, IL6 can 
also act in an anti-inflammatory manner by inhibiting TNFα production while inducing the expression 
of anti-inflammatory cytokines (e.g. IL1 receptor antagonist and the soluble p55 TNFα receptor) in 
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leukocytes (Scheller et al., 2011). TNFα also has conflicting roles in the development of vascular 
disease. Initially, it was widely accepted that, in cultured VSMCs, TNFα activates the NFkB signalling 
pathway and decreases the expression of myocardin and myocardin-dependent genes by NFkB (p65) 
binding to the Myocd promoter (Singh and Zheng, 2014; Tang et al., 2008b; Yoshida et al., 2013). 
Conversely, Singh and colleagues have shown that TNFα treatment in Myocd over expressing 
cultured VSMCs significantly potentiates myocardin and myocardin-dependent contractile gene 
expression by stabilising myocardin mRNA via the NFκB and MAPK pathway (Singh and Zheng, 2014). 
This finding suggests TNFα differentially regulates myocardin depending on the VSMC phenotypic 
state.   
 
1.2.3 Matrix metalloproteinases in vascular function and disease 
 
MMPs comprise a family of proteases and play a central role in many CVDs which are associated with 
structural changes in blood vessels (Galis and Khatri, 2002; Johnson, 2014). Some MMPs are induced 
by inflammatory signals, such as interleukin 1 (IL-1α), to regulate vascular remodelling (Nagase et al., 
2006). VSMCs only constitutively express MMP2 (Newby, 2005) but exhibit enhanced expression of 
several MMPs within diseased blood vessels (Choudhary et al., 2006).  VSMCs from human 
atherosclerotic plaque shoulder regions and areas of foam cell accumulation display increased 
MMP3, MMP9 and MMP12 activity compared to their medial counterparts. However, even though 
MMP2 activity is enhanced in atherosclerotic plaques, there is no difference in MMP2 activity 
between these regions. The increase in MMP3, MMP9 and MMP12 activity corresponds to regions 
containing higher levels of IL-1α released from necrotic VSMCs and macrophages (Galis et al., 1994b). 
This IL-1α-induced expression of MMP genes can be observed in vitro. IL-1α treatment of cultured 
VSMCs induces the transcription of MMP3, MMP9 and MMP12 while MMP2 is unaffected (Galis et 
al., 1994a). 
 
MMPs can promote angiogenesis, the accumulation of macrophage cells and degrade major 
components of the ECM. MMPs are known to influence the migration and proliferation of VSMCs, 
infiltration of inflammatory cells into tissue and the stability of atherosclerotic plaques (Figure 1.6) 
(Galis and Khatri, 2002; Johnson, 2014; Nagase et al., 2006). Studies using MMP knockout mice have 
shown that MMP2 and MMP9 contribute to the development of atherosclerosis in apolipoprotein E 
(ApoE) deficient mice (Cho and Reidy, 2002; Galis and Khatri, 2002; Kuzuya et al., 2003; Kuzuya et al., 
2006; Luttun et al., 2004). Furthermore, it has been observed that MMP3 is required to activate 
MMP9 for neointima formation after carotid ligation in mice and for VSMC migration in vitro, 
whereas MMP12 plays a redundant role (Johnson et al., 2011b). Some MMPs are thought to stabilise 
atherosclerotic plaques by increasing VSMC migration and proliferation to thicken the fibrous cap. 
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For instance, ApoE and MMP2/ MMP9 double knockout mice exhibit less stable lesions with fewer 
VSMCs than macrophages compared to ApoE single knockout controls (Johnson et al., 2005a; Kuzuya 
et al., 2006). In contrast, other MMPs appear to promote plaque rupture by destruction of the ECM, 
which induces thinning of the fibrous cap. For example, a selective MMP12 inhibitor has been shown 
to slow atherosclerotic plaque rupture in ApoE knockout mice (Johnson et al., 2011a). As MMPs can 
both promote plaque stability and rupture, the development of direct MMP inhibitors to treat 
vascular disease has been problematic (Galis and Khatri, 2002; Newby, 2012).  
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Figure 1.6: Results of in vivo studies evaluating the effects of MMPs on atherosclerotic plaque. 
Abbreviations: VSMCs, vascular smooth-muscle cells; Mø, macrophages; BCA, brachiocephalic artery; ND, not 
determined; ↓, decreased; ↑, increased; ↔, no change. In separate studies where different vascular sites 
have been assessed and discrepancies in effects are observed, red and green text colour are used to define the 
different sites (from Johnson, 2017). 
 
1.3 Transcriptional regulation of VSMC gene expression 
 
1.3.1 Transcriptional regulation of contractile VSMC genes 
 
Many contractile VSMC genes are regulated by serum response factor (SRF), a transcription factor 
which binds to CC(A/T-rich)6GG (CArG) cis-elements of all known CArG dependent contractile VSMC 
genes, including ACTA2, CNN1, TAGLN and MYH11. MYOCD, a gene only expressed in the vasculature 
by VSMCs, associates with SRF to activate the expression of CArG dependent contractile VSMC genes 
(Rensen et al., 2007). It has been suggested that the presence of H4 acetylation and H3K4me2 
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exclusively at VSMC CArG boxes may permit binding of MYOCD/SRF complexes to specifically activate 
VSMC-marker genes rather than other SRF-dependent genes, such as cFOS (Liu et al., 2015b; 
McDonald et al., 2006). Interestingly, Myocd +/- mice on ApoE -/- background exhibit accelerated 
atherosclerosis with increased numbers of VSMC-derived macrophage like cells compared with 
Myocd +/+ littermate controls (Ackers-Johnson et al., 2015).  
 
The pluripotency factor KLF4 is also widely reported to influence VSMC phenotype. KLF4 both down 
regulates MYOCD expression and interacts with SRF to repress MYOCD-induced activation of 
contractile VSMC genes (He et al., 2015; Liu et al., 2005; Liu et al., 2003). In addition, KLF4 has been 
shown to repress contractile VSMC gene expression in VSMCs by binding to the TGFβ control 
element within their promoters, blocking the recruitment of activating complexes (Guo and Chen, 
2012; Liu et al., 2003). Furthermore, VSMC specific conditional knockout of Klf4 results in reduced 
numbers of VSMC-derived macrophage and mesenchymal stem cell like cells in mice (Shankman et 
al., 2015). Many studies have also shown that the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFkB) family of transcription factors play a role in regulating the expression of 
contractile VSMC genes. Activation of the NFkB signalling pathway in VSMCs eventuates in NFkB (p65 
subunit) binding to the MYOCD promoter, decreasing the expression of MYOCD and MYOCD-
dependent contractile genes (e.g. ACTA2, TAGLN and MYH11) (Singh and Zheng, 2014; Tang et al., 
2008b; Yoshida et al., 2013). 
 
1.3.2 Transcriptional regulation of injury/inflammation-induced VSMC genes 
 
From in vitro and in vivo studies, it has long been recognised that both the NFκB and activator 
protein-1 (AP-1) family of transcription factors regulate numerous processes in the cardiovascular 
system, including inflammation, apoptosis, differentiation, proliferation and cell migration 
(Chistiakov et al., 2018; Muslin, 2008; van der Heiden et al., 2010). Therefore, it is not surprising that 
dysregulation of NFκB and AP-1 signalling is strongly associated with the initiation and progression of 
vascular dysfunction. Figure 1.7 summarises the stimuli that activate NFκB and AP-1 signalling 
pathways and the genes under NFκB and AP-1 transcriptional control. 
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Figure 1.7: Stimuli that activate the NFκB and AP-1 signalling pathways (blue squares) and genes under NFκB 
and AP-1 transcriptional control (red circles).  
 
1.3.3 The NFκB signalling pathway  
 
The NFκB family of transcription factors is composed of five structurally related proteins: p50, p52, 
p65 (RelA), RelB and cRel. These proteins share a N-terminal Rel homology domain (RHD), which 
mediates DNA binding, dimerisation and nuclear translocation. The RHD allows NFκB family members 
to form homo- and hetero-dimers, which constitute their biologically active form. RelB, cRel and p65 
contain C-terminal transcriptional activation domains (TADs), which enable them to participate in a 
number of protein-protein interactions with various regulatory proteins including other co-activating 
transcription factors (e.g. AP-1 family members) and chromatin modifying complexes (e.g. HDMs and 
HATs). In contrast, p50 and p52 do not contain TADs and are therefore involved in transcriptional 
repression unless they dimerise with a protein containing a TAD, such as p65 (Liu et al., 2017; Zhang 
et al., 2017). 
 
In unstimulated cells, NFκB is sequestered in the cytoplasm by the IκB kinase (IKK) complex. The IKK 
complex consists of catalytic kinase subunits (IKKα and IKKβ) and the regulatory non-enzymatic 
scaffold protein NEMO (NFκB essential modulator otherwise known as IKKγ). In response to a variety 
of stimuli (Figure 1.7) NFκB dimers are activated by IKK-mediated phosphorylation of IkB. 
Phosphorylation of IkB triggers the rapid ubiquitination of IkBꭤ and its subsequent degradation 
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releasing NFκB from its inactive cytoplasmic state. NFkB subunits are then able to migrate to the 
nucleus and promote the expression of target genes (Figure 1.8). To add further complexity, recent 
studies have shown that NFκB proteins, especially the p65 subunit, are subject to a wide variety of 
post translational modifications including phosphorylation, acetylation and ubiquitination. These 
modifications determine the activation status of NFκB transcription factors and can either enhance 
or repress their transcriptional activity (Liu et al., 2017; Zhang et al., 2017).  
 
Hundreds of genes contain the NFkB consensus sequence (GGGRNNYYCC) within their regulatory 
DNA elements. The genes transcriptionally regulated by NFκB include cytokines, chemokines, 
immunoreceptors, MMPs, growth factors and other transcription factors and are involved in 
numerous cellular processes (Figure 1.7). As NFκB signalling plays a pathogenic role in various 
inflammatory diseases, several inhibitors have been developed to block different steps of the NFkB 
signalling pathway. Pharmacological compounds can inhibit IkBα degradation (e.g. BAY11 -7082 
(Ghashghaeinia et al., 2011)), block the nuclear translocation of NFkB subunits and prevent NFkB 
binding with target DNA (Liu et al., 2017; Zhang et al., 2017). 
 
 
 
Figure 1.8: The canonical NFκB signalling pathway. Ligand binding to a receptor activates the IKK complex 
which phosphorylates IkBα and triggers its proteosomal degradation. NFκB is then released and translocates to 
the nucleus to activate target gene expression. Multiple pharmacological compounds can block different steps 
of the NFkB signalling pathway (adapted from Liu et al., 2017). 
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1.3.4 The AP-1 signalling pathway 
 
Like NFκB, the mitogen-activated protein kinase (MAPK)/AP-1 signalling pathway orchestrates gene 
expression in response to a variety of stimuli and therefore plays an important role in various cellular 
processes (Figure 1.7). MAP Kinases make up a family of serine/threonine kinases which function in 
tiered protein kinase cascades. Extracellular stimuli activate MAPKK kinases (MAPKKKs) via receptor-
dependent and -independent mechanisms. MAPKKKs then phosphorylate and activate a downstream 
MAPK kinase (MAPKK), which in turn phosphorylates threonine and tyrosine residues on MAPKs 
leading to their activation. There are three main subfamilies of MAPKs: c-Jun N-terminal kinases 
(JNK1, JNK2 and JNK3), extracellular signal regulated kinases (ERK1 and ERK2) and p38 (p38α, p38β, 
p38δ and p38γ) (Figure 1.8) (Kim and Choi, 2015; Sun et al., 2015; Yang et al., 2013). 
 
MAPKs regulate AP-1 transcription factors at the transcriptional and post transcriptional level (Figure 
1.9) (Kim and Choi, 2015; Sun et al., 2015; Yang et al., 2013). AP-1 transcription factors describe a 
group of proteins that belong to the Jun (cJUN, JUNB, and JUND) and Fos (cFOS, FOSB, FRA1, and 
FRA2) subfamilies. These proteins share an evolutionary conserved basic leucine zipper domain 
(LZD), essential for AP-1 dimerisation. AP-1 dimerisation is required to bring two DNA binding 
domains (DBDs) into juxtaposition, thereby facilitating the interaction of protein dimers with the AP-
1 DNA consensus sequence (5′--TGAG/CTCA-3'), which is present at many regulatory DNA elements. 
In contrast to Jun proteins, Fos proteins cannot homodimerize among themselves due to a small 
difference in the composition of their LZD. However, Fos proteins can partner with Jun proteins to 
form Jun-Fos heterodimers, which are more stable and have a higher DNA binding activity compared 
to Jun-Jun homodimers. Apart from FRA1 and FRA2, AP-1 proteins also possess a transactivation 
domain (TAD), which contains binding sites for other proteins such as transcriptional co-regulators 
and chromatin modifying enzymes (Cargnello and Roux, 2011; Ye et al., 2014). cJUN, cFOS and FOSB 
are considered strong activators, while JUNB, JUND, FRA1 and FRA2 are relatively weaker and may 
sometimes act as repressors by displacing stronger dimers (Hess et al., 2004). More recently, other 
groups of structurally related transcription factors, including Atf (ATFα, ATF2, and ATF3) and Jdp 
(JDP1 and JDP2) proteins, have been shown to form heterodimers with AP-1 and bind to the AP-1 
consensus motif (Cargnello and Roux, 2011; Ye et al., 2014). 
 
After MAPKs are activated, they regulate downstream transcription factors which induce the 
transcription of AP-1 family genes. Activation of FOS and JUN transcription occurs via MAPK-
dependent phosphorylation of transcription factors such as TCF, MEF2C, ATF2 and cJUN. At the post 
translational level, via phosphorylation and dephosphorylation, the MAPK pathway modifies AP-1 
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subunit stability, transactivation activity and binding to target DNA (Zhang et al., 2017). For example, 
cJUN phosphorylation at serine 63 and 73 is known to increase its transcriptional output (Smeal et 
al., 1992).  
 
Historically, MAPKs were not considered to regulate transcriptional outcomes at the chromatin level. 
However, recent studies have shown that in some cases MAPKs can bind to DNA directly and 
indirectly via transcriptional regulators and chromatin bound factors (Klein et al., 2013; Pokholok et 
al., 2006; Suganuma et al., 2010; Tiwari et al., 2012). Furthermore, regulatory proteins that modulate 
MAPK function can be co-recruited to chromatin (Klein et al., 2013). Interestingly, constitutive 
tethering of JNK to AP-1 response elements at the cJUN promoter has been observed in HeLa cells 
(Bruna et al., 2003). Such data suggests JNK can be activated in the nucleus while pre-assembled in 
transcription complexes.  
 
As MAPK signalling is involved in many cellular processes associated with disease, numerous 
compounds have been developed to inhibit each MAPK family (English and Cobb, 2002; Uehling 
and Harris, 2015). For example, SP600125, a small molecule drug, has been reported to specifically 
inhibit JNK activity without influencing ERK, p38β or NFkB signalling in vitro (Han et al., 2001). 
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Figure 1.9: The MAPK/AP-1 signalling pathway. A simplified schematic of the MAPK/AP-1 signalling pathway. 
Ligand binding to a receptor initiates a signalling cascade leading to MAPK phosphorylation. Phosphorylation of 
MAPK allows it to function as an enzyme to phosphorylate and activate a range of AP-1 family transcription 
factors, culminating in the expression of AP-1 target genes.  
 
1.4 Epigenetic regulation of gene expression 
 
Eukaryotic cells package DNA into a highly ordered compact structure to actively regulate gene 
expression and ultimately cell phenotype. In the nucleus, DNA wraps around histone proteins 
forming nucleosomes. Each nucleosome consists of a 147bp segment of DNA wound around eight 
core histone proteins (H2A, H2B, H3 and H4). Nucleosomes are connected by linker chromatin, 
composed of mainly DNA and histone H1 (Figure 1.10). Epigenetic modifications of DNA and histone 
proteins remodel the chromatin and result in either increased or reduced accessibility to the 
transcription machinery. Such epigenetic modifications therefore regulate gene expression without 
changing the underlying DNA sequence (Kouzarides, 2007). The N-terminal tails of histone proteins, 
which are not bound to the nucleosome core particle and are exposed to the nuclear environment, 
32 
 
are prone to numerous reversible post translational modifications at specific residues (Figure 1.10, 2) 
(Chi et al., 2010; Kouzarides, 2007; Strahl and Allis, 2000). 
 
 
 
Figure 1.10: Epigenetic regulation of gene expression. DNA methylation, histone modifications and RNA-based 
mechanisms regulate chromatin structure and gene expression (from Matouk and Marsden, 2008). 
 
1.4.1 Histone modifications mark regulatory DNA elements  
 
Gene transcription is mediated by regulatory DNA regions such as promoters and enhancers. 
Promoters are located close to the transcriptional start site (TSS) and are required to initiate 
transcription. Enhancers specify when, in which cell type and at what level each of our genes is 
expressed by binding to transcriptional activators or repressors. Enhancers can be located almost 
anywhere in relation to the gene to be influenced and often relay their regulatory information over 
long distances to a gene's promoter. Historically, promoters and enhancers were thought to be 
distinct from each other but recent studies have shown significant overlap in their functionality 
(Kowalczyk et al., 2012; Mikhaylichenko et al., 2018). 
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Histone post-translational modifications are known to regulate promoter and enhancer activity to 
control gene expression. Histone modifications are particularly labile and are subject to over 60 
different types of modification including methylation, acetylation, phosphorylation, ubiquitylation 
and sumoylation (Kouzarides, 2007). Certain histone modifications are associated with particular 
functional DNA elements within mammalian genomes. For instance, active gene promoters often 
display high levels of histone acetylation, H3K4me2 and H3K4me3 whereas repressed gene 
promoters are commonly enriched for H3K9me2, H3K9me3 and H3K27me3. Furthermore, 
increased levels of H3K36me3 and H3K79me2 have been observed at transcribed regions while 
enhancers are linked to greater H3K4me1, H3K4me3 and H3K27ac (Figure 1.11) (Zhou et al., 
2011). 
 
 
 
Figure 1.11: Histone modifications mark functional elements in mammalian genomes (from Zhou et al., 
2011). Histone modifications can coexist and influence each other and often cannot be generalised with 
respect to transcriptional outcome. This observation has lead to the histone code hypothesis, which proposes 
that the transcription of genetic information is regulated by different combinations of histone modifications 
(Chi et al., 2010; Strahl and Allis, 2000). Studies suggest that a combination of active and inactive histone 
modifications control the expression of lineage-specific genes (Azuara et al., 2006). This has been termed gene 
priming and is associated with rapid changes in gene expression following physiological alterations in the 
cellular environment (Shah et al., 2014). Such gene priming provides a possible mechanism to explain how 
VSMCs reversibly switch between a spectrum of phenotypes.  
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1.4.2 Histone methylation  
 
Histone methylation is associated with both gene repression and activation depending on which 
residue is modified. Histone residues can be mono-, di- or tri-methylated by a range of specific 
histone methyltransferases (HMTs) (Chi et al., 2010; Kouzarides, 2007). Histone methylation was 
thought to be an irreversible mark of both gene activation and silencing for decades. However, the 
discovery of a number of histone demethylases (HDMs) uncovered the dynamic nature of this mark 
(Klose and Zhang, 2007).  
 
1.5 H3K9me2  
 
Multiple studies have shown that H3K9me2 is associated with transcriptional repression (Hublitz et 
al., 2009; Peters et al., 2003; Wen et al., 2009). H3K9me2 levels are higher at silent compared to 
active genes in a 10kb region surrounding the transcriptional start site (TSS) (Barski et al., 2007). 
H3K9me2 represses gene expression both passively, by prohibiting acetylation (Wang et al., 2008) 
and therefore binding of RNA polymerase or its regulatory factors, and actively, by recruiting 
transcriptional repressors (Nakayama et al., 2001; Shinkai and Tachibana, 2011; Zhang et al., 2016). 
H3K9me2 has also been found in megabase blocks, termed Large Organised Chromatin K9 domains 
(LOCKS), which are primarily located within gene-sparse regions but also encompass genic and 
intergenic intervals (Filion and van Steensel, 2010; McDonald et al., 2011; Wen et al., 2009). In recent 
years, many studies have reported that H3K9me2 is important for various biological processes 
including cell lineage commitment, the reprogramming of somatic cells to induced pluripotent stem 
cells and regulation of the inflammatory response (Chen et al., 2013; Rodriguez-Madoz et al., 2017; 
Shi et al., 2008).  
 
1.5.1 H3K9me2 regulates cell lineage commitment and reprogramming  
 
H3K9me2 plays a key role in regulating cell lineage commitment and reprogramming. Interestingly, 
Wen and colleagues found that H3K9me2 LOCKS cover 10-46% of the genome in differentiated cells 
compared to only 4% in embryonic stem cells (ESCs), can be lineage specific and are substantially lost 
in cancer cell lines (Wen et al., 2009). These findings prompted speculation over the role of H3K9me2 
in establishing and maintaining cell identity. However, Filion and van Steensel reanalyzed the original 
data sets and disputed these findings, claiming that there are no significant differences in H3K9me2 
LOCKS in ESCs compared to differentiated cells and suggest that the algorithm used by Wen et al may 
have introduced a detection bias (Filion and van Steensel, 2010). Nevertheless, other groups have 
found evidence to suggest H3K9me2 LOCKS are functionally relevant. For instance, reduction of 
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H3K9me2 LOCKS was observed in epithelial-to-mesenchymal transition (EMT), a process in which 
cells acquire a multipotent phenotype (McDonald et al., 2011). Additionally, hematopoietic stem and 
progenitor cells display lower global levels of H3K9me2 compared to mature bone marrow cells (Li et 
al., 2018).  
 
Furthermore, studies have shown that inhibition of H3K9me2 improves the reprogramming efficiency 
of human cells by heterochromatin relaxation and facilitating transcription factor binding (Chen et 
al., 2013; Rodriguez-Madoz et al., 2017). Interestingly, inhibition of H3K9me2 potentiates the 
inflammatory activation of fibroblasts in response to IFN (Fang et al., 2012) and inflammation is 
known to improve the reprogramming efficiency of somatic cells to induced pluripotent stem cells 
(Lee et al., 2012). Together, these observations point towards a role of H3K9me2 in the maintenance 
of differentiated cell states.  
 
1.5.2 H3K9me2 regulates the expression of inflammation-induced genes 
 
H3K9me2 often marks genes that are involved in processes that require tight and dynamic 
regulation, including the inflammatory response. For instance, enriched levels of H3K9me2 at IFN-
stimulated genes (ISGs) in fibroblasts, cardiac myocytes and neuroblastoma cells results in a far 
weaker type 1 IFN response compared to bone marrow-derived macrophages and dendritic cells 
where H3K9me2 is either absent or present at low levels at ISGs (Fang et al., 2012). Furthermore, 
elevated levels of G9A-dependent H3K9me2 have been linked to endotoxin and LPS tolerance 
associated gene repression in various immune cell types (Chen et al., 2009; Liu et al., 2014; Yoshida 
et al., 2015).  
 
Many studies report that the aberrant expression of a number of MMP and inflammatory genes is 
associated with H3K9me2-depletion at their promoters. For example, loss of H3K9me2 has been 
observed at inflammatory and MMP gene promoters, which display increased expression, in 
monocytes (Miao et al., 2007) and retinal endothelial cells (Zhong and Kowluru, 2013b) derived from 
diabetic patients compared to controls.  
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1.6 G9A/GLP are required for H3K9 dimethylation  
 
In mammals, the G9A/GLP enzymatic complex functions to establish and maintain H3K9me2 
(Shankar et al., 2013; Shinkai and Tachibana, 2011). G9A and GLP are expressed ubiquitously and play 
multiple roles in development, physiology and disease (Shinkai and Tachibana, 2011; Tachibana et al., 
2008). Interestingly, G9a and Glp -/- mouse embryos display early lethality at E9.5 to E12.5, due to 
severe growth defects (Tachibana et al., 2002). In addition, dysregulation of G9A and/or GLP has 
been implicated in many inflammatory (Chang et al., 2011; Chen et al., 2009) and cardiovascular 
diseases (Thienpont et al., 2017).  
 
1.6.1 G9A/GLP structure and function 
 
G9A and its highly related homologue G9A-like protein (GLP) share an evolutionary SET domain, 
responsible for their methyltransferase activity (Shinkai and Tachibana, 2011). The SET domains of 
G9A and GLP share the same substrate specificity and primarily function to establish and maintain 
H3K9 mono and di-methylation. However, both enzymes  have also been reported to catalyze H1, 
H3K27 and H3K56 methylation (Shankar et al., 2013; Shinkai and Tachibana, 2011; Xiong et al., 2017). 
When transiently over expressed, G9A and GLP form homo- and heterodimers via their SET domain. 
However, endogenously both enzymes function exclusively as a heteromeric complex (Tachibana et 
al., 2005). Although G9A and GLP can exert their methyltransferase activities independently in vitro, 
if either G9a or Glp are knocked out in vivo, global levels of H3K9me2 are severely reduced and are 
equivalent to H3K9me2 levels in G9a and Glp double knockout mice (Shinkai and Tachibana, 2011). 
Therefore, it is thought that G9A cannot compensate for the loss of GLP methyltransferase activity in 
vivo, and vice versa (Shinkai and Tachibana, 2011).  
 
Another important functional domain, which G9A and GLP both share, is a region containing ankryin 
repeats, which is involved in protein-protein interactions. The ankyrin repeat domain also contains 
H3K9me1 and H3K9me2 binding sites (Figure 1.12) (Shinkai and Tachibana, 2011). Therefore, the 
G9A/GLP complex can both methylate histone tails and bind to mono- and di-methylated H3K9 to 
recruit molecules, such as DNA methyltransferases, to the chromatin (Shinkai and Tachibana, 2011; 
Zhang et al., 2016). H3K9me2 is a reversible modification and can be removed by a wide range of 
histone lysine demethylases (KDMs) including KDM1, KDM3, KDM4 and KDM7 family members 
(Cloos et al., 2008; Delcuve et al., 2009; Shinkai and Tachibana, 2011). 
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Figure 1.12: Structure of G9A and GLP. (Pre) pre-SET domain; (SET) SET domain; (Post) post-SET domain. The 
pre-SET, SET and post-SET domains are important for substrate recognition and enzymatic activity. The ankyrin 
repeats are important for protein-protein interactions and binding to H3K9me1/2 (adapted from Shinkai and 
Tachibana, 2011). 
 
1.6.2 G9A/GLP have non-histone targets 
 
In addition to their role as histone lysine methyltransferases (HMTs), several studies have shown that 
G9A/GLP are also able to methylate a wide range of non-histone proteins (Figure 1.13) (Biggar and Li, 
2015).  However, as most of the reported methylation sites have been derived from mass 
spectrometry analyses, the function of many of these modifications remain unknown. Nevertheless, 
increasing evidence suggests methylation of non-histone proteins may influence protein stability (Lee 
et al., 2015), protein-protein interactions (Lee et al., 2010; Ling et al., 2012) and regulate cellular 
signalling pathways (Biggar and Li, 2015; Pless et al., 2008). For example, G9A has been shown to 
methylate the SOX2 protein to regulate its stability in breast cancer cells and mouse embryonic stem 
cells (Lee et al., 2015). In addition, G9A/GLP can methylate a number of transcription factors to 
regulate their transcriptional activity, including MyoD (Ling et al., 2012), C/EBP (Pless et al., 2008), 
Reptin (Lee et al., 2010), p53 (Huang et al., 2010b), MEF2D (Choi et al., 2014), MEF2C (Ow et al., 
2016) and MTA1 (Nair et al., 2013). Furthermore, G9A/GLP are able to methylate non-histone 
proteins to regulate complexes which recruit DNA methyltransferases to gene promoters to repress 
transcription via the methylation of CpG islands (Chang et al., 2011; Leung et al., 2011; Zhang et al., 
2011). Therefore, G9A and/or GLP have wide-ranging roles in development (Choi et al., 2014; Ling et 
al., 2012; Ow et al., 2016), establishing and maintaining cell identity (Ling et al., 2012; Purcell et al., 
2012), cell cycle regulation (Huang et al., 2010a) and cellular responses to environmental stimuli (Lee 
et al., 2010; Leung et al., 2011),  which are dependent on their non-histone protein 
methyltransferase activity. 
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Figure 1.13: A Lys methylation network is presented for known Lys methyltransferase (KMT)–substrate 
associations based on currently published literature. G9A can methylate at least 17 non-histone proteins, 
whereas GLP can methylate at least 4 non-histone proteins (from Biggar and Li, 2015).  
 
Apart from their ability to methylate proteins, G9A and GLP also have methyltransferase-
independent activities through their N-terminal domain. For example, the Stallcup group 
demonstrated that G9A binds to co-activators GRIP1, CARM1 and p300 to initiate transcription of a 
subset of hormone receptors. Here, G9A acts as a positive regulator of transcription independent of 
its methyltransferase activity, as demonstrated by the insensitivity of G9A co-activator function to 
UNC0646 (a small molecule G9A-specific methyltransferase inhibitor) (Bittencourt et al., 2012). 
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1.6.3 Inhibition of G9A/GLP by chemical probes 
 
Several chemical probes have been developed to specifically inhibit the methyltransferase activity of 
G9A/Glp. A high throughput screen identified BIX-01294 (Kubicek et al., 2007) as the first small 
molecule inhibitor, which acts by binding to the SET domain of G9A and GLP in the peptide binding 
site, preventing methylation (Chang et al., 2009). BIX-01294 was further optimised through structure-
activity relationships to produce UNC0224, UNC0321, E72, UNC0642 and UNC0638 (Chang et al., 
2010; Liu et al., 2013; Liu et al., 2009). For the in vitro experiments described in this thesis UNC0638 
was used; a potent, specific, stable and cell-permeable inhibitor of G9A/Glp (Liu et al., 2013; Vedadi 
et al., 2011). However, UNC0638 has poor pharmacokinetics for in vivo use (Liu et al., 2013). 
Therefore, for the in vivo experiments described in this thesis A366 was used; a G9A/Glp inhibitor 
with better pharmocokinetics and no overt toxicity (Sweis et al., 2014). The Roderick group 
successfully administered mice with A366 via osmotic mini pump (30 mg/kg/ for 10 days) to inhibit 
G9A/Glp and lower H3K9me2 in cardiomyocytes (Thienpont et al., 2017). 
 
1.7 H3K9me2 demethylases 
 
Historically, like other methylated histone modifications, H3K9me2 was thought to be irreversible 
due to the high thermodynamic stability of the N-CH3 bond (Cloos et al., 2008). It was previously 
thought that histone methylation could only be removed by histone exchange or by cleavage of the 
methylated histone tail (Cloos et al., 2008). However, the discovery of the histone demethylase 
(HDM) KDM1A in 2004 changed this perception (Shi et al., 2004). Since then, a number of HDMs have 
been reported to target H3K9me2, including KDM1A, KDM3A, KDM3B, KDM4A, KDM4B, KDM4C, 
KDM4D, JHDM1D and PHF8 (Cloos et al., 2008; Hyun et al., 2017). Many of these HDM proteins are 
also known to target other protein substrates and can be found in bacteria that do not contain 
histones (Cloos et al., 2008). These observations suggest HDM proteins serve other purposes in 
addition to demethylating histones. 
 
1.8 Epigenetic regulation of VSMC phenotype 
 
It is becoming increasingly evident that epigenetic mechanisms, including histone modifications, play 
an important role in controlling VSMC phenotype (Alexander and Owens, 2012; McDonald et al., 
2006; Turunen et al., 2009; Villeneuve et al., 2008b).  
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1.8.1 Histone methylation regulates VSMC gene expression 
 
Interestingly, the activating H3K4me2 mark has been shown to persist at contractile VSMC marker 
genes in VSMCs after phenotypic switching despite their transcriptional silencing (Alexander and 
Owens, 2012). Therefore, it has been suggested histone lysine methylation serves as a mechanism 
for epigenetic cell lineage memory to enable phenotypically modulated VSMCs to switch back to 
their contractile state (Alexander and Owens, 2012). This information has been used to identify 
phenotypically switched VSMCs in human atherosclerotic plaque, using in situ hybridisation proximity 
ligation to detect H3K4me3 at VSMC marker gene promoters. This work combined with fluorescent in 
situ hybridisation for other cell type and VSMC marker genes demonstrated that VSMCs are able to 
transition to macrophage and mesenchymal stem cell-like cells within human atheroma (Shankman 
et al., 2015). 
 
1.8.2 H3K9me2 and G9A/GLP regulate VSMC phenotype 
 
Intriguingly, H3K9me2 has been reported to affect the growth rate, migration and contractility of 
different smooth muscle cell types (Clifford et al., 2012; Yang et al., 2012). For example, global loss of 
H3K9me2, by pharmacological inhibition of the associated methyltransferases G9A/Glp, reduced the 
expression of Calponin and the contractility of ovine foetal pulmonary artery SMCs (Yang et al., 
2012). Moreover, compared to VSMCs from healthy aortic tissue, global levels of H3K9me2 are 
reduced in human VSMCs from atherosclerotic lesions that contain phenotypically modulated 
VSMCs. In addition, Chen et al observed that VSMCs derived from diabetic rats display lower levels of 
H3K9me2 compared to non-diabetic controls and found evidence to suggest that dysregulation of 
H3K9me2 might underlie vascular complications associated with diabetes (Chen et al., 2017; Zhang et 
al., 2018). Together, these findings implicate H3K9me2 in the regulation of VSMC phenotype.  
 
1.9 In vivo mouse models of vascular remodelling and disease 
 
The vasculature is comprised of multiple cell types, which are influenced by a variety of signals in the 
surrounding milieu including shear stress, circulating blood cells and cytokines. In vitro studies fail to 
mimic this complex environment; therefore in vivo models are required to validate and substantiate 
in vitro results. The mouse has proven to be a powerful and flexible model system to explore the 
development of human CVD and assess therapeutic feasibility. Remarkably, 50% of coronary artery 
disease-associated pathways derived from mouse genome wide association studies overlapped with 
those identified from human studies (von Scheidt et al., 2017). We share 95% of our protein 
encoding genes with mice (von Scheidt et al., 2017) and regulatory elements often share 
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evolutionary conserved histone modifications which can signify their function (Diehl and Boyle, 
2018).  
 
However, despite phylogenetic similarities between mice and humans there are still many 
differences between the two species and conserved chromatin signatures do not always equate to 
conserved regulatory functions (Diehl and Boyle, 2018; von Scheidt et al., 2017). For instance, in 
contrast to mice, a significant number of VSMCs exist within the intima in conserved locations, 
including branch sites and areas of turbulent blood flow, prior to disease within human vasculature 
(Doran et al., 2008). Furthermore, wild type mice are relatively resistant to atherosclerosis because 
they have a very different lipid profile compared to humans. Models, including genetically 
engineered ApoE-/- mice fed a high fat diet (Nakashima et al., 1994), have been developed to 
overcome this problem but are unlikely to perfectly reflect the mechanisms which cause 
atherosclerosis in humans. Consequently, mice created to mimic human disease frequently have 
phenotypes that differ from their human counterparts (Perlman, 2016). Therefore, it is important to 
validate findings drawn from mouse models in human samples. 
 
1.9.1 VSMC-specific conditional lineage tracing  
 
VSMCs down regulate contractile VSMCs genes in response to injury and inflammation. Furthermore, 
many contractile VSMC markers are also expressed by other cell types (Gomez and Owens, 2012). 
Therefore, studying VSMC behavior in vascular disease is difficult. However, recent studies have 
overcome this problem by using transgenic mice expressing CreERT2 recombinase under the control 
of the Myh11 promoter (Figure 14A, B), regarded as a VSMC specific marker (Nguyen et al., 2013), 
with fluorescent Cre-dependent reporter genes. Such VSMC-specific conditional lineage tracing has 
proved to be extremely useful to efficiently and specifically identify VSMC and VSMC-derived cells 
and can therefore be used to test effects on VSMC and VSMC-derived cells in vivo (Albarrán-Juárez et 
al.; Chappell et al., 2016; Herring et al., 2014; Herring et al., 2017; Shankman et al., 2015).  
 
The Cre recombinase used in this VSMC lineage tracing model is fused to a mutant form of the 
oestrogen receptor, which binds the synthetic oestrogen 4-hydroxytamoxifen instead of its natural 
ligand 17β-estradiol. CreER(T2) resides within the cytoplasm and can only translocate to the nucleus 
following tamoxifen administration, allowing tight temporal control of recombination. The CreERt2 
sequence was inserted into the ATG site of a bacterial artificial chromosome (BAC) carrying the 
Myh11 gene, the most specific marker of mature contractile VSMCs (Nguyen et al., 2013). The 180kb 
BAC was then injected into the pro-nuclei of mice oocytes. Myh11-CreER(T2) transgenic mice where 
the transgene had integrated into the Y chromosome were chosen for breeding onto the C57BL/6 
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background (Wirth et al., 2008), excluding its application in female mice. Gender has been identified 
as a risk factor for multiple vascular diseases (Mosca et al., 2011), therefore the use of only male 
mice in the studies described in this thesis is a limitation.  
 
The multicolour Confetti (Figure 14A)/single colour EYFP (Figure 14B) reporter located within the 
ROSA26 locus, contains a CAG promoter, permitting high expression of the fluorescent transgene 
reporter, a loxP flanked stop cassette, ensuring the expression of the transgene is Cre-recombinase 
dependent and the reporter sequence (Livet et al., 2007; Snippert et al., 2010). The multicolour 
Confetti reporter sequence, Brainbow 2.1, contains floxed cDNA for green (GFP), yellow (YFP), red 
(RFP) and cyan (CFP) fluorescent proteins whereas the single colour EYFP reporter sequence contains 
floxed cDNA for enhanced yellow fluorescent protein (EYFP).  
 
In Myh11-CreERt2, ROSA26-Confetti (Chappell et al., 2016)/EYFP (Gomez et al., 2013) mice, upon Cre 
driven recombination, the stop cassette is excised, allowing reporter genes to express specifically in 
Myh11-positive cells. For the Confetti construct, Cre driven recombination leads to the stochastic 
expression of one of the four fluorescent proteins described. GFP localises to the nucleus, YFP and 
RFP localise to the cytoplasm and CFP is recruited to the membrane (Livet et al., 2007; Snippert et al., 
2010). Since removal of the stop cassette is permanent, the reporter genes are expressed in all the 
progeny produced by the initial cells where the Cre was once activated. 
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Figure 1.14: Schematic of 'Confetti' multi-colour and EYFP single-colour VSMC lineage tracing system. (A) 
Schematic of the Myh11-CreERt2 transgene (Wirth et al., 2008) and the ROSA26-Confetti reporter allele 
(Snippert et al., 2010). Tamoxifen-induced recombination at the ROSA26-Confetti locus results in the 
expression of one of four fluorescent proteins, which are stably propagated independent of Myh11 expression 
levels within progeny. (B) Schematic of the Myh11-CreERt2 transgene and the ROSA-EYFP reporter allele.  
Tamoxifen-induced recombination at the ROSA-EYFP locus results in the expression of EYFP protein, which is 
stably propagated independent of Myh11 expression levels within progeny (Adapted from Chappell et al., 
2016). 
 
1.9.2 Carotid ligation model 
 
Vascular remodelling of the carotid artery, characterised by medial and intimal thickening, is a 
hallmark of many human CVDs (Davis et al., 2001) and can be mimicked using animal models (Emini 
Veseli et al., 2017). In mice, complete ligation of the left common carotid artery near the carotid 
bifurcation causes extensive vascular remodelling in the response to cessation of blood flow, leading 
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to neointima formation over time (Ali et al., 2013; Herring et al., 2017; Kumar and Lindner, 1997b). 
Carotid ligation rapidly elicits reproducible vessel growth and remodelling concomitant with changes 
in VSMC gene expression (Ali et al., 2013; Herring et al., 2014; Herring et al., 2017; Kumar and 
Lindner, 1997b). Analyses of the medial layer of carotid arteries, both 3 and 14 days post ligation, 
have revealed decreased expression of contractile VSMC genes accompanied by a significant increase 
in pro-inflammatory and MMP gene expression (Figure 1.15) (Ali et al., 2013; Herring et al., 2017). 
Furthermore, studies using lineage labelled adult VSMCs have shown that the neointima begins to 
develop between 7 and 14 days post ligation and that the neointimal cells mostly arise from medial 
VSMCs (Chappell et al., 2016; Herring et al., 2014).  
 
A disadvantage of the mouse carotid ligation injury model is that it is performed on healthy blood 
vessels that lack pre-existing atherogenic or vasoproliferative pathologies (Baylis et al., 2017; Lee et 
al., 2017). Therefore, mechanisms underlying vascular remodelling due to arterial ligation may not 
recapitulate those involved in human disease. However, this model elicits an acute VSMC response to 
injury, which is quicker and more reproducible than many alternative models of vascular disease (Lee 
et al., 2017). Therefore, the carotid ligation model provides a good system to test effects on the early 
VSMC gene expression changes associated with vascular remodelling and disease. 
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Figure 1.15: The carotid ligation-injury mouse model. (A) Schematic of carotid anatomy and left common 
carotid artery (Left CCA) ligation site.  (B) Microarray analysis of mRNA levels from the medial layer of the left 
CCA 3 days after ligation relative to no surgery controls (Herring et al., 2017). (C) RT-qPCR analysis of mRNA 
levels from the medial layer of the left CCA 14 days after ligation relative to no surgery controls (Ali et al., 
2013). 
 
1.9.3 ApoE-/-, high fat diet mouse model of atherosclerosis 
 
In atherosclerotic plaque, VSMCs display significant plasticity; many VSMCs down regulate contractile 
markers and adopt a more proliferative, migratory and synthetic phenotype and can often acquire 
macrophage, osteo-chondrocytic and mesenchymal stem cell markers (Alexander and Owens, 2012; 
Bennett et al., 2016). Atherosclerosis can be induced in a reasonable time frame using mouse 
models. However, wild type mice are relatively resistant to atherosclerosis because they have a very 
different lipid profile compared to humans (Nakashima et al., 1994). Unlike humans, in mice 
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cholesterol is mostly transported in high density lipoprotein (HDL) like particles, which are less 
atherogenic compared to low density lipoprotein (LDL) and very low density lipoprotein (VLDL) 
(Nakashima et al., 1994). Therefore, genetic manipulation of the mouse's lipid metabolism is 
required to induce atherosclerosis. Genetic ablation of apolipoprotein E (ApoE), a glycoprotein 
involved in the clearance of lipoproteins and cholesterol from the body, elevates levels of 
atherogenic LDL, VLDL and plasma cholesterol (Nakashima et al., 1994). Consequently, 
atherosclerotic lesions develop in regions of the vasculature subject to flow disturbance, where shear 
stress is low and/or oscillatory, in a process similar to that observed in human disease (Figure 16). In 
ApoE-/- mice, monocytes attach to endothelial cells from 6 weeks of age and foam cell lesions are 
detectable by 8 weeks. From 15 to 20 weeks of age atherosclerotic plaques consisting of VSMCs, ECM 
and a necrotic core covered with a fibrous plaque can be observed. When fed a high fat diet, 
atherosclerosis is greatly accelerated in ApoE-/- mice (Emini Veseli et al., 2017; von Scheidt et al., 
2017). 
 
A caveat of the ApoE-/- HFD mouse model is that plaques within these mice typically do not rupture 
and therefore fail to recapitulate the deadliest late stage events associated with atherosclerosis 
(Baylis et al., 2017). Furthermore, ApoE is known to play a role in inflammation, which may influence 
plaque development (Emini Veseli et al., 2017). However, the plaques within ApoE-/- mice follow 
similar developmental steps observed within humans. The model is extensively used to study 
atherosclerosis and has greatly advanced our understanding of the disease (Lee et al., 2017; Meir and 
Leitersdorf, 2004; Nakashima et al., 1994).  
 
 
 
Figure 1.16: Overview of atherosclerosis model in ApoE-knockout mice fed on a high-fat diet. 
The figure describes total plasma cholesterol levels on normal (ND) and high fat western-type diet (WD), 
lipoprotein profile, plaque characteristics and the advantages and limitations of the model. The distribution of 
the plaques in the thoracic aorta is shown for mice fed a WD for at least 20 weeks (from Emini Veseli et al., 
2017). 
1.10 Hypothesis and aims 
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VSMC phenotypic switching directly contributes to the development and progression of 
cardiovascular disease (CVD) (Herring et al., 2014; Nguyen et al., 2013), the leading cause of death 
worldwide (WHO, 2015). In response to inflammation and injury, VSMCs can reversibly change from 
their quiescent “contractile” phenotype to an active “synthetic” state (Owens et al., 2004). Synthetic 
VSMCs are characterised by the loss of contractile marker expression and the ability to upregulate 
selective gene sets in response to environmental stimuli. For example, stimulation of VSMCs with 
pro-inflammatory cytokines such as IL-1α activates both NFkB and AP-1 signalling associated 
transcription, inducing the expression of matrix metalloproteinases (MMPs), inflammatory cytokines 
(e.g. IL6) and chemokines (CCL2). Such inducible genes are essential for vascular repair and 
remodelling but can often become dysregulated and contribute to disease development. 
 
The epigenetic mechanisms underlying phenotypic switch-associated changes in VSMC gene 
expression remain relatively unexplored. Interestingly, decreased levels of H3K9me2, a repressive 
mark associated with inactive gene promoters, have been observed in VSMCs derived from 
atherosclerotic plaques compared to healthy tissue in humans. Furthermore, H3K9me2 has been 
reported to affect the growth rate, migration and contractility of different smooth muscle cell types 
(Clifford et al., 2012; Yang et al., 2012) and numerous studies have found that H3K9me2 marks genes 
involved in processes that require tight and dynamic regulation, including those involved in cell fate 
switching (Chen et al., 2013; Chen et al., 2012) and the inflammatory response (Chen et al., 2009; 
Fang et al., 2012; Liu et al., 2014; Miao et al., 2007; Yoshida et al., 2015). Therefore, the experiments 
performed in this thesis attempt to assess the function and physiological importance of H3K9me2 in 
VSMCs. 
 
Hypothesis: H3K9me2-mediated gene regulation is functionally important in VSMCs and influences 
their phenotypic plasticity.  
 
Aims: 
 
(1) Use murine in vitro and in vivo models of VSMC phenotypic switching to: 
a) assess global and local changes in H3K9me2 upon loss of the contractile state 
b) and test the functional role of H3K9me2 on disease-associated VSMC gene expression. 
 
(2) Determine whether H3K9me2-mediated regulation of disease-associated VSMC genes is 
 conserved in human VSMCs. 
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(3) Investigate the mechanism underlying H3K9me2-mediated regulation of disease-associated 
 VSMC gene expression. 
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CHAPTER 2 - METHODS 
  
50 
 
2.1 Mouse VSMC isolation 
 
Whole aortas from C57BL/6J mice were dissected in PBS under an inverted Leica M80 microscope, 
applying aseptic technique. Fat and connective tissue were removed before the vessels were opened 
longitudinally to scrape off blood and endothelial cells. For primary mouse VSMC culture, each aorta 
was incubated in 1 ml of 1 mg/ml of collagenase II and 1 U/ml of elastase (Worthington) in DMEM at 
37 ֯C, 5 % CO2 for 10 minutes to peel off and remove the adventitia. Aortas intended for RNA 
extraction were stored in RNAlater (ThermoFisher) at -20 ֯C. Enzymatic digestion was not used to aid 
removal of the adventitia for ex vivo VSMC isolation intended for RNA extraction or ChIP; instead the 
adventitia was removed manually in PBS. The isolated medial layer of VSMCs was then washed in PBS 
before being snap frozen in liquid nitrogen or being further processed for culture. 
 
2.2 Primary mouse VSMC culture 
 
After isolating the medial layer of VSMCs, the tissue was further digested in 1 ml of 2.5 mg/ml of 
collagenase II (Invitrogen) and 2.5 U/ml of elastase (Worthington) in DMEM at 37 ֯C, 5 % CO2 for 
approximately 2 hours, mixing every 20 minutes, until a single cell suspension was reached. The 
dissociated VSMCs were plated in VSMC growth medium (DMEM supplemented with 10 % (v/v) of 
FBS, 100 U/ml of penicillin, 100 mg/ml of streptomycin and 2 mM of glutamine). 1 well of a 12-well 
plate (Corning) was used per aorta. VSMCs were maintained at 37 ֯C, 5 % CO2 in growth medium and 
split 1:2 every 5-7 days when approximately 90 % confluent. To split, the cells were washed in PBS 
and incubated in Trypsin-EDTA solution (T4049, Sigma-Aldrich) at 37 0C, 5 % CO2 for approximately 5 
minutes. Experiments were carried out using passage 4 VSMCs. 
 
2.3 Derivation of human VSMCs 
 
Human aortic VSMCs were isolated from patients undergoing aortic valve replacement surgery under 
informed consent with protocols approved by the Cambridge or Huntingdon Research Ethical 
Committee. Adventitia and endothelial cells were manually removed from aortic explants before 
being cut into ~2-3 mm2 sections. The medial VSMC layer was either analysed directly or four ~2-3 
mm2 sections were placed in a 6-well plate with a cover slip placed on top and cultured in growth 
medium (DMEM supplemented with 10 % (v/v) of FBS, 100 U/ml of penicillin, 100 mg/ml of 
streptomycin and 2 mM of glutamine). VSMCs were cultured to approximately 90 % confluence 
before passaging. To split, the cells were washed in PBS and incubated in Trypsin-EDTA solution 
(T4049, Sigma-Aldrich) at 37 ֯C, 5 % CO2 for ~5 minutes. The passage number of the VSMCs used is 
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indicated in the figure legends. Table 1 describes the age and sex of the donors from which the 
VSMCs were derived. 
 
Table 1: Human donor information 
 
Figure ID: P# Age: Sex: 
 
Figure ID: P# Age: Sex: 
5.1 N/A 78 Male 
 
5.5 9 20 Male 
5.1 N/A 65 Male 
 
5.5 8 33 Female 
5.1 N/A 53 Female 
 
5.5 7 56 Male 
5.1 7 36 Male 
 
5.5 11 64 Female 
5.1 8 53 Male 
 
6.1/6.4 6 41 Male 
5.1 7 59 Male 
 
6.1/6.4 9 53 Female 
5.2 9 20 Male 
 
6.1/6.4 7 45 Male 
5.2 8 33 Female 
 
6.2/6.3 12 44 Male 
5.2 7 56 Male 
 
6.2/6.3 7 69 Male 
5.2 11 64 Female 
 
6.2/6.3 11 71 Female 
5.2 8 32 Male 
 
6.2/6.3 9 77 Male 
5.2 13 44 Male 
 
6.5 6 41 Male 
5.2 10 71 Female 
 
6.5 11 45 Male 
5.2 11 77 Female 
 
6.5 15 53 Female 
5.3 8 53 Male 
 
6.5 11 71 Female 
5.3 6 64 Female 
 
6.6/6.7 8 32 Male 
5.3 6 66 Male 
 
6.6/6.7 13 44 Male 
5.3 6 78 Male 
 
6.6/6.7 10 71 Female 
5.4 8 32 Male 
 
6.6/6.7 11 77 Female 
5.4 13 44 Male 
 
6.8 6 41 Male 
5.4 10 71 Female 
 
6.8 11 45 Male 
5.4 11 77 Female 
 
6.8 15 53 Female 
P# = Passage number 
         
2.4 Animal experiments 
 
All experiments were carried out according to the UK Home Office regulations (PPL70/7565) and 
were approved by the local ethics committee. C57Bl/6 and ApoE-/- mice were purchased from 
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Charles River. Myh11-CreERt2, ROSA26-Confetti and ROSA26-EYFP mice have all been previously 
described (Basak et al., 2014; Chappell et al., 2016; Majesky et al., 2017; Snippert et al., 2010; Wirth 
et al., 2007). Myh11-CreERt2/ROSA26-Confetti and Myh11-CreERt2/ROSA26-EYFP males (as the 
Myh11-CreERt2 transgene is Y linked) received intraperitoneal injections of tamoxifen at 3-8 weeks 
of age (10 injections of 1 mg/ml each) for lineage labelling. 
 
For A366 treatment experiments, Myh11-CreERt2+, ROSA26-Confetti+ or Myh11-CreERt2, ROSA26-
EYFP+ males were anaesthetised using 2.5-3% isofluorane (by inhalation) and given a pre-operative 
analgesic (Temgesic). Mini osmotic pumps filled with 30 mg/kg/day of A366 dissolved in 98:2 PEG 
400/polysorbate 80 or 98:2 PEG 400/polysorbate 80 without active compound were then implanted 
subcutaneously (2002, Azlet). The aorta and right and left common carotid arteries were removed 
either 7- or 14-days post-surgery and processed for western blot or immunofluorescence to analyse 
global H3K9me2 levels in the VSMCs.  
 
For A366 treatment plus carotid ligation experiments, 14 days after osmotic pump insertion carotid 
ligation surgery was performed. For carotid ligation experiments, Myh11-CreERt2+, ROSA26-
Confetti+ or Myh11-CreERt2, ROSA26-EYFP+ males were anaesthetised using 2.5-3% isofluorane (by 
inhalation) and given a pre-operative analgesic (Temgesic). The left common carotid artery was tied 
firmly with one knot using 6-0 silk suture just below the bifurcation point. Both the right and left 
carotid arteries were removed 7 days post-surgery and processed for microscopy or FACS to isolate 
lineage labelled EYFP+ VSMCs.  
 
2.4 Western blot 
 
Cell pellets were lysed directly in 2X Laemmli sample buffer (20% glycerol, 4% SDS, 100 mM Tris HCl 
pH 6.8, 200 mM DTT), incubated at 98 ֯C for 5 minutes and sonicated for 1 minute at medium 
intensity using a standard Bioruptor (Diagenode). Total protein (10-30 μg) was resolved with SDS-
PAGE and transferred to PVDF membranes. The membranes were incubated in blocking buffer (5% 
w/v non-fat dry milk in TBS (50 mM Tris-HCl, pH 7.5, 150 mM NaCl) for one hour at room 
temperature. The membranes were then probed with primary antibodies (Table 2) overnight at 4 ֯C 
followed by secondary antibodies conjugated to horseradish peroxidase (HRP) (Table 3) for 30-60 
minutes at room temperature. All antibody incubation steps were done in blocking buffer. Protein 
was detected using the ECL system (GE Healthcare), following the manufacturer's instructions. 
 
Table 2: Primary antibodies used for western blot 
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Protein Size Species‡ mg/ml Dilution Product ID 
GLP 
140, 165 
kDa 
Mouse 
mAb 
1 1:1000 
R&D Systems 
(#PP-B0422-00) 
G9A 138 kDa 
Mouse 
mAb 
1 1:500 
R&D Systems 
(#PP-A8620A-00) 
H3K9me2 17 kDa 
Mouse 
mAb 
1 1:1000 Abcam (#ab1220) 
NFkB-p65 64 kDa 
Rabbit 
pAb 
0.1 1:100 
Santa Cruz 
(sc-372) 
cJUN 43 kDa 
Rabbit 
pAb 
1 1:1000 
Abcam 
(#ab31419) 
p- cJUN (Ser63) 42 kDa 
Rabbit 
mAb 
0.1 1:1000 
Abcam 
(#ab32385) 
p-JNK 
(Thr183/Tyr185) 
46, 54 
kDa 
Rabbit 
mAb 
ND 1:1000 
Cell Signaling 
(#4668) 
p-ERK1/2 
(Thr202/Tyr204) 
42, 44 
kDa 
Rabbit 
pAb 
ND 1:1000 
Cell Signaling 
(#9101) 
p-p38 
(Thr180/Tyr182) 
43 kDa 
Rabbit 
pAb 
ND 1:1000 
Cell Signaling 
(#9211) 
ACTB 45 kDa 
Mouse 
mAb 
1 1:10,000 
Sigma-Aldrich 
(#A2228) 
Β-TUBULIN 55 kDa 
Rabbit 
pAb 
ND 1:1000 
Cell Signaling 
(#2146) 
‡mAb, monoclonal antibody; pAb, polyclonal antibody; ND, not determined; WB, western blot; p-, 
phosphorylated. 
 
Table 3: Secondary antibodies used for western blot 
 
Protein Dilution Product ID 
Anti-rabbit IgG, HRP linked 1:5000 Cell Signaling (#7074) 
Anti-mouse IgG, HRP linked 1:5000 Cell Signaling (#7076) 
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2.5 Quantitative Real Time-Polymerase Chain Reaction (RT-qPCR) 
 
Total RNA was extracted with TRIzol (Life Technologies) and 0.4-1 μg was reverse transcribed using a 
QuantiTect Reverse Transcription kit (Qiagen), according to the manufacturer's directions.  
 
For quantification, cDNA (diluted 1:5-1:10) or gDNA from ChIP was amplified, in technical duplicates, 
with a QuantiTect SYBR Green PCR kit (Qiagen) and primer pairs listed in Tables 4 to 7, using a 
Corbett Life Science Rotor Gene 6000 PCR system. RT-qPCR-obtained values were normalised to the 
average of two housekeeping genes (HMBS and YWHAZ or HPRT1).  
 
2.5.1 Primer design and validation 
 
Primers for RT-qPCR were designed as following: amplicon size of 100‐ 200bp, primer GC content of 
45‐55%, primer melting temperature 58‐62°C, low 3’ stability (no more than 2 C’2 and/or G’s in the 
last 5bp of the primer) and primer size of 18‐25 bp. For cDNA analysis primers were designed 
targeting different exons. Target sequences were obtained using the Ensembl genome browser and 
the primers were aligned to the genome using the NCBI BLAT function and checked using the UCSB 
In-Silico PCR tool. For each pair of primers designed, the efficiency in RT-qPCR was tested in 3-fold 
dilutions of gDNA/cDNA. Primers were chosen which yielded a good linear fit (R2<0.98) in Ct vs. 
logarithm of the dilution factor plot and when the efficiency calculated was between 1.8 and 2.2 
(Efficiency=10(1/slope)). 
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Table 4: Mouse RT-qPCR primer sequences 
     Gene Species Forward 5'-3' Reverse 5'-3' Type 
Hprt1 Mouse 
TGGATACAGGCC
AGACTTTGTT 
CAGATTCAACTTG
CGCTCATC 
Housekeeping 
Hmbs Mouse 
ACTGGTGGAGTA
TGGAGTCTCAGAT
GGC 
GCCAGGCTGATG
CCCAGGTT 
Housekeeping 
Ywhaz Mouse 
CGTTGTAGGAGC
CCGTAGGTCAT 
TCTGGTTGCGAAG
CATTGGG 
Housekeeping 
Acta2 Mouse 
AGATCTGGCACCA
CTCTTTC 
GTGAGTCACACCA
TCTCCAG 
Contractile vSMC 
Myocd Mouse 
ACTCCTGGATGTC
CTCATTG 
GTTGGCGTAGTG
ATCGAAG 
Contractile vSMC 
Tagln Mouse 
AGTATGACGAGG
AGCTGGAG 
AAGAATTGAGCC
ACCTGTTC 
Contractile vSMC 
Cnn1 Mouse 
TCATCAAAGCCAT
TACCAAG 
TGCCTTCTCTCAA
CTTCTCC 
Contractile vSMC 
Smtn Mouse 
GCAAGGCCATGA
TTGAGAAG 
CAGCAACATCTGC
TTGATGC 
Contractile vSMC 
Tagln Mouse 
AGTATGACGAGG
AGCTGGAG 
AAGAATTGAGCC
ACCTGTTC 
Contractile vSMC 
Myh11 Mouse 
CTGAGGGAGCGA
TACTTCTC 
TGTAGCATGCTTC
TGTAGGC 
Contractile vSMC 
Mmp2 Mouse 
ACTACGATGATGA
CCGGAAG 
TCGGAAGTTCTTG
GTGTAGG 
MMP 
Mmp3 Mouse 
GGATTTGCCAAG
ACAGAGTG 
ATAGGCATGAGC
CAAGACTG 
MMP 
Mmp9 Mouse 
CTCAAGTGGGAC
CATCATAAC 
CGACACCAAACTG
GATGAC 
MMP 
Mmp12 Mouse 
AGCCACACATATC
CCAGGAGCA 
TCCTGCCTCACAT
CATACCTCCA 
MMP 
Il6 Mouse 
TCAATTCCAGAAA
CCGCTATG 
GTCTCCTCTCCGG
ACTTGTG 
Inflammatory 
Ccl2 Mouse 
GGCTCAGCCAGA
TGCAGTTA 
CTTCTTTGGGACA
CCTGCTG 
Inflammatory 
Cd34 Mouse 
AGGCTGATGCTG
GTGCTAG 
AGTCTTTCGGGAA
TAGCTCTG 
Vascular 
progenitor 
Cd45 Mouse 
GAGGTGTCTGAT
GGTGCAAG 
TGTATTCCACTAA
AGCCTGATGAA 
Bone marrow 
derived 
Pdgfra Mouse 
GGTCCCAACCTGT
AATGAAG 
GTAAATGGGACC
TGACTTGG 
Adventitial 
fibroblast 
Cd31 Mouse 
GTCATGGCCATG
GTCGAGTA 
CTCCTCGGCATCT
TGCTGAA 
Endothelial 
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Table 5: Human RT-qPCR primer sequences 
 
Gene Species Forward 5'-3' Reverse 5'-3' Type 
HMBS Human 
GGTTGTTCACTCC
TTGAAGG 
TTCTCTGGCAGGG
TTTCTAG 
Housekeeping 
YWHAZ Human 
CGTTGTAGGAGC
CCGTAGGTCAT 
TCTGGTTGCGAAG
CATTGGG 
Housekeeping 
HPRT1 Human 
GTAATTGGTGGA
GATGATCTCTCAA
CT 
TGTTTTGCCAGTG
TCAATTATATCTTC 
Housekeeping 
ACTA2 Human 
AGATCTGGCACCA
CTCTTTC 
GTGAGTCACACCA
TCTCCAG 
Contractile vSMC 
MYOCD Human 
CCAACAACCCTCA
CTTTCTG 
AGAATGGGGAGA
GAAGCTTG 
Contractile vSMC 
TAGLN Human 
TCTTTGAAGGCAA
AGACATGG 
TTATGCTCCTGCG
CTTTCTT 
Contractile vSMC 
CNN1 Human 
GTCCACCCTCCTG
GCTTT 
AAACTTGTTGGTG
CCCATCT 
Contractile vSMC 
SMTN Human 
GGCAGTATGAAG
ACCACATTC 
CACTACTGGTGCT
GAGTAGGG 
Contractile vSMC 
MMP2 Human 
ACTACGATGATGA
CCGGAAG 
TCGGAAGTTCTTG
GTGTAGG 
MMP 
MMP3 Human 
CTGGGCTATCAGA
GGAAATG 
CTTATCAGAAATG
GCTGCATC 
MMP 
MMP9 Human 
TTGACAGCGACA
AGAAGTGG 
GCCATTCACGTCG
TCCTTAT 
MMP 
MMP12 Human 
CACACCTGACATG
AACCGTG 
ATGCCAGATCCAG
GTCCAAA 
MMP 
IL6 Human 
GGTACATCCTCGA
CGGCATCT 
GTGCCTCTTTGCT
GCTTTCAC 
Inflammatory 
CCL2 Human 
AAGATCTCAGTGC
AGAGGCTCG 
TTGCTTGTCCAGG
TGGTCCAT 
Inflammatory 
JUN Human 
ATCAAGGCGGAG
AGGAAGCG 
TGAGCATGTTGGC
CGTGGAC 
AP-1 TF 
P65 Human 
ATCCCATCTTTGA
CAATCGTGC 
CTGGTCCCGTGAA
ATACACCTC 
NFkB TF 
G6PD Human 
GCCAACCGCCTCT
TCTACCT 
GATGATGCGGTTC
CAGCCTA 
Negative 
regulator of 
contractile VSMC 
genes 
KLF4 Human 
ATCTTTCTCCACG
TTCGCGTCTG 
AAGCACTGGGGG
AAGTCGCTTC 
Negative 
regulator of 
contractile VSMC 
genes 
IL1R1 Human 
CCTGCTATGATTT
TCTCCCAATAAA 
AACACAAAAATAT
CACAGTCAGAGG
TAGAC 
IL-1αreceptor 
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Table 6: Mouse ChIP-qPCR Primers 
 Gene Species Forward 5'-3' Reverse 5'-3' Region 
Magea2 mouse 
TTGGTGGACAGG
GAAGCTAGGGGA 
CGCTCCAGAACAA
AATGGCGCAGA 
Promoter 
ActB mouse 
CCACATAGGAGTC
CTTCTG 
ACCTGTTACTTTG
GGAGTGG 
Promoter 
Acta2 mouse 
TATAACCCTTCAG
CGTTCAG 
TCATTCAGATTCC
CACAGAC 
Promoter 
Tagln mouse 
TGCCCATAAAAG
GTTTTTCC 
GAAGTCTGCTTGG
CTCACC 
Promoter 
Cnn1 mouse 
GTCTGTGTCATCT
GCACCTC 
CACAGGTAGGAG
GGATTTTG 
Promoter 
Myocd mouse 
CCGGCTGTTAAGA
CTCCTG 
TTCCTGGCTGATG
TCATAGG 
Promoter 
Smtn mouse 
AGAGAATTGGCT
GGGACAG 
GACCCGGTAGAT
GCAGTAGAG 
Promoter 
Mmp2 mouse 
AGTATCCCTCCAA
AGGCAAG 
TTCTTCCCACCTCT
TCTTCC 
Promoter 
Mmp3 mouse 
AAGAAGGTGGAC
CTAGAAGGAG 
CACTGTCATGCAA
TGGGTAG 
Promoter 
Mmp9 mouse 
AAGGCTGAGACC
ACTGAATG 
GTGATTCCATGGT
TTGGTG 
Promoter 
Mmp12 mouse 
GGCTTTAAGGGA
ACTTGCAG 
ACTGTCATTCATG
GGAGCAG 
Promoter 
Il6 mouse 
CCCACCCTCCAAC
AAAGATT 
GCTCCAGAGCAG
AATGAGCTA 
Promoter 
Ccl2 mouse 
CTTCCACTTCCTG
GAAACAC 
GGCAGCCTTTTAT
TGTAAGC 
Promoter 
Promoter = within 500bp of transcriptional start site. 
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Table 7: Human ChIP-qPCR primer sequences 
 
Gene Species Forward 5'-3' Reverse 5'-3' Region 
MAGEA2 Human 
CCTACACCAACAC
CATCTTC 
AGAATCTCGCTGT
CCTCTG 
Promoter 
ACTB Human 
CCATTGGCAAGA
GCCCGGCT 
GACACCCCACGCC
AGTTCGG 
Promoter 
ACTA2 Human 
CCAGTGGAATGC
AGTGGAAGAGA 
AGGGAAGCTGAA
AGCTGAAGGGTT 
Promoter 
TAGLN Human 
TAGGTCCTCAGGA
AAGGTTG 
AATAGAGTCTGG
CTGGAGAGAG 
Promoter 
CNN1 Human 
TGCTTCAAGACTC
CAGAGAG 
GACAGAGACCAG
CCTTCTTC 
Promoter 
MYOCD Human 
TCTCCAGATGCGC
CGTGTCA 
TCAGGGCACTGG
CAGAGACGA 
Promoter 
SMTN Human 
GTATGAATTGGCA
GGAGGTG 
TGTCATTCCCCCA
GGTATAG 
Promoter 
MMP2 Human 
ACGTAGAGGCCA
GGAGTAGC 
GCCTGAGGAAGT
CTGGATG 
Promoter 
MMP3 Human 
GCAAGGATGAGT
CAAGCTG 
TGTCTCTATGCCT
TGCTGTC 
Promoter (IL-1-
responsive 
element 
(Quinones et al., 
1994), cJUN bs 
(Clark et al., 
2008)) 
MMP9 Human 
AGAGAGGAGGAG
GTGGTGTAAGC 
ACCCCACCCCTCC
TTGAC 
Promoter 
MMP12 Human 
CAGACGACATGG
ATCAATTAGC 
GTAGGATAGGTG
GACGTAGAGGC 
Promoter 
IL6 Human 
CGTGCATGACTTC
AGCTTTAC 
TGCAGCTTAGGTC
GTCATTG 
Promoter 
CCL2 Human 
CCGAGAGGCTGA
GACTAACC 
CTATGAGCAGCA
GGCACAGA 
Promoter 
IL6 Human 
TAGAGCTTCTCTT
TCGTTCCCGGT 
TGTGTCTTGCGAT
GCTAAAGGACG 
NFkB, cJUN bs 
(Gomard et al., 
2010). 
CCL2 Human 
CCTGGAAATCCAC
AGGATGC 
CGAGAGTGCGAG
CTTCAG 
NFkB, cJUN bs 
(Sutcliffe et al., 
2009). 
MMP3 Human 
CATCAAAGGAAT
GGAGAACC 
GACAGAGGTTTC
ACTATGTTGC 
NFkB bs 
(Borghaei et al., 
2004). 
‡bs, binding site. Promoter = within 500bp of transcriptional start site. 
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2.6 ChIP for histone modifications 
 
Cultured VSMCs and ex vivo tissue from the medial layer of the aorta were washed in PBS and fixed 
in 1% formaldehyde in PBS for 10 minutes at room temperature before quenching with 0.125 mM 
glycine for 5 minutes. Subsequently, the cells/tissue were washed three times in PBS.  Ex vivo tissue 
was snap frozen and homogenised using a metal mortar. The cells/homogenised tissue were 
resuspended in nuclear lysis buffer (50 mM Tris-HCl pH 8.1, 10 mM EDTA pH 8.0, 1% SDS) 
supplemented with protease inhibitors (Roche) and incubated on ice for a minimum of 5 minutes.  
 
A Bioruptor Pico sonication device (Diagenode) set at high power, 30 seconds on and 30 seconds off 
for 15 to 20 cycles, was used to fragment the chromatin to approximately 0.2-1 kb. The sonicated 
chromatin was centrifuged at 12,000 g at 4 0C for 15 minutes to remove insoluble debris. The DNA 
concentration was determined using a Nanodrop ND-1000 spectrometer. Fragmentation of 
chromatin was confirmed by Bioanalyzer analysis (DNA High Sensitivity Analysis Kit, Agilent 
Technologies) of a 0.5 μg aliquot after de-cross-linking. To de-cross link, the 0.5 μg aliquots were 
incubated in elution buffer (20 mM Tris-HCl pH8.0, 5mM EDTA pH 8.0, 50 mM NaCl, 1% SDS, 50 
μg/ml Proteinase K, 100 μg/ml RNase A) at 37 0C for an hour and then at 68 0C overnight.  
 
Sonicated chromatin (2-20 μg) was incubated with the appropriate antibodies (Table 8) or control IgG 
(IgG of the same species as the primary antibody) with BSA (100 μg/ml) and yeast tRNA (20 μg/ml), 
diluted 10x in RIPA-140 (10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 
0.10% SDS, 0.10% sodium deoxycholate, 140 mM NaCl) supplemented with protease inhibitors 
(Roche), overnight at 4 ֯C. 10% of the chromatin used for each ChIP was directly de-cross-linked as 
described above. 600 μg of protein A and protein G magnetic beads (Life Technologies), washed 
twice in RIPA-140 buffer were added to the samples and incubated at 4 ֯C on a rotating wheel for 2 
hours. Samples were then washed twice in RIPA-140, twice in RIPA-500 (10 mM Tris-HCl pH 7.5, 1 
mM EDTA pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 0.10% SDS, 0.10% sodium deoxycholate, 500 mM 
NaCl), RIPA-LiCl (10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 0.10% 
SDS, 0.10% sodium deoxycholate, 250 mM LiCl) and twice in TE (10 mM Tris-HCl pH 8.1, 1 mM EDTA 
pH 8.0) before being resuspended in 200 μl of elution buffer. Samples were incubated in elution 
buffer at 37 ֯C for an hour and then 68 ֯C overnight. The gDNA samples were purified using a gel 
extraction kit (Qiagen) following the manufacturer's protocol and eluted in 50-100 μl of TE. The 
purified gDNA was analysed by RT-qPCR as described in section 2.5.  
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Table 8: Antibodies used for ChIP of histone modifications 
 
Protein Size Species‡ mg/ml Dilution Product ID 
H3K9me2 17 kDa 
Mouse 
mAb 
1 1:150 Abcam (#ab1220) 
H3K4me3 17 kDa 
Rabbit 
pAb 
1 1:300 
Abcam 
(#ab8580) 
H3K27me2/3 17 kDa 
Mouse 
mAb 
1 1:150 
Active Motif 
(#39535) 
‡mAb, monoclonal antibody; pAb, polyclonal antibody. 
 
2.7 UNC0638 (UNC)/SP600125/IL-1α/TNFα treatment 
 
Mouse and human VSMCs were seeded in 12-well plates in growth medium at a ratio of 1:2. When 
the cells became 70 % confluent the medium was changed to chemically defined medium (CDM; 1:1 
mixture of Iscove’s modified Dulbecco’s medium plus Ham's F-12 medium, both supplemented with 
GlutaMAX (Gibco, Life technologies), 5 mg/ml bovine serum albumin, 450 μM monothioglycerol, 15 
mg/ml Transferrin, 7 mg/ml Insulin, 1 x lipids (100 x chemically defined lipid concentrate, Gibco Life 
Technologies), 1 x penicillin/streptomycin (100 x penicillin/streptomycin, Gibco Life Technologies). 24 
hours later the medium was replaced with CDM with 1 μM UNC0638 (Tocris) and/or 10 μM 
SP600125 (Abcam) or vehicle control DMSO, a further 24 hours later this was refreshed. After 48 
hours of UNC0638/SP600125/UNC0638+SP600125/DMSO treatment, 2 ng/ml of human recombinant 
IL-1α (Peprotech) or 90 ng/ml of human recombinant TNFα (Peprotech) was added to the 
appropriate wells. After 6 hours of IL-1α or TNFα stimulation, unless otherwise indicated in the figure 
legends, the cells were washed twice with PBS before harvest. To harvest, cells were dissociated with 
Trypsin (Sigma Aldrich) and washed twice with PBS. Cell pellets were frozen at -80 ֯C.  
 
Cytotoxicity of small molecule inhibitors (UNC0638, SP600125) was assessed after VSMCs were 
treated as described above with a hemocytometer and Trypan Blue staining (T8154, Sigma Aldrich) or 
MTT cell viability assay (V13154, ThermoFisher Scientific). Neither UNC0638 and SP600125 alone or 
in combination led to significant loss of cell viability compared to vehicle control.  
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2.8 DQ-gelatin ECM degradation assay 
 
Immediately after UNC0638 and/or IL-1α treatment of primary mouse VSMCs, 1 ml of 50 μg/ml of 
DQ-gelatin (Thermofisher Scientific), dissolved in CDM, was added per 9.5 cm2 well. After 2 hours of 
DQ-gelatin treatment the cells were washed twice in CDM before incubating with 300 nM of DAPI in 
PBS for 2 minutes. The cells were then washed once with PBS and mounted in VECTASHIELD Antifade 
mounting medium (Vector laboratories).  
 
Degradation-induced fluorescence was used to measure MMP activity. The DQ-gelatin treated 
VSMCs were imaged using a 20x objective with a fluorescence microscope (ZEISS Axio Vert A.1). The 
corrected total fluorescence (CTF) was quantified using ImageJ software as follows; CTF = [(area x 
mean pixel intensity) - (area x mean pixel intensity of 5 background readings)]/ cell number. Cell 
numbers were determined by counting DAPI stained nuclei. The average CTF of 5 fields of view was 
used to quantify the MMP activity of each sample to limit variability. 
 
2.9 FACS of lineage labelled VSMCs 
 
Labelled tamoxifen injected Myh11-CreERt2, ROSA26-EYFP+ male mice were culled by 
CO2 asphyxiation. Carotid arteries were removed, dissected free from adipose and connective tissue 
and digested in 2.5 mg/ml of Collagenase Type IV (Life Technologies) and 2.5 U/ml of porcine 
pancreatic elastase (Worthington) in DMEM at 37 ֯C, 5 % CO2 (0.5 ml per carotid artery) for 
approximately 2 hours, mixing every 20 minutes, until a single cell suspension was reached. The 
dissociated cells were washed once in PBS, resuspended in 1 % BSA in PBS, filtered through a 40 μm 
cell strainer and index-sorted on an Aria-fusion flow cytometry-assisted cell sorter (BD Bioscience) 
with help from the NIHR Cambridge BRC Cell Phenotyping Hub. Isolated EYFP+ cell pellets were 
resuspended in 500 μl of TRIzol and stored at -80 ֯C. 
 
2.10 RT-qPCR analysis of mRNA levels from lineage labelled YFP+ VSMCs isolated by FACS 
 
Total RNA was extracted with TRIzol and cleaned using a RNeasy Micro Kit (Qiagen) following the 
manufacturer's instructions. RNA integrity was analysed using an Agilent 2100 Bioanalyzer and RNA 
6000 Pico Kit (Agilent Technologies). 2.5 ng of total RNA with a RIN value >8 was reverse transcribed 
using a QuantiTect Reverse Transcription kit (Qiagen), according to the manufacturer's directions. For 
quantification, cDNA (diluted 1:4) was amplified, in technical duplicates, with a QuantiTect SYBR 
Green PCR kit (Qiagen) and primer pairs listed in Table 4, using a Corbett Life Science Rotor Gene 
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6000 PCR system. RT-qPCR-obtained values were normalised to the average of two housekeeping 
genes (HMBS and YWHAZ or HPRT1).  
 
2.11 Tissue processing for immunofluorescent staining 
 
Mice were culled by CO2 asphyxiation. The arteries were removed and dissected free from adipose 
and connective tissue, fixed with 4% (v/w) paraformaldyhyde (Sigma-Aldrich) in PBS for 20 minutes at 
room temperature, washed for 5 minutes in PBS, incubated in 30% sucrose in PBS at 4 ֯C overnight. 
Tissue was then transferred to a 50:50 solution of 30% sucrose in PBS: O.C.T (VWR) for one hour at 
room temperature before a final incubation of 1 hour in O.CT. Samples were then embedded in O.C.T 
using plastic molds and frozen using dry ice before storage at -80 ⁰C. The arteries were then cut 
transversely into 14 µm thick sections, mounted on SuperFrost Plus Adhesion microscope slides 
(Thermo Scientific) and stored at -80 ֯C. 
 
2.12 Immunofluorescent staining of cryosections 
 
Serial cryosections were rinsed in PBS, permeabilised in 0.5 % Triton x-100 in PBS for 30 minutes at 
room temperature and blocked for 1 hour at room temperature in 1% BSA, 10 % normal goat serum, 
0.1 % Triton x-100 in PBS. Sections were then incubated with anti-H3K9me2 antibody conjugated to 
Alexa Fluor-647 (1:100 ab203851, Abcam) in blocking buffer overnight at 4 ֯C. The sections were then 
washed twice for 5 minutes in PBS before staining the nuclei with 300 nM of DAPI in PBS for 10 
minutes. The sections were then washed twice in PBS and mounted in RapiClear 1.52 (Sunjinlab). 
 
2.13 Imaging and image processing of immunofluorescent stained cryosections 
 
Immunofluorescent stained cryosections were imaged using confocal laser scanning 
microscopy (Leica SP5 or SP8) with laser lines and detectors set for maximal sensitivity without 
spectral overlap for DAPI (405 laser, 417-508 nm), CFP (458 laser, 454-502 nm), GFP (488 laser, 498-
506 nm), YFP (514 laser, 525-560 nm), RFP (561 laser, 565-650 nm) and Alexa Fluor 647 (633 laser, 
650-700 nm).  Cryosections were imaged using a 20x oil objective, and data were acquired at an 
optical section resolution of 1024 x 1024. Image stacks were collected over a 12 μm stack thickness 
with 1 μm z-steps.  
 
VSMCs were identified by fluorescent Myh11-lineage labelling and their nuclei defined by DAPI 
staining. Ten individual Myh11-lineage labelled nuclei were chosen per cryosection with Alexa Fluor 
647 omitted to eliminate bias. Three cryosections per CCA were analysed to limit variability due to 
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the immunofluorescent staining protocol itself. ImageJ software was used to measure the mean pixel 
intensity of H3K9me2-Alexa Fluor 647 staining of each Myh11-lineage labelled nuclei to denote 
H3K9me2 signal. H3K9me2 signal of each Confetti+ or EYFP+ nucleus is relative to the average 
Confetti+ or EYFP+ nuclear mean H3K9me2 signal of the control samples. 
 
2.14 G9A SiRNA knock down 
 
300,000 cultured human VSMCs were plated per well of a 6-well plate in VSMC growth medium. 8 
hours after plating the medium was changed to CDM BSA without penicillin/streptomycin. 24 hours 
after plating, the cells were transfected with either a 100 nM pool of siRNA targeted against G9A (sc-
43777, Santa Cruz) or a 100 nM pool of control scrambled siRNA (sc-37007, Santa Cruz) using 
HiPerfect transfection reagent (Qiagen), following the manufacturer's protocol (12 μl of HiPerfect 
was used per transfection). 48 hours after transfection the cells were treated with or without 2ng/ml 
of human recombinant IL-1α (Peprotech) before harvest 6 hours later. To harvest, cells were 
dissociated with Trypsin (Sigma) and washed twice with PBS. Cell pellets were frozen at -80 ⁰C. 
 
2.15 ChIP for NFkB-p65 and AP-1-cJUN 
 
3 to 4 million cultured human VSMCs were used per ChIP. Human VSMCs were washed in PBS and 
fixed with 1% formaldehyde and Cross-link gold (Diagenode) following the manufacturers protocol. 
Fixed cells were incubated at room temperature for 30 minutes, then quenched with 0.125 M glycine 
for 15 min at room temperature. The cells were then lysed using buffers from the iDeal ChIP-seq Kit 
for Transcription Factors (Diagenode), following the manufacturer's instructions. The chromatin was 
sheared using a Bioruptor Pico sonication device (Diagenode) set at high power, 30 seconds on and 
30 seconds off for 20 cycles, to fragment the chromatin to approximately 0.2-1 kb. Fragmentation of 
chromatin was confirmed by Bioanalyzer analysis (DNA High Sensitivity Analysis Kit, Agilent 
Technologies) of a 0.5 μg aliquot after de-cross-linking. To de-cross-link, the 0.5 μg aliquots were 
incubated in elution buffer (20 mM Tris-HCl pH8.0, 5mM EDTA pH 8.0, 50 mM NaCl, 1% SDS, 50 
μg/ml Proteinase K, 100 μg/ml RNase A) at 37 0C for an hour and then at 68 0C overnight. Chromatin 
immunoprecipitation was carried out using an iDeal ChIP-seq Kit for Transcription Factors 
(Diagenode), using the appropriate antibodies (Table 9) or control IgG, according to the 
manufacturer's protocol. The gDNA samples were purified using iPure magnetic beads (Diagenode) 
and eluted in 40 μl of the elution buffer provided in the iDeal ChIP-seq Kit for Transcription Factors. 
The purified gDNA was analysed by RT-qPCR as described in section 2.5.  
 
Table 9: Antibodies used for ChIP for NFkB-p65 and AP1-cJUN 
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Protein Size Species‡ mg/ml Dilution Product ID 
NFkB-p65 64 kDa 
Rabbit 
pAb 
ND 1ul per IP 
Diagenode 
(#C15310256) 
cJUN 43 kDa 
Rabbit 
pAb 
1 5μg per IP 
Abcam 
(#ab31419) 
‡ pAb, polyclonal antibody; ND, not determined. 
 
2.16 NFkB-p65 immunofluorescent staining of cultured VSMCs 
 
Primary human VSMCs were treated with 1 μM UNC0638 or vehicle control DMSO for 48 hours as 
previously described before being stimulated with 2 ng/ml of IL-1α or 90 ng/ml of TNFα for one hour. 
The cells were then washed twice with PBS and fixed with 4 % paraformaldyhyde for 10 minutes at 
room temperature. Cells were subsequently incubated with 0.5 % Triton-X100 (Sigma) for 20 minutes 
at room temperature before being washed three times with PBS and blocked with 10% normal goat 
serum (Dako) in PBS for 1 hour at room temperature. Cells were then incubated with NF-kB p65 
antibody diluted 1:100 in blocking buffer (sc-372, Santa Cruz) for 2 hours at room temperature before 
being washed three times with blocking buffer. The cells were then incubated with Alexa-Fluor488-
conjugated goat anti-rabbit IgG (ab150077, Abcam) diluted 1:1000 in blocking buffer at room 
temperature for 1 hour and washed twice with PBS. After incubating the cells with 300 nM of DAPI in 
PBS for 2 minutes, the cells were washed once with PBS and mounted in VECTASHIELD Antifade 
mounting medium (Vector laboratories).  
 
The staining specificity was determined by omitting the primary antibody. The cells were imaged 
using a 10 x objective with a fluorescent microscope (ZEISS Axio Vert A.1). The nuclear/cytoplasmic 
ratio of p65 was measured using ImageJ software (http://dev.mri.cnrs.fr/projects/imagej-
macros/wiki/Intensity_Ratio_Nuclei_Cytoplasm_Tool). The nuclear/cytoplasmic ratio measures the 
mean grey value of nuclear area defined by DAPI divided by the mean grey value of the cytoplasmic 
area. The average nuclear/cytoplasmic p65 ratio of 3 fields of view was used to calculate the 
nuclear/cytoplasmic ratio of p65 of each sample to limit variability. 
2.17 Statistics. 
 
Data are expressed as mean ± SEM of ≥3 independent experiments (indicated in figure legends). 
unpaired student t-tests or, if groups were larger than two, one-way ANOVA with Bonferroni 
correction were performed to determine significance using GraphPad Prism 4.02 (GraphPad 
Software, Inc., La Jolla, CA, USA). Nested ANOVA was applied to immunofluorescence data sets 
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where multiple measurements per sample were available. Changes were accepted to be significant 
when the P-value was below 0.05.  
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CHAPTER 3 - RESULTS: Assessing the role of 
H3K9me2 in maintaining the contractile VSMC state.  
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3.1 Introduction 
 
VSMCs are highly differentiated and specialised yet retain the capacity to undergo profound and 
reversible changes in phenotype. Such VSMC phenotypic switching directly contributes to the 
development and progression of cardiovascular disease, the leading cause of death worldwide. In 
response to injury or inflammation, VSMCs downregulate contractile proteins and upregulate genes 
associated with vascular remodelling, including matrix metalloproteinases (MMPs) and pro-
inflammatory cytokines. However, the epigenetic mechanisms which regulate these changes in gene 
expression remain unclear. 
 
H3K9me2, an epigenetic mark associated with transcriptional repression (Hublitz et al., 2009; Peters 
et al., 2003; Tachibana et al., 2005; Wen et al., 2009), has been reported to influence smooth muscle 
cell behaviour (Yang et al., 2012), cell fate commitment (Cloos et al., 2008) and cell reprogramming 
(Chen et al., 2013). H3K9me2 is found both at isolated regions near genes and in large megabase 
blocks, termed Large Organised Chromatin K9 domains.  These H3K9me2-marked domains cover up 
to 46% of the genome in terminally differentiated cell types compared to only 4% in embryonic stem 
cells (Wen et al., 2009), prompting speculation over the role of H3K9me2 in maintaining cell identity. 
In support of this theory, bulk levels of H3K9me2 appear to diminish during epithelial-mesenchymal 
transition, a process in which cells acquire stem cell like properties (McDonald et al., 2011). 
Furthermore, hematopoietic stem and progenitor cells display lower global H3K9me2 levels 
compared to mature bone marrow cells (Li et al., 2018). These observations suggest that H3K9me2 
deposition is patterned according to cell identity and must be reset to specify new fates. In support 
of this notion, global loss of H3K9me2 has been shown to improve the reprogramming efficiency of 
human cells by heterochromatin relaxation and facilitating transcription factor binding (Chen et al., 
2013; Rodriguez-Madoz et al., 2017).  
 
Interestingly, H3K9me2 inhibition attenuates the contractility of different smooth muscle cell types 
(Yang et al., 2012) and reduced levels of H3K9me2 have been observed in VSMCs from human 
atherosclerotic lesions compared to healthy aortic tissue in patients (Greißel et al., 2015). 
Collectively, these findings indicate H3K9me2 could be involved in maintaining the contractile VSMC 
state, a role that has not been explored. Expression levels of contractile marker genes gradually 
decrease when VSMCs are cultured (Rensen et al., 2007). Therefore, I will compare H3K9me2 levels 
in ex vivo VSMCs directly isolated from mouse aorta to cultured murine VSMCs. VSMCs are also 
known to downregulate contractile genes in response to inflammation and/or injury (Rensen et al., 
2007). Therefore, I will use VSMC-lineage labelled mice, as described in section 1.9.1, to assess global 
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levels of H3K9me2 in VSMCs within ligated and atherosclerotic common carotid arteries (CCAs) 
compared to those within control tissue. 
 
Aims: 
 
1. Assess global changes in H3K9me2 upon loss of the contractile VSMC state using in vitro and 
in vivo models of VSMC phenotypic switching. 
2. Assess local levels of H3K9me2 at contractile VSMC genes upon loss of the contractile VSMC 
state using an in vitro model of VSMC phenotypic switching and chromatin 
immunoprecipitation. 
3. Test the functional role of H3K9me2 on contractile VSMC gene expression in vitro using small 
molecule inhibition of the main H3K9 di-methyltransferases G9A/GLP. 
 
3.2 Results 
 
3.2.1 Global levels of H3K9me2, and the associated histone methyltransferase GLP, are reduced in 
cultured relative to ex vivo VSMCs, concomitant with loss of the contractile state. 
 
To test whether global levels of H3K9me2 are affected by VSMC state, mouse VSMCs (mVSMCs) 
freshly isolated from the aortic media (ex vivo) were compared to those cultured for four passages 
(Figure 3.1).  
 
 
Figure 3.1: Schematic of in vitro model of VSMC phenotypic switching. The medial VSMC layer from 8-12 week 
old C57BL/6 mice was freshly isolated from the aortic media (ex vivo) and compared to enzymatically digested 
medial VSMC layer cultured to passage 4. The triangle represents loss of contractile VSMC gene expression 
upon culture.   
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Upon culture, mVSMCs downregulate contractile VSMC genes encoding structural (Cnn1, Tagln, 
Acta2 and Smtn) and regulatory proteins (Myocd) (Figure 3.2 A). Interestingly, western blot analysis 
revealed a 5-fold reduction of H3K9me2 in cultured compared to ex vivo mVSMCs (Figure Figure 3.2 
B, C). H3K9me2 is catalyzed by the G9A/GLP enzymatic complex (Shinkai and Tachibana, 2011). Loss 
of H3K9me2 was accompanied by a decrease in GLP at both the protein (98-fold) (Figure 3.2 B-D) and 
mRNA level (2.4-fold) (Figure 3.2 D). In contrast, G9a mRNA showed a modest increase in cultured 
compared to ex vivo mVSMCs (1.6-fold) (Figure 3.2 D), and no difference in G9A protein levels was 
observed (Figure 3.2 B, C). RT-qPCR analysis revealed that histone demethylases (HDMs) targeting 
H3K9me2 were either downregulated upon mVSMC culture or not expressed in ex vivo or cultured 
mVSMCs (Figure 3.2 D). Taken together, these results imply that H3K9me2 is reduced upon loss of 
the contractile VSMC state, which is perhaps explained by repression of GLP, suggesting H3K9me2 is 
involved in regulating VSMC-phenotype.  
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Figure 3.2: Global levels of H3K9me2 are reduced upon culture-induced VSMC phenotypic switching. (A) RT-
qPCR analysis of contractile VSMC gene expression in ex vivo compared to cultured mVSMCs. Data are relative 
to ex vivo mVSMCs and normalised to the average of two housekeeping genes (Hprt1 and Ywhaz). Data 
represent means ± SEM of 4 biological replicates. Asterisks indicate significant differences (P<0.05) in 
expression level in cultured versus ex vivo mVSMCs by unpaired student's t test. (B, C) Representative western 
blot (B) and densitometric analysis (C) of H3K9me2, GLP and G9A in ex vivo and cultured mVSMCs. Data are 
relative to ex vivo mVSMCs and normalised to b-TUBULIN. Data represent means ± SEM of 4 biological 
replicates. Asterisks indicate significant differences (P<0.05) in protein level in cultured versus ex vivo mVSMCs 
by unpaired student's t test. (D) RT-qPCR analysis of known histone demethylases (HDMs) and histone 
methyltransferases (HMT) which target H3K9me2 in ex vivo and cultured mVSMCs. Data are relative to ex vivo 
mVSMCs and normalised to the average of two housekeeping genes (Hprt1 and Ywhaz). Data represent means 
± SEM of 3 to 7 biological replicates. n=4 for Kdm1a, Kdm3a, Kdm3b, Kdm4a, Kdm4b, Kdm4c, Kdm4d, Jhdm1d 
and Phf8 n= 4, n= 7 for Glp and n= 3 for G9a. Asterisks indicate significant differences (P<0.05) in expression 
level in cultured versus ex vivo mVSMCs by unpaired student's t test. 
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3.2.2 Assessing the role of H3K9me2 in VSMC phenotypic switching using in vivo mouse models of 
CVD. 
 
In vivo models of cardiovascular disease were used to investigate the role of H3K9me2 in VSMC 
phenotypic switching. VSMCs were genetically labelled by combining the Myh11-CreERt2 transgene 
(Wirth et al., 2008), which is specifically expressed by mature VSMCs, with the multi-colour ROSA26-
Confetti or single colour ROSA26-EYFP reporter (Gomez and Owens, 2012). Both Myh11-
CreRTt2/ROSA26-Confetti and Myh11-CreERt2/ROSA26-EYFP mice were used to make use of extra 
tissue generated by Dr Joel Chappell from previous experiments and comply with the 3R's of animal 
research. Recombination was induced in healthy mice with a pulse of tamoxifen, which results in 
stable fluorescent protein expression (Nemenoff et al., 2011; Wirth et al., 2008). Expression of the 
lineage reporter was specific to cells in the medial layer of the vasculature (Chappell et al., 2016; 
Gomez and Owens, 2012), where the recombination efficiency was 70-95% for the Confetti reporter 
(Chappell et al., 2016) and 40-60% for the EYFP reporter (Dobnikar et al., 2018). Importantly, the 
specific fluorescent label was stably transferred to all progeny after VSMC proliferation independent 
of the expression status of the Myh11-CreERt2 transgene (Chappell et al., 2016). 
 
3.2.2.1 Global levels of H3K9me2 are reduced in VSMCs upon vascular injury, concomitant with loss 
of the contractile state. 
 
The carotid ligation-injury mouse model of CVD rapidly elicits vessel growth and remodelling 
concomitant with changes in VSMC gene expression, including decreased expression of contractile 
VSMC genes (Ali et al., 2013; Herring et al., 2017; Kumar and Lindner, 1997a). Therefore, this method 
was used to explore whether global levels of H3K9me2 are reduced upon loss of the contractile 
VSMC state. After tamoxifen labelling Myh11-CreERt2/ROSA26-Confetti or Myh11-CreERt2/ROSA26-
EYFP animals, the left common carotid artery (CCA) was ligated and tissues were harvested 1, 3, 5, 7 
and 28 days later (Figure 3.3). 
  
72 
 
 
 
Figure 3.3: Schematic of the mouse carotid ligation model of vascular injury. The left common carotid artery 
(CCA) was ligated in tamoxifen labelled 10-14-week-old male Myh11-CreERt2+/ROSA26-Confetti+ (CFP, YFP, 
RFP, GFP) or Myh11-CreERt2+/ROSA26-EYFP+ mice, and tissues were harvested 1, 3, 5, 7 or 28 days later (D1-
28). 
 
Immunofluorescence staining of CCA cryosections revealed global levels of H3K9me2 were 
significantly reduced in the nuclei of cells expressing the Confetti (Confetti+) or EYFP reporter, which 
are derived from Myh11-expressing VSMCs, seven days following carotid ligation injury compared to 
no surgery controls (Figure 3.4 A, B). To assess the timing of this vascular injury-induced 
downregulation of H3K9me2 in VSMCs, H3K9me2 signal in Confetti+ or EYFP+ nuclei were also 
analysed 1, 3, 5 and 28 days post carotid ligation. Both 1- and 3-days post ligation, H3K9me2 levels in 
Confetti+ and EYFP+ nuclei from ligated CCAs appeared unchanged compared to those within non-
ligated internal control CCAs (Figure 3.4 C). However, levels of H3K9me2 in Confetti+ and EYFP+ 
nuclei began to fall 5 days post ligation (Figure 3.4 C) and were significantly reduced 7 days post 
surgery (Figure 3.4 B). Levels of H3K9me2 in Confetti+ and EYFP+ nuclei appeared downregulated to 
the same level 28 days post surgery as those within 7 day post carotid ligation CCAs compared to 
non-ligated controls (Figure 3.4 C). Previous studies have shown that contractile VSMC genes are 
rapidly downregulated upon vascular injury and are dramatically reduced 7 days post carotid ligation 
compared to non-ligated controls (Herring et al., 2014; Herring et al., 2017; Sayers et al., 2008; Shi et 
al., 2013). However, studies have reported that contractile VSMC genes become upregulated again 
around 9 to 28 days post carotid ligation surgery (Allagnat et al., 2016; Shi et al., 2013). Therefore, 
even though H3K9me2 levels appear reduced upon loss of the contractile VSMC state but H3K9me2 
may not directly influence the expression of contractile VSMC genes.  
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Figure 3.4: Global levels of H3K9me2 are reduced in VSMCs upon vascular injury. (A) Immunofluorescence 
staining for H3K9me2 in representative 12 μm LCCA cryosections from ligated (D7 post surgery) and non-
ligated control mice. Signals for H3K9me2-Alexa Fluor 647 (magenta), Confetti reporter proteins (red, blue, 
yellow, green) and nuclei counter stained with DAPI (white) are shown. Scale bars, 100 μm. A, adventitia; NI, 
neo-intima; M, media; L, Lumen. White dashed lines outline the media as determined by auto-fluorescence of 
the inner and outer elastic lamina. (B) Box plot showing H3K9me2 signal in Confetti+ or EYFP+ VSMC nuclei as 
determined by immunofluorescence analysis of LCCAs from ligated (D7 post surgery) and non-ligated control 
mice. n= 5 animals per group. The asterisk indicates significant difference (P<0.05) in H3K9me2 levels in ligated 
versus no surgery control by nested ANOVA testing. (C) Box plot showing H3K9me2 signal in Confetti+ or EYFP+ 
VSMC nuclei as determined by immunofluorescence analysis of ligated left (L) and non-ligated right internal 
control (IC) CCAs. At D28, the HK9me2 signal was quantified separately for the media (LM) and intima (LI). n= 2 
animals per group. For immunofluorescence analyses, each dot shows H3K9me2 signal intensity in one 
Confetti+ or EYFP+ nucleus.  
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3.2.2.2 Global levels of H3K9me2 are reduced in VSMCs within atherosclerotic plaque compared to 
healthy vascular tissue, concomitant with loss of the contractile state. 
 
H3K9me2 levels in VSMCs were further analysed using a mouse model of atherosclerosis. Myh11-
CreERt2/ROSA26-Confetti animals were crossed onto an ApoE-/- background. Recombination was 
induced in 8-12-week-old animals prior to feeding them either an atherosclerosis-inducing high fat 
diet (HFD) (21% fat, 0.2% cholesterol) or control safe diet (SD) for 3.5 to 7 months (Figure 3.5).  
 
 
 
Figure 3.5: Schematic of the mouse model of atherosclerosis. 8-12-week-old Myh11-CreERt2+/ROSA26-
Confetti, ApoE-/- male mice were labelled using tamoxifen prior being fed either a safe (SD) or high fat diet 
(HFD) for 3.5-7 months before the CCAs were harvested. 
 
Western blot analysis comparing the aorta from mice fed a HFD, which contained many visible 
atherosclerotic lesions, to those from mice fed a SD, which contained little or no plaque, revealed 
that loss of H3K9me2 upon HFD correlates with reduced expression of MYH11 (Figure 3.6 A, B). 
Immunofluorescence staining of their LCCAs demonstrated VSMC nuclei within plaque from mice fed 
a HFD exhibited decreased levels of H3K9me2 compared to medial contractile VSMCs from mice fed 
a SD (Figures 3.6 C, D). VSMCs within different regions of atherosclerotic plaque are known to 
express different levels of contractile VSMC genes. For instance, VSMCs within the plaque core 
express lower levels of contractile VSMC genes compared to those within the media or cap (Bennett 
et al., 2016; Chappell et al., 2016). Therefore, levels of H3K9me2 in Confetti+ nuclei within the plaque 
media, core and cap were compared but no significant differences were observed (Figure 3.6 C, D). 
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Figure 3.6: Global levels of H3K9me2 are reduced in VSMCs within atherosclerotic lesions compared to 
healthy vessels. (A, B) Representative western blots (A) and densitometric analysis (B) for MYH11 and 
H3K9me2 in whole aorta's, with adventitia and endothelial cells removed, from mice either fed a SD (black 
76 
 
bars) or HFD (white bars). Data are normalised to ACTB. Data represent means ± SEM of 3 biological replicates. 
The asterisk indicates significant difference (P<0.05) in protein level in HFD versus SD by unpaired student's t 
test. (C) Immunofluorescence staining for H3K9me2 in representative 12 μm LCCA cryosections from mice fed 
either a SD or HFD. Signals for H3K9me2-Alexa Fluor 647 (magenta), Confetti reporter proteins (red, blue, 
yellow, green) and nuclei counter stained with DAPI (white) are shown. Scale bars, 200 μm. The two outer 
white dashed lines outline the media as determined by auto-fluorescence of the inner and outer elastic lamina, 
the third inner dashed lined outlines the DAPI positive plaque. (D) Box plot shows H3K9me2 signal in Confetti+ 
VSMC nuclei as determined by immunofluorescence analysis of LCCAs from mice either fed a SD or HFD. For 
mice fed a HFD, the HK9me2 signal was quantified separately for the plaque media (orange dots), core (red 
dots) and cap (brown dots). n= 3 animals for SD, n= 5 animals for HFD. The asterisks indicate significant 
differences (P<0.05) in H3K9me2 levels versus SD Medial (black dots) by nested ANOVA testing. Each dot shows 
H3K9me2 signal intensity in one Confetti+ or EYFP+ nucleus.  
 
3.2.3 H3K9me2 is enriched at contractile VSMC gene promoters upon culture-induced phenotypic 
switching. 
 
Chromatin Immunoprecipitation (ChIP) was used to analyse local levels of H3K9me2 at contractile 
VSMC gene promoters in ex vivo contractile mVSMCs compared to culture-induced phenotypically 
switched mVSMCs. H3K9me2 was not present at any of the contractile VSMC gene promoters 
analysed in ex vivo cells (Figure 3.7 A) but was recruited to Cnn1 and Myocd upon culture (Figure 3.7 
B), concomitant with their repression (Figure 3.2 A). These findings suggest H3K9me2 enrichment at 
the promoters of Cnn1 and Myocd could be responsible for the culture-induced repression of these 
genes. H3K4me3, a mark widely used to identify active gene promoters, was present at contractile 
VSMC gene promoters in both ex vivo and cultured VSMCS albeit at reduced levels (Figure 3.7 C, D), 
independent of their transcriptional state (Figure 3.2 A). Therefore, H3K4me3 may serve as a 
mechanism for epigenetic cell lineage memory to enable phenotypically modulated VSMCs to switch 
back to their contractile state.  
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Figure 3.7: Local levels of histone modifications at contractile VSMC gene promoters in ex vivo and cultured 
murine VSMCs. (A, B) ChIP-qPCR analysis for H3K9me2 (red bars) and negative control IgG (white bars) in ex 
vivo (A) and cultured mVSMCs (B) showing levels of enrichment at control loci (Magea2, positive and Actb, 
negative) and contractile VSMC genes. Data are relative to 1% input and normalised to enrichment at Magea2 
(red bar). Data represent means ± SEM of 3 to 10 biological replicates. Ex vivo mVSMCs: Magea2 n= 7, Actb n= 
7, Cnn1 n= 5, Tagln n= 4, Myocd n= 7, Acta2 n= 5, Smtn n= 3. Cultured mVSMCs: Magea2 n= 10, Actb n= 10, 
Cnn1 n= 10, Tagln n= 3, Myocd n= 10, Acta2 n= 10, Smtn n= 10. Background levels of H3K9me2 are based on 
enrichment in negative control IgG samples and are indicated by a dashed line. Asterisks indicate significant 
differences (p<0.05) in H3K9me2 levels versus IgG negative control samples by unpaired student's t test. 
Amanda Dalby performed 4 of these ex vivo mVSMC ChIP experiments. (C, D) ChIP qPCR analysis for H3K4me3 
(green bars) and negative control IgG (white bars) in ex vivo (C) and cultured mVSMCs (D) showing levels of 
enrichment at control loci (Magea2, negative and Actb, positive) and contractile VSMC genes. Data are relative 
to 1% input and normalised to enrichment at Actb (green bar). Data represent means ± SEM of 3 biological 
replicates. Background levels of H3K4me3 are based on enrichment at the Magea2 negative control locus and 
are indicated by a dashed line. Asterisks indicate significant differences (P<0.05) in enrichment versus IgG 
negative control samples by unpaired student's t test. 
 
  
78 
 
3.2.4 Loss of H3K9me2 accelerates downregulation of contractile VSMC marker genes upon culture. 
 
To assess whether local enrichment of H3K9me2 at the Cnn1 and Myocd promoters regulates the 
expression of these genes, cultured mVSMCs were treated with UNC0638 (UNC), a small molecule 
inhibitor of the G9A/GLP methyltransferase, to reduce H3K9me2. UNC treatment resulted in a 4-fold 
reduction of global H3K9me2 levels (Figure 3.8 A, B) and effectively eliminated H3K9me2 levels 
locally at contractile VSMC gene promoters (Figure 3.8 C). Compared to mVSMCs directly isolated 
from tissue, initial culture of mVSMCs in serum (P0) resulted in a marked reduction in expression of 
contractile genes, with a further reduction on subsequent passage (Figure 3.8 D). Interestingly, loss 
of H3K9me2 did not relieve repression of Cnn1, Myocd and other contractile VSMC genes in freshly 
cultured cells (P0) or after prolonged culture (P4), but instead exacerbated the culture-induced 
decrease in expression levels (Figure 3.8 D).  
 
 
 
Figure 3.8: Loss of H3K9me2 accelerates downregulation of contractile VSMC marker genes. (A, B) 
Representative western blot (A) and densitometric analysis (B) of H3K9me2 levels in untreated control (-UNC) 
and UNC0638 treated (+UNC) mVSMCs cultured to passage 4 (p4). Data are relative to untreated control (-UNC) 
mVSMCs and normalised to ACTB. Data represent means ± SEM of 3 biological replicates. The asterisk indicates 
significant difference (P<0.05) in H3K9me2 levels in UNC treated (+UNC) versus untreated control (-UNC) 
mVSMCs by unpaired student's t test. (C) ChIP-qPCR analysis for H3K9me2 in untreated control (-UNC, red bars) 
and UNC0638 treated (+UNC, pink bars) mVSMCs cultured to passage 4 (p4) showing levels of enrichment at 
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control loci (Magea2, positive and Actb, negative) and the promoters of contractile VSMC genes compared with 
enrichment observed using negative control IgG (white and grey bars). Background levels of H3K9me2 are 
based on enrichment at the Actb negative control locus and are indicated by a dashed line. Data represent 
means ± SEM of 3 biological replicates. Asterisks indicate significant differences (P<0.05) in H3K9me2 levels in 
UNC treated (+UNC, pink bars) versus untreated control (-UNC, red bars) mVSMCs by one-way ANOVA with 
Bonferroni correction. (D) RT-qPCR analysis of Cnn1, Tagln, Myocd, Acta2, Smtn and Ywhaz transcript levels in 
ex vivo mVSMCs (black bars), untreated control mVSMCs cultured to passage 0 (P0 Cultured -UNC, white bars), 
UNC treated mVSMCs cultured to passage 0 (P0 Cultured +UNC, red bars), untreated control mVSMCs cultured 
to passage 4 (P4 Cultured -UNC, grey bars) and UNC treated mVSMCs cultured to passage 4 (P4 Cultured +UNC, 
pink bars). Data are relative to ex vivo mVSMCs and normalised to the average of two housekeeping genes 
(Hmbs and Ywhaz). Data represent means ± SEM of 3 biological replicates. Asterisks indicate significant 
differences (P<0.05) versus ex vivo VSMCs (black bars) as determined by one-way ANOVA with Bonferroni 
correction. 
 
These results suggest that although H3K9me2 is recruited to VSMC contractile gene promoters in 
cultured cells, H3K9me2 at these promoters is not required for their repression. Rather, the 
accelerated downregulation of contractile VSMC gene expression upon global loss of H3K9me2 
suggests that the modification indirectly regulates these genes to maintain VSMCs in a contractile 
state. 
 
3.3 Summary and Conclusions 
 
In summary, the results described in this chapter point towards a role for H3K9me2 in the regulation 
of VSMC phenotype. Global levels of H3K9me2 were reduced in phenotypically switched VSMCs in 
vitro and in vivo, concomitant with decreased levels of contractile VSMC gene expression. In 
agreement with our findings, work by Yang and colleagues showed that global loss of H3K9me2, by 
pharmacological inhibition of G9A/GLP using BIX01294, blocks the expression of CNN1 and 
contractility in ovine fetal pulmonary artery SMCs (Yang et al., 2012). Furthermore, compared to 
VSMCs from healthy aortic tissue, global levels of H3K9me2 are reduced in human VSMCs from 
atherosclerotic lesions, suggesting H3K9me2 may contribute to VSMC phenotypic switching observed 
in human disease (Greissel et al., 2015). Interestingly, loss of H3K9me2 upon VSMC culture correlated 
with reduced GLP expression (Figure 3.2). Therefore, it is tempting to speculate that GLP may 
regulate H3K9me2 to facilitate VSMC phenotypic switching. 
 
Like human VSMCs, mouse VSMCs within atherosclerotic plaque displayed reduced levels of 
H3K9me2 compared to healthy tissue (Figure 3.6). However, levels of H3K9me2 in VSMC nuclei did 
not fluctuate between the media, core or cap of atherosclerotic plaque, which are known to express 
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different levels of contractile VSMC genes (Figure 3.6). Furthermore, H3K9me2 levels in LCCA VSMC 
nuclei were not significantly reduced until 7 days post carotid ligation compared to non-ligated 
controls (Figure 3.6) whereas contractile VSMC genes have been reported to be significantly reduced 
as soon as 1 day post ligation (Shi et al., 2013). Moreover, I observed the same downregulated levels 
of H3K9me2 in LCCA VSMC nuclei 28 days post ligation compared to 7 days post surgery while 
contractile VSMC genes have been shown to become upregulated around 9 to 28 days post carotid 
ligation (Allagnat et al., 2016; Shi et al., 2013). These observations imply H3K9me2 does not directly 
regulate VSMC contractility. Perhaps, H3K9me2 instead regulates the VSMC response to stimuli such 
as injury or inflammation, which indirectly influences the expression of contractile VSMC genes.  
 
H3K4me3, a mark associated with active gene promoters, was observed at contractile VSMC genes in 
both ex vivo and cultured VSMCs (figure 3.7 C, D), despite downregulation of their expression upon 
culture (Figure 3.2). Similar to this observation,  H3K4me2, a mark linked to active and poised gene 
promoters, has been shown to persist at contractile VSMC genes after phenotypic switching, 
independent of their transcriptional state (Alexander and Owens, 2012). These findings suggest 
H3K4me2/3 may serve as a mechanism for epigenetic cell lineage memory to enable phenotypically 
modulated VSMCs to switch back to their contractile state. 
 
Intriguingly, local H3K9me2 was recruited to a subset of contractile VSMC gene promoters upon 
culture (Figure 3.7 A, B), concomitant with their repression (Figure 3.2). However, global loss of 
H3K9me2 by inhibiting the methyltransferase activity of G9A/GLP, did not upregulate but further 
attenuated contractile VSMC gene expression (Figure 3.8). This finding implies reduced levels of 
H3K9me2 may be causally related to loss of the contractile VSMC state. G9A and GLP are both known 
to have methyltransferase-independent activity and can methylate a range of non-histone proteins 
as discussed in the introduction of this thesis (Shinkai and Tachibana, 2011). For example, G9A can 
act as a positive regulator of transcription by binding to co-activators (Bittencourt et al., 2012). 
Therefore, it is possible that G9A/GLP indirectly act to maintain the expression of contractile VSMC 
genes by altering the activity of a transcriptional activator or repressor at the transcriptional or post 
transcriptional level. 
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CHAPTER 4 - RESULTS: H3K9me2 plays a functional 
role in regulating inflammation/injury-induced gene 
expression in VSMCs. 
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4.1 Introduction 
 
Experiments described in Chapter 3 demonstrate that H3K9me2 is reduced in phenotypically 
switched VSMCs associated with vascular disease. Interestingly, it has been reported that 
phosphorylated p65 (Serine 536), a marker of vascular inflammation, is markedly increased seven 
days post carotid ligation in mice (Song et al., 2011). Furthermore, in ApoE-/- mice, mRNA levels of 
numerous pro-inflammatory cytokines known to elicit the VSMC inflammatory response including 
IL1A, IL1B and TNFA, peak seven days post carotid ligation (Alberts-Grill et al., 2012). With these 
observations in mind, it is tempting to speculate that loss of H3K9me2 in VSMCs seven days post 
carotid ligation (Figure 3.4) is concomitant with vascular inflammation. H3K9me2 often marks genes 
involved in processes that require tight and dynamic regulation, including those involved in the 
inflammatory response (Chen et al., 2009; Fang et al., 2012; Liu et al., 2014; Miao et al., 2007; 
Yoshida et al., 2015). In various cell types, altered levels of H3K9me2 at MMP and inflammatory gene 
promoters have been linked to inflammatory and autoimmune diseases (Chen et al., 2017; El 
Mansouri et al., 2014; Zhong and Kowluru, 2013b). Together, these findings suggest H3K9me2 may 
play a functional role in regulating the inflammatory activation of VSMCs. 
 
The vascular inflammatory response requires bidirectional interaction between resident vascular 
cells and inflammatory cells, which is governed in part by pro-inflammatory cytokines. Bone marrow-
derived, adventitial, endothelial and VSMCs are all able to produce and respond to pro-inflammatory 
cytokines, which stimulate NFκB, AP-1, JAK-STAT and Smad signalling pathways (Schober, 2008; 
Sprague and Khalil, 2009). Activation of such signalling pathways regulate the VSMC inflammatory 
response, prompting VSMCs to secrete a diverse range of pro-inflammatory mediators including 
MMPs, cytokines, chemokines and adhesion molecules. For example, the pro-inflammatory cytokines 
IL-1α and IL-1β induce VSMCs to switch from a contractile to a synthetic phenotype, stimulating NFκB 
and AP-1-dependent transcription of cytokines (e.g. IL6), chemokines (e.g. CCL2) and MMPs (Lim and 
Park, 2014; Nagase et al., 2006).  
 
MMPs comprise a family of proteases capable of degrading major components of the ECM and 
processing a variety of signalling molecules including cytokines and cell surface receptors (Fanjul-
Fernández et al., 2010). MMPs are important for the migration and proliferation of VSMCs, 
infiltration of inflammatory cells and the stability of atherosclerotic plaque (Galis and Khatri, 2002; 
Johnson, 2014; Nagase et al., 2006). For instance, MMP3 and MMP9 promote VSMC migration and 
neointima formation after carotid ligation in mice (Johnson et al., 2011b) and numerous animal 
atherosclerosis studies implicate MMP12 in plaque development and instability (Johnson et al., 
2005b; Liang et al., 2006; Yamada et al., 2008). Interestingly, increased MMP3, MMP9 and MMP12 
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expression has been observed in vulnerable compared to stable human atherosclerotic lesions (Galis 
et al., 1994b; Halpert et al., 1996; Muller et al., 2014; Thomas et al., 2007).  
 
IL6 and CCL2 are also implicated in the progression of CVD (Schober, 2008; Stoner et al., 2013; 
Tousoulis et al., 2016). IL6 attenuates VSMC contractility while promoting VSMC migration, 
proliferation and vascular calcification (Kurozumi et al., 2016; Lee et al., 2016; Watanabe et al., 2004) 
whereas CCL2 recruits leukocytes to the vessel wall and stimulates VSMC migration and proliferation 
(Schober, 2008; Selzman et al., 2002). Human studies have revealed that elevated serum levels of IL6 
and CCL2 are associated with greater CVD risk (Anderson et al., 2013; Biasucci et al., 1999; Piemonti 
et al., 2009; Tousoulis et al., 2016).  
 
The VSMC inflammatory response is associated with the initiation and progression of vascular 
dysfunction and adverse clinical outcome (Schober, 2008; Sprague and Khalil, 2009). Indeed, directly 
reducing inflammation with Canakinumab, an IL1- neutralising antibody, significantly lowered the 
rate of cardiovascular events compared to placebo in patients (Ridker et al., 2017; Weber and von 
Hundelshausen, 2017). Identification of mechanisms that regulate inflammation-associated changes 
in VSMC gene expression is therefore of considerable therapeutic importance. This chapter 
investigates the role of H3K9me2 in regulating the VSMC inflammatory response using an in vitro and 
in vivo model of VSMC inflammatory activation.   
 
Aims: 
 
1. Assess levels of H3K9me2 at MMP and pro-inflammatory VSMC gene promoters, which are 
strongly associated with CVD, using chromatin immunoprecipitation. 
2. Test the functional role of H3K9me2 on MMP and pro-inflammatory VSMC gene expression 
in vitro using small molecule inhibition of the main H3K9 di-methyltransferases G9A/GLP 
prior to IL-1α stimulation. 
3. Test the functional role of H3K9me2 on MMP and pro-inflammatory VSMC gene expression 
in vivo using VSMC-lineage labelled mice and small molecule inhibition of the main H3K9 di-
methyltransferases G9A/GLP prior to carotid ligation injury. 
  
84 
 
4.2 Results 
 
4.2.1 H3K9me2 marks IL-1α-responsive gene promoters in mVSMCs. 
 
ChIP was performed to investigate local levels of H3K9me2 at specific gene promoters implicated in 
the inflammatory activation of VSMCs. Intriguingly, ChIP revealed high levels of H3K9me2 locally at a 
subset of IL-1α-induced genes including Mmp3, Mmp9 and Mmp12 in both ex vivo (Figure 4.1 A) and 
cultured murine VSMCs (mVSMCs) (Figure 4.1 B) compared to the Actb negative control locus, which 
persisted after IL-1α stimulation in cultured mVSMCs (Figure 4.1 C, D). Unlike cultured mVSMCs, ex 
vivo mVSMCs also displayed modest enrichment of the H3K9me2 mark at the promoters of Il6 and 
Ccl2 (Figure 4.1 A, B), which are also induced by IL-1α treatment (Figure 4.1 C). The Mmp2 promoter, 
a gene constitutively expressed by VSMCs and unaffected by IL-1α treatment (Figure 4.1 C), also 
displayed modest levels of H3K9me2 in both ex vivo and cultured mVSMCs (Figure 4.1 A, B). Aberrant 
expression of a number of MMP genes is associated with H3K9me2 depletion at their promoter 
(Miao et al., 2007; Zhong and Kowluru, 2013a). Therefore, we decided to investigate whether 
H3K9me2 plays a role in controlling the level of IL-1α-induced MMP gene expression in cultured 
mVSMCs. 
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Figure 4.1: IL-1α-responsive MMP gene promoters are highly enriched for H3K9me2 in both ex vivo and 
cultured mVSMCs. (A, B) ChIP-qPCR analysis for H3K9me2 (red bars) and negative control IgG (white bars) in ex 
vivo (A) and cultured (B) mVSMCs, showing levels of enrichment at control loci (Magea2, positive and Actb, 
negative) and the promoters of Mmp2, Mmp3, Mmp9, Mmp12, Il6 and Ccl2. Background levels of H3K9me2 are 
based on enrichment at the Actb negative control locus and are indicated by a dashed line. Data represent 
means ± SEM of 3-10 biological replicates (Ex vivo samples: n=3 for Mmp2, Mmp9, Il6, Ccl2; n=4 for Mmp12; 
n=7 for Magea2, Actb, Mmp3. Cultured samples: n=3 for Il6, Ccl2; n=10 for Magea2, Actb, Mmp2, Mmp3, 
Mmp9, Mmp12). Asterisks indicate significant differences (p<0.05) in H3K9me2 levels versus IgG negative 
control by unpaired student's t test. (C) RT-qPCR analysis of Mmp2, Mmp3, Mmp9 and Mmp12 transcript levels 
in untreated control (black bars) and IL-1α-treated (white bars) cultured mVSMCs. Data are relative to IL-1α-
treated cultured VSMCs (white bars) and normalised to two housekeeping genes (Hprt1 and Ywhaz). Data 
represent means ± SEM of 6 biological replicates. Asterisks indicate significant differences (p<0.05) in 
expression level in IL-1α-treated (+IL-1α, white bars) versus untreated control (-IL-1α, black bars) cultured 
mVSMCS by unpaired student's t test. (D) ChIP-qPCR analysis for H3K9me2 in untreated control (-IL-1α, red 
bars) and IL-1α treated (+IL-1α, pink bars) cultured mVSMCs showing levels of enrichment at control loci 
(Magea2, positive and Actb, negative) and the promoters of Mmp2, Mmp3, Mmp9, Mmp12, Il6 and Ccl2 
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compared with enrichment observed using negative control IgG (grey bars). Background levels of H3K9me2 are 
based on enrichment at the Actb negative control locus and are indicated by a dashed line. Data represent 
means ± SEM of 3 biological replicates. n.s indicates no significant differences (P<0.05) in H3K9me2 levels in IL-
1α treated (+IL-1α, pink bars) versus untreated control (-IL-1α, red bars) cultured mVSMCs by one-way ANOVA 
with Bonferroni correction.  
 
4.2.2 Loss of H3K9me2, by pharmacological inhibition of G9A/GLP (UNC0638), potentiates MMP gene 
expression in cultured mVSMCs. 
 
To test the functional importance of H3K9me2 at the MMP gene promoters, cultured VSMCs were 
pretreated with UNC0638 (UNC), a G9A/GLP inhibitor, prior to IL-1α stimulation. UNC treatment 
significantly reduced H3K9me2 levels both globally (Figure 4.2 A, B) and locally at the MMP 
promoters (Figure 4.2 C). The reduced level of H3K9me2 did not directly affect MMP gene 
expression, but significantly potentiated IL-1α-mediated upregulation of Mmp3 (3.2 fold), Mmp9 (1.8 
fold) and Mmp12 (7.1 fold) relative to cells treated with IL-1α alone (Figure 4.2 D). Neither IL-1α nor 
UNC treatment alone, or in combination, affected the expression of Mmp2 (Figure 4.2 D). To test 
whether the effect of UNC on MMP expression is due to a general upregulation of the inflammatory 
response, we analysed expression of the pro-inflammatory cytokines Il6 and Ccl2, which showed no 
H3K9me2 enrichment in cultured VSMCs (Figure 4.2 C). IL-1α treatment induced the expression of 
both Il6 and Ccl2, whereas UNC alone or in combination with IL-1α had no effect (Figure 4.2 D). These 
results imply that H3K9me2 acts to repress specific MMP promoters, possibly to prevent spurious 
induction of their expression.  
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Figure 4.2: Global reduction of H3K9me2, by pharmacological inhibition of G9A/GLP, significantly potentiates 
IL-1α-mediated MMP gene induction in cultured mVSMCs. (A, B) Representative western blot (A) and 
densitometric analysis (B) of H3K9me2 in UNC0638 (+UNC) treated cultured mVSMCs relative to untreated 
controls (-UNC), normalised to ACTB. Data represent means ± SEM of 3 biological replicates. The Asterisk 
indicates significant difference (p<0.05) in H3K9me2 levels in untreated (-UNC) versus UNC treated (+UNC) 
cultured mVSMCs by unpaired student's t test. (C) ChIP-qPCR analysis for H3K9me2 in untreated control (black 
bars) and UNC0638 (UNC) treated cultured mVSMCs (red bars) showing levels of enrichment at control loci 
(Magea2, positive and Actb, negative) and the promoters of Mmp2, Mmp3, Mmp9, Mmp12, Il6 and Ccl2 
compared with enrichment observed using negative control IgG (white and grey bars). Background levels of 
H3K9me2 are based on enrichment at the Actb negative control locus and are indicated by a dashed line. Data 
represent means ± SEM of 3 biological replicates. Asterisks indicate significant differences (p<0.05) in H3K9me2 
levels in UNC treated (+UNC, red bars) versus untreated control (-UNC, black bars) cultured mVSMCs by one-
way ANOVA with Bonferroni correction. (D) RT-qPCR analysis of Mmp2, Mmp3, Mmp9, Mmp12, Il6 and Ccl2 
transcript levels in untreated control (white bars), IL-1α (black bars), UNC (grey bars) and IL-1α plus UNC-
treated (red bars) cultured mVSMCs. Data are relative to UNC plus IL-1α-treated cultured mVSMCs (+UNC +IL-
1α, red bars) and normalised to two housekeeping genes (Hmbs and Ywhaz). Data represent means ± SEM of 3 
biological replicates. Asterisks indicate significant differences (p<0.05) in expression level by one-way ANOVA 
with Bonferroni correction. 
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4.2.3 Loss of H3K9me2, by pharmacological inhibition of G9A/GLP (UNC0638), potentiates IL-1α-
induced ECM degradation of gelatin by cultured mVSMCs. 
 
MMPs govern vascular remodelling by degradation of the ECM. Vascular remodelling and 
degradation of the ECM is associated with the development of vascular disease, including 
atherosclerosis (Johnson, 2017; Xu and Shi, 2014). To investigate whether enhanced IL-1α-induced 
MMP expression by H3K9me2 inhibition increased proteolytic activity, cultured mVSMCs were pre-
treated with IL-1α and/or UNC prior to incubation with dye quenched (DQ) gelatin, which, upon 
digestion, is converted into fluorescent fluorescein-labelled peptides. The fluorescent fluorescein 
signal was quantified (CTF) to measure ECM degradation and denote levels of MMP activity. As 
shown in Figure 4.3, inhibition of H3K9me2 by UNC further increased IL-1α-induced digestion of the 
DQ gelatin by 1.5-fold compared to VSMCs treated with IL-1α alone. These results provide additional 
evidence to support the role of H3K9me2 in the negative regulation of MMP activity in VSMCs.  
 
 
 
Figure 4.3: In cultured mVSMCs, H3K9me2 protects against IL-1α-induced extra cellular matrix (ECM) 
degradation. (A) Representative immunofluorescence images showing cultured mVSMCs treated with vehicle 
control or UNC0638 (UNC) and/ or IL-1α prior to incubation with dye-quenched (DQ) gelatin. Upon digestion, 
DQ gelatin releases a fluorescent fluorescein signal represented in green. Nuclei were counterstained with DAPI 
(blue). Images were taken using a 20x objective with a fluorescence microscope (ZEISS Axio Vert A.1). (B) Bar 
plot shows levels of DQ gelatin digestion, as represented by the corrected total fluorescence (CTF), by cultured 
mVSMCs treated with vehicle control or UNC and/ or IL-1α. The CTF was quantified using ImageJ software as 
follows; CTF = [(area x mean pixel intensity) - (area x mean pixel intensity of 5 background readings)]/ cell 
number. Cell numbers were determined by counting DAPI stained nuclei (blue). Data represent the average CTF 
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of 5 fields of view per group and are normalised to untreated control (-UNC -IL-1α) cultured mVSMCs. Data 
represent means ± SEM of 3 biological replicates. Asterisks indicate significant differences (p<0.05) in CTF 
compared to vehicle control (-UNC -IL-1α) cultured mVSMCs by one-way ANOVA with Bonferroni correction. 
 
4.2.4 Loss of H3K9me2, by pharmacological inhibition of G9A/GLP (A366), significantly potentiates 
injury-induced Mmp3, Mmp12 and Il6 gene expression in the VSMCs in vivo. 
  
The vasculature is comprised of multiple cell types, which are influenced by a variety of signals in the 
surrounding milieu including shear stress, circulating blood cells and cytokines. In vitro studies fail to 
mimic this complex environment. Therefore, to validate and substantiate the in vitro findings, the 
impact of G9A/GLP inhibition on injury-induced MMP expression was next explored in vivo. To 
determine whether a pharmacological model could be used to reduce H3K9me2 in VSMCs in vivo, 
non-labelled Myh11-CreERt2/ROSA26-EYFP mice were implanted with osmotic pumps delivering 
either vehicle control or A366 (30 mg/kg body weight (BW)/day) (Figure 4.4), a small molecule 
inhibitor which has potent and specific inhibitory effects on the enzymatic activity of G9A/GLP 
without cytotoxicity (Sweis et al., 2014; Thienpont et al., 2017). A366 has better pharmacokinetics 
compared to UNC for in vivo use (Sweis et al., 2014). Non-labelled rather than tamoxifen-labelled 
Myh11-CreERt2/ROSA-EYFP mice were used to comply with the 3R's of animal research. The medial 
layer of blood vessels, which predominantly contains VSMCs, can be easily defined by the elastic 
lamina. Therefore, it is possible to assess the effect of A366 on H3K9me2 in VSMCs in vivo without 
labelling VSMCs with a fluorescent reporter, which would cause unnecessary pain due to the 
administration of tamoxifen intra-peritoneal injections. 
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Figure 4.4: Experimental protocol to test the effect of A366, a small molecule inhibitor of G9A/GLP, on 
H3K9me2 levels in mVSMCs in vivo. Osmotic pumps delivering either A366 or vehicle control were inserted 
into 8-10 weeks old non-labelled Myh11-CreERt2/ ROSA26-EYFP male mice for 7 or 14 days. H3K9me2 levels 
within the aortic medial cell layer were analysed by western blot and H3K9me2 levels in VSMCs within the LCCA 
were analysed by immunofluorescence staining. 
 
Western blot analysis revealed that 7 days post osmotic pump insertion, H3K9me2 levels were not 
significantly different within the aortic medial VSMC layer from mice administered A366 compared to 
vehicle controls (Figure 4.5 A, B). However, by 14 days post osmotic pump insertion, H3K9me2 levels 
were significantly downregulated by approximately 40% within the aortic medial VSMC layer from 
mice administered A366 compared to vehicle controls (Figure 4.5 A, B). This loss of H3K9me2 was 
also evident in cells within the medial VSMC layer of the left common carotid artery (LCCA) by 
immunofluorescence analysis (Figure 4.5 C, D).  
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Figure 4.5: A366, a small molecule inhibitor of G9A/GLP, reduces H3K9me2 in VSMCs in vivo.  
(A, B) Representative western blot (A) and densitometric analysis (B) of H3K9me2 levels in the aortic medial 
VSMC layer of mice administered vehicle control (grey and black bars) or A366 (pink and red bars) for 7 (grey 
and pink bars) or 14 (black and red bars) days. Data are relative to vehicle control treated mice (grey and black 
bars) and normalised to ACTB. Data represent means ± SEM of 3 biological replicates from 3 animals. The 
asterisk indicates significant difference (p<0.05) in H3K9me2 levels in the aortic medial VSMC layer from A366 
(pink and red) versus vehicle control (grey and black) treated mice by unpaired student's t test. (C) 
Immunofluorescence staining for H3K9me2 in representative 12 μm LCCA cryosections from mice administered 
vehicle control or A366 for 14 days. Signals for H3K9me2-Alexa Fluor 647 (magenta, right panels) and nuclei 
counter stained with DAPI (white, left panels) are shown. Scale bars, 50 μm. M, media; L, Lumen. White dashed 
lines outline the media as determined by auto-fluorescence of the inner and outer elastic lamina. (D) Dot plot 
shows H3K9me2 signal in medial cell nuclei, defined by their location between elastic lamina, as determined by 
immunofluorescence analysis of LCCAs from mice administered vehicle control (black dots) or A366 (red dots) 
for 14 days. Each dot shows H3K9me2 signal intensity in one LCCA medial cell nucleus. n= 4 animals for vehicle, 
n= 3 animals for A366. The analysis was performed blindly. The asterisk indicates significant difference (p<0.05) 
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in H3K9me2 levels in LCCA medial cell nuclei from mice treated with A366 (red dots) versus mice treated with 
vehicle control (black dots) by nested ANOVA testing.  
 
To test whether H3K9me2-mediated regulation of VSMC gene expression is functional in vivo, VSMCs 
were genetically labelled by combining the Myh11-CreERt2 transgene (Wirth et al., 2008), which is 
specifically expressed by mature VSMCs, with the ROSA26-EYFP reporter allele (Gomez and Owens, 
2012). Recombination was induced in healthy mice with a pulse of tamoxifen, which resulted in 
stable fluorescent protein (EYFP) expression. As demonstrated previously, expression of the lineage 
reporter is specific to cells in the medial layer of the vasculature where the recombination efficiency 
is 40-60%  (Dobnikar et al., 2018). Carotid ligation was performed 14 days after mice received 
osmotic pumps delivering either vehicle or A366 (30 mg/kg BW/day), when H3K9me2 levels in cells 
within the medial VSMC layer were reduced by 40% in mice administered A366 compared to vehicle 
controls (Figure 4.5). Common carotid arteries (CCAs) were harvested 7 days following carotid 
ligation surgery and cells expressing the EYFP reporter, which are derived from Myh11-expressing 
VSMCs, were isolated by FACS allowing analysis of VSMC mRNA levels via RT-qPCR (Figure 4.6).   
  
93 
 
  
94 
 
Seven days after ligation, Myh11 and Acta2 mRNA levels are downregulated whereas Mmp3, Il6 and 
Ccl2 mRNA levels are upregulated in EYFP+ cells from the ligated CCAs compared to all the controls 
(Figure 4.7 A). Interestingly, like culture-induced phenotypically switched VSMCs (Figure 3.2 D), 
EYFP+ cells from ligated left CCAs (green and red striped bars) displayed a trend towards lower levels 
of Glp mRNA compared to those from non-ligated right CCA (green and red bar) and no ligation 
surgery CCA (black, grey, light green and pink bars) controls (Figure 4.7 A), although this did not reach 
statistical significance. G9a mRNA levels in EYFP+ cells were not influenced by carotid ligation injury 
(Figure 4.7 A). The reduced level of H3K9me2 in EYFP+ cells by A366 (pink bars) treatment (Figure 
4.5) did not directly affect the expression of any of the genes analysed (Figure 4.7 A). A366 treatment 
(red striped bars) also did not influence ligation injury-induced downregulation of Myh11 or Acta2 in 
EYFP+ cells (Figure 4.7 A). However, the reduced level of H3K9me2 in EYFP+ cells by A366 treatment 
(red striped bars) significantly potentiated ligation injury-induced upregulation of Mmp3 (2.1 fold), 
Mmp12 (2.6 fold) and Il6 (3.8 fold) (Figure 4.7 A). This observation correlates with what appears to be 
reduced levels of H3K9me2 at the promoters of Mmp3, Il6 and Ccl2 in the medial cell layer of aortas 
derived from mice administered A366 (red bars) for 21 days compared to vehicle controls (green 
bars) (Figure 4.7 B). A366 treatment (red striped bars) did not significantly influence ligation injury-
induced upregulation of Mmp2 or Ccl2 (Figure 4.7 A).  
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Figure 4.7: Global reduction of H3K9me2, by pharmacological inhibition of G9A/GLP (A366), significantly 
potentiates injury-mediated Mmp3, Mmp12 and Il6 gene induction in mVSMCs in vivo. (A) RT-qPCR analysis 
of Hmbs, Myh11, Acta2, G9a, Glp, Mmp2, Mmp3, Mmp12, Il6 and Ccl2 transcript levels in EYFP+ cells within 
common carotid arteries (CCAs). NS L/R (black/ grey bars) = left/right CCAs from mice which had not undergone 
surgery. V/A L+R (light green/ pink bars) = left plus right CCAs from mice administered an osmotic pump 
delivering vehicle/A366. V/A + CL R (green/ red bars) = right non-ligated CCAs from mice administered an 
osmotic pump delivering vehicle/A366 and subjected to left CCA ligation surgery. V/A + CL L (green striped/ red 
striped bars) = left ligated CCAs from mice administered an osmotic pump delivering vehicle/A366 and 
subjected to left CCA ligation surgery. Data are relative to [V+CL L (lig)] samples and normalised to two 
housekeeping genes (Hprt1 and Hmbs). Data represent means ± SEM of 4 experiments as detailed in the figure. 
Asterisks indicate significant differences (p<0.05) in expression versus [V + CL L (lig)] samples (green striped 
bars) by one-way ANOVA with Bonferroni correction. (B) ChIP-qPCR analysis for H3K9me2 in the aortic medial 
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cell layer, with adventitial and endothelial cells removed, from mice administered either vehicle control (V L+R, 
green bars) or A366 (A L+R, red bars) showing levels of enrichment at control loci (Magea2, positive and Actb, 
negative) and the promoters of Mmp3, Mmp12, Il6 and Ccl2 compared with enrichment observed using 
negative control IgG (white and grey bars). Background levels of H3K9me2 are based on enrichment at the Actb 
negative control locus and are indicated by a dashed line. Data represent means ± SEM of 3 biological replicates 
from 3 mice. Asterisks indicate significant differences (p<0.05) versus vehicle control (Vehicle H3K9me2, green 
bars) by one-way ANOVA with Bonferroni correction. 
 
RT-qPCR analysis revealed no significant differences in expression levels of bone marrow-derived 
(Cd45), endothelial (Cd31) and adventitial fibroblast cell (Pdgfra) markers between treatment groups, 
which suggests that differences in transcript levels in EYFP+ cells between treatment groups is not 
due to contamination by these cell types (Figure 4.8). These results confirm H3K9me2 plays a 
functional role in regulating the expression of Mmp3, Mmp12 and Il6 in vivo and may therefore be 
relevant in the context of human CVD.    
 
 
 
Figure 4.8: Levels of bone marrow-derived endothelial and adventitial cell marker gene expression is 
independent of sample treatment. RT-qPCR analysis of Cd45 (a bone marrow-derived cell marker), Cd31 (a 
endothelial cell marker) and Pdgfra (a adventitial fibroblast cell marker) transcript levels in EYFP+ cells within 
CCAs.  V/A L+R (light green/ pink bars) = left plus right CCAs from mice administered an osmotic pump 
delivering vehicle/A366. V/A + CL L (green striped/ red striped bars) = left ligated CCAs from mice administered 
an osmotic pump delivering vehicle/A366 and subjected to left CCA ligation surgery. Data are relative to EYFP -
ve cells, from no surgery control left CCAs, and normalised to two housekeeping genes (Hprt1 and Hmbs). Data 
represent means ± SEM of 4 experiments as described in the figure. Asterisks indicate significant differences 
(p<0.05) in expression versus EYFP -ve cells (white bars) by one-way ANOVA with Bonferroni correction.  
 
4.3 Summary and conclusions 
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Chromatin immunoprecipitation revealed high levels of H3K9me2 at a subset of IL-1α-mediated gene 
promoters, including Mmp3, Mmp9 and Mmp12, in both ex vivo and cultured mVSMCs (Figure 4.1 A, 
B). H3K9me2 was also observed at the promoters of Il6 and Ccl2 in ex vivo mVSMCs, albeit at modest 
levels, while the mark was absent in cultured mVSMCs (Figure 4.2 A, B). Upon culture, VSMCs alter 
their phenotype and downregulate the expression of contractile genes (Figure 3.2 A) and become 
more proliferative (Metz et al., 2012). Both IL6 and CCL2 are known to upregulate VSMC proliferation 
(Lee et al., 2016; Schober, 2008). Perhaps, loss of H3K9me2 at the Il6 and Ccl2 promoter upon culture 
reflects induction of their expression. Therefore, it would be interesting to compare Il6 and Ccl2 
transcript levels in ex vivo compared to cultured VSMCs.  
 
Interestingly, in cultured mVSMCs, IL-1α-responsive MMP gene promoters retained high levels of 
H3K9me2 after IL-1α stimulation (Figure 4.1 D). Perhaps, H3K9me2 blocks spurious expression of 
these genes under inflammatory conditions. Indeed, reduction of H3K9me2, by pharmacological 
inhibition of G9A/GLP using UNC, potentiated IL-1α-mediated upregulation of MMP gene expression 
and activity in cultured mVSMCs (Figure 4.2). However, there is a possibility that UNC has off-target 
effects (Pappano et al., 2015), which could be responsible for this observation. Therefore, it is 
important to validate these results via an alternative method such as siRNA knock down of G9A. 
Importantly, the mouse carotid ligation injury model of vascular disease demonstrates that loss of 
H3K9me2, by pharmacological inhibition of G9A/GLP, also potentiates injury-induced expression of 
MMP and pro-inflammatory VSMC genes in vivo (Figure 4.7). However, A366 is also likely to inhibit 
G9A/GLP in other cell types, which influence VSMC gene expression. Therefore, the differences in 
transcript levels in VSMCs between treatment groups may be due to the effects of A366 on other cell 
types, such as bone marrow-derived cells. Furthermore, like UNC, A366 may have off target effects. 
Therefore, it would be interesting to delete G9A or GLP specifically in VSMCs, by introducing the 
appropriate Cre-deleter transgene onto Flox/Flox mice, to substantiate these findings.  
 
In accordance with our data, several studies report an inverse correlation between H3K9me2 
occupancy at MMP and other inflammatory gene promoters and the ability of other cell types to 
express these genes (Fang et al., 2012; Gesumaria et al., 2015; Liu et al., 2014; Zhong and Kowluru, 
2013b). For example, H3K9me2 depletion at the Mmp9 promoter correlates with elevated Mmp9 
expression in retinal endothelial cells from diabetic rats compared to controls (Zhong and Kowluru, 
2013b). Furthermore, solar-stimulated ultraviolet radiation (ssUVR) induces loss of H3K9me2 at the 
MMP3 promoter in primary human dermal fibroblasts, correlating with enhanced MMP3 mRNA 
levels following ssUVR exposure (Gesumaria et al., 2015). In addition, genetic ablation or 
pharmacological inhibition of G9A/GLP stimulates the expression of inflammatory genes in mouse 
embryonic fibroblasts (MEFs) (Fang et al., 2012). Similar to what is reported here, reduction of 
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H3K9me2 levels in MEFs, further potentiated poly(I:C)-induced upregulation of inflammatory genes 
(Fang et al., 2012). These observations support the conclusion that H3K9me2 is functionally 
important to block excessive inflammation-induced VSMC gene expression.  
 
MMPs play a central role in many CVDs which are associated with structural changes in blood vessels 
(Galis and Khatri, 2002; Johnson, 2014). MMPs are known to influence the migration and 
proliferation of VSMCs, infiltration of inflammatory cells into tissue and the stability of 
atherosclerotic plaques (Figure 1.6) (Galis and Khatri, 2002; Johnson, 2014; Nagase et al., 2006). For 
instance, MMP3 and MMP9 promote VSMC migration and neointima formation after carotid ligation 
in mice (Johnson et al., 2011b) and numerous animal atherosclerosis studies implicate MMP12 in 
plaque development and instability (Johnson et al., 2005b; Liang et al., 2006; Yamada et al., 2008). 
Interestingly, increased MMP3, MMP9 and MMP12 expression have been observed in vulnerable 
compared to stable human atherosclerotic lesions. IL6 is also involved in vascular dysfunction and 
elevated serum levels of IL6 associated with greater cardiovascular disease risk (Anderson et al., 
2013; Biasucci et al., 1999; Piemonti et al., 2009; Tousoulis et al., 2016). IL6 has been shown to 
upregulate VSMC migration, proliferation and vascular calcification whilst attenuating VSMC 
contraction (Kurozumi et al., 2016; Lee et al., 2016; Watanabe et al., 2004).  
 
The experiments described in this chapter suggest H3K9me2 is functionally required for correct 
regulation of MMP and IL6 gene expression under inflammatory conditions. Interestingly, the recent 
CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) trial demonstrates diverse 
clinical benefits to inhibiting IL-1β for cardiovascular events (Ridker et al., 2017; Weber and von 
Hundelshausen, 2017). IL-1β has distinct properties from IL-1α but shares many pro-inflammatory 
actions and can also induce VSMCs to express MMP3, MMP9, MMP12 and IL6 (Libby, 2017; Rader, 
2012). Antibody reagents that neutralize IL-1α have entered clinical trials and hold potential for the 
treatment of CVD (Libby, 2017; Pradère et al., 2016). Enzymes that regulate epigenetic mechanisms 
have been successfully targeted in cancer treatments (Song et al., 2016). Perhaps, manipulation of 
the expression of IL-1α-responsive genes by interfering with the H3K9me2 pathway provides an 
alternative strategy to the development of IL-1α inhibitors. 
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CHAPTER 5 - RESULTS: The functional role of 
H3K9me2 in regulating VSMC gene expression 
changes associated with vascular disease is 
conserved in human 
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5.1 Introduction 
 
Mouse models have greatly developed our understanding of human CVD and have been instrumental 
in evaluating the effectiveness of new therapies. Strikingly, we share 95% of our protein encoding 
genes with mice (von Scheidt et al., 2017) and regulatory elements are often marked by 
evolutionarily conserved histone modifications which signify their function (Diehl and Boyle, 2018). 
Indeed, out of 46 genes with strong association signals in human coronary artery disease-genome 
wide association studies that were studied in mice, 45 significantly affected atherosclerosis (von 
Scheidt et al., 2017). The murine findings discussed in Chapters 3 and 4 suggest that H3K9me2 plays 
an indirect role in maintaining the contractile VSMC state and acts directly at IL-1α-responsive gene 
promoters to block spurious induction of a pro-inflammatory state. 
 
However, despite phylogenetic similarities between mice and humans there are still many 
differences between the two species and conserved chromatin signatures do not always equate to 
conserved regulatory functions (Diehl and Boyle, 2018; von Scheidt et al., 2017). In contrast to mice, 
within human vasculature, a significant number of VSMCs exist within the intima in conserved 
locations, including branch sites and areas of turbulent blood flow, prior to disease (Doran et al., 
2008). Furthermore, as wild-type mice are resistant to plaque development, mouse models of 
atherosclerosis are based on genetic modifications of lipid metabolism with additional dietary 
changes and are therefore unlikely to perfectly reflect the mechanisms which underlie human 
disease. For example, a disadvantage of the ApoE-/- high fat diet mouse model of atherosclerosis is 
lack of plaque rupture (Emini Veseli et al., 2017). In addition, ApoE is known to play a role in 
inflammation, which may influence plaque development (Emini Veseli et al., 2017). Consequently, 
mice created to mimic human disease frequently have phenotypes that differ from their human 
counterparts (Perlman, 2016). Perhaps, the lack of success of CVD clinical trials can, in part, be 
attributed to differences between mice and humans (Baylis et al., 2017). Therefore, whether the 
functional role of H3K9me2 in the regulation of vascular disease associated gene expression is 
conserved in human VSMCs (hVSMCs) and could therefore be relevant in the context of human CVD 
was explored. 
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Aims: 
 
Use human VSMCs to: 
 
1. Assess local levels of H3K9me2 at contractile VSMC genes upon loss of the contractile VSMC 
state using an in vitro model of VSMC phenotypic switching and chromatin 
immunoprecipitation. 
2. Test the functional role of H3K9me2 on contractile VSMC gene expression in vitro using small 
molecule inhibition and siRNA knock down of the main H3K9 di-methyltransferases G9A/GLP. 
3. Assess local levels of H3K9me2 at MMP and pro-inflammatory VSMC gene promoters, which 
are strongly associated with CVD, by chromatin immunoprecipitation. 
4. Test the functional role of H3K9me2 on MMP and pro-inflammatory VSMC gene expression 
in vitro using small molecule inhibition or siRNA knock down of the main H3K9 di-
methyltransferases G9A/GLP prior to IL-1α stimulation. 
 
5.2 Results 
 
5.2.1 Global levels of H3K9me2 are reduced in cultured relative to ex vivo human VSMCs, concomitant 
with loss of the contractile state. 
 
To explore whether the functional role of H3K9me2 in the regulation of VSMC gene expression is 
conserved in human, hVSMCs were derived from explant cultures from patients undergoing aortic 
valve replacement surgery. Similar to mouse, cultured hVSMCs display absent or low levels of 
H3K9me2 at contractile VSMC gene promoters compared to the ACTB negative control locus (Figure 
5.1 A). Furthermore, contractile VSMC genes (CNN1, TAGLN, MYOCD, ACTA2, STMN) retained the 
active H3K4me3 chromatin mark (Figure 5.1 B) but were 20-100-fold downregulated in cultured 
compared to ex vivo tissue samples (Figure 5.1 C). Retention of H3K4me3 is commonly used to 
identify active gene promoters and does not normally mark repressed gene promoters. Therefore, 
like H3K4me2, if H3K4me3 marks contractile gene promoters specifically in VSMCs, the H3K4me3 
mark could be used for VSMC lineage tracing in human tissue using in situ hybridisation proximity 
ligation (Shankman et al., 2015). Furthermore, this finding supports the theory that H3K4me2/3 may 
serve as a mechanism for epigenetic cell lineage memory to enable phenotypically modulated VSMCs 
to switch back to their contractile state. 
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Figure 5.1: The repressive H3K9me2 mark is absent while the active H3K4me3 mark is retained at contractile 
VSMC gene promoters in cultured human VSMCs, despite their transcriptional silencing. (A) ChIP-qPCR 
analysis for H3K9me2 (red bars) and negative control IgG (white bars) in hVSMCs cultured to passage 7-8 
showing levels of enrichment at control loci (MAGEA2, positive and ACTB, negative) and contractile VSMC 
genes. Data are relative to 1% input and normalised to enrichment at MAGEA2 (red bar). Data represent means 
± SEM of 3 biological replicates using VSMCs derived from independent biopsies. Background levels of 
H3K9me2 are based on enrichment at the ACTB negative control locus and are indicated by a dashed line. 
Asterisks indicate significant differences (P<0.05) in enrichment versus IgG negative control by unpaired 
student's t test. (B) ChIP qPCR analysis for H3K4me3 (green bars) and negative control IgG (white bars) in 
hVSMCs cultured to passage 7-8 showing levels of enrichment at control loci (MAGEA2, negative and ACTB, 
positive) and contractile VSMC genes. Data are relative to 1% input and normalised to enrichment at ACTB 
(green bar). Data represent means ± SEM of 3 biological replicates using VSMCs derived from independent 
biopsies. Background levels of H3K4me3 are based on enrichment at the MAGEA2 negative control locus and 
are indicated by a dashed line. Asterisks indicate significant differences (P<0.05) in enrichment versus IgG 
negative control by unpaired student's t test. (C) RT-qPCR analysis of CNN1, TAGLN, MYOCD, ACTA2, SMTN and 
YWHAZ transcript levels in ex vivo hVSMCs and hVSMCs cultured to passage 7-8. Data are relative to ex vivo 
hVSMCs from different biopsies and normalised to two housekeeping genes (HMBS and YWHAZ). Data 
represent means ± SEM of 3 biological replicates using VSMCs derived from independent biopsies. Asterisks 
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indicate significant differences (P<0.05) in expression level in cultured versus ex vivo hVSMCs by unpaired 
student's t test. 
 
To investigate whether H3K9me2 also influences the expression of contractile markers in cultured 
hVSMCs, the methyltransferases G9A/GLP were pharmacologically inhibited by UNC treatment. 
Consistent with how UNC affects mouse VSMCs, the resulting global loss of H3K9me2 (Figure 5.2 A, 
B) further attenuated the expression of MYOCD and MYOCD-dependent contractile VSMC genes 
including CNN1, TAGLN, ACTA2 (Figure 5.2 C). However, SMTN, a MYOCD-independent contractile 
VSMC gene, was not influenced by UNC treatment (Figure 5.2 C). I therefore hypothesised that, in 
hVSMCs, H3K9me2 acts to inhibit a negative regulator of MYOCD and therefore MYOCD-dependent 
genes. Potent repressors of MYOCD and MYOCD-dependent genes include KLF4, P65 and G6PD 
(Chettimada et al., 2016; Dhagia et al., 2014; Herring et al., 2017; Liu et al., 2005; Turner et al., 2013; 
Yoshida et al., 2013). Inhibition of H3K9me2 in cultured human VSMCs did not influence the 
expression of KLF4 or P65 but upregulated levels of G6PD by 1.6-fold compared to untreated VSMCs 
(Figure 5.2 C).  
 
 
 
Figure 5.2: Loss of H3K9me2 correlates with the downregulation of contractile genes in human VSMCs. (A, B)  
Representative western blot (A) and densitometric analysis (B) of H3K9me2 levels in untreated control (-UNC) 
and UNC treated (+UNC) hVSMCs. hVSMCs were treated after 7-13 passages of culture. Data are relative to 
untreated control (-UNC) hVSMCs and normalised to ACTB. Data represent means ± SEM of 3 biological 
replicates using VSMCs derived from independent biopsies. The asterisk indicates significant difference 
(P<0.05) in H3K9me2 levels in UNC treated (+UNC) versus untreated control (-UNC) hVSMCs by unpaired 
student's t test. (C) RT-qPCR analysis of CNN1, TAGLN, ACTA2, MYOCD, SMTN, KLF4, P65, G6PD and YWHAZ 
transcript levels in untreated control (-UNC, black bars) and UNC treated (+UNC, white bars) hVSMCs. hVSMCs 
were treated after 7-13 passages of culture. Data are relative to untreated control (-UNC, black bars) hVSMCs 
and normalised to the average of two housekeeping genes (HPRT1 and YWHAZ). Data represent means ± SEM 
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of 3-8 biological replicates using VSMCs derived from independent biopsies (n= 3 for P65 and TAGLN, n= 4 for 
CNN1 and KLF4, n= 5 for MYOCD and SMTN, n= 6 for ACTA2 and n= 8 for G6PD and YWHAZ). Asterisks indicate 
significant differences (P<0.05) in expression level in UNC treated (+UNC, white bars) versus untreated control 
(-UNC, black bars) hVSMCs by unpaired student's t test. 
 
In summary, reduced levels of H3K9me2 correlate with increased expression of G6PD, a potent 
repressor of MYOCD (Chettimada et al., 2016; Dhagia et al., 2014; Gupte et al., 2011). Interestingly, a 
study has found that G6PD activity is increased, while expression of MYOCD and MYOCD-dependent 
genes is decreased, in large blood vessels from obese-diabetic compared to non-obese-diabetic 
patients and that MYOCD downregulation is blocked by G6PD inhibition or knockdown (Dhagia et al., 
2014). Furthermore, it has been reported that compared to VSMCs from healthy aortic tissue, global 
levels of H3K9me2 are reduced in human VSMCs from atherosclerotic lesions (Greißel et al., 2015). 
Therefore, it is interesting that inhibition of H3K9me2 by UNC treatment upregulated G6PD 
transcript levels, whilst attenuating the expression of MYOCD and MYOCD-dependent contractile 
VSMC gene expression.  Based on these observations, it is tempting to speculate that H3K9me2 
inhibits the expression of G6PD, which could explain the reduced level of MYOCD and MYOCD-
dependent contractile VSMC gene expression upon UNC treatment.  
 
5.2.2 H3K9me2 marks IL-1α-responsive gene promoters in human VSMCs. 
 
Consistent with findings using mouse VSMCs, ChIP revealed high levels of H3K9me2 locally at a 
subset of IL-1α-induced genes including MMP3, MMP9 and IL6 in cultured hVSMCs (Figure 5.3 A, B) 
compared to the ACTB negative control locus, which persisted after IL-1α stimulation (Figure 5.3 B). 
However, the MMP2 promoter, a gene constitutively expressed by VSMCs and uninfluenced by IL-1α 
treatment (Figure 5.3 A), did not display H3K9me2 (Figure 5.3 B). Like in mouse, H3K9me2 was not 
observed at the CCL2 promoter, a IL-1α-induced gene, in cultured hVSMCs with or without IL-1α 
stimulation (Figure 5.3 A, B). 
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Figure 5.3: A subset of IL-1α-responsive gene promoters, including MMP3, MMP9 and IL6, are highly 
enriched for H3K9me2 in cultured hVSMCs. (A) RT-qPCR analysis of MMP2, MMP3, MMP9, IL6, CCL2 and 
HPRT1 transcript levels in untreated control (-IL-1α, black bars) and IL-1α-treated (+IL-1α, white bars) cultured 
hVSMCs. hVSMCs were treated at passage 6-8. Data are relative to IL-1α-treated (+IL-1α, white bars) cultured 
hVSMCs and normalised to two housekeeping genes (HPRT1 and YWHAZ). Data represent means ± SEM of 4 
biological replicates using hVSMCs derived from independent biopsies. Asterisks indicate significant differences 
in expression level in IL-1α-treated (+IL-1α, white bars) versus untreated control (-IL-1α, black bars) hVSMCs by 
unpaired student's t test. (B) ChIP-qPCR analysis for H3K9me2 in untreated control (-IL-1α, red bars) and IL-1α-
treated (+IL-1α, pink bars) cultured hVSMCs (treated at passage 6-8), showing levels of enrichment at control 
loci (MAGEA2, positive and ACTB, negative) and the promoters of MMP2, MMP3, MMP9, IL6 and CCL2 
compared with enrichment observed using negative control IgG (grey bars). Background levels of H3K9me2 are 
based on enrichment at the ACTB negative control locus and are indicated by a dashed line. Data represent 
means ± SEM of 4 biological replicates using hVSMCs derived from independent biopsies. n.s indicates no 
significant differences in H3K9me2 levels in IL-1α-treated (+IL-1α, pink bars) versus untreated control (-IL-1α, 
red bars) cultured hVSMCs by one-way ANOVA with Bonferroni correction. 
 
 5.2.3 Inhibition of H3K9me2 potentiates IL6 and MMP gene expression in human VSMCs 
 
To explore whether the levels and/or kinetics of IL-1α-induced VSMC gene expression are altered by 
H3K9me2 inhibition we analysed cultured hVSMCs at numerous time points following IL-1α 
stimulation with or without prior UNC0638 (UNC) treatment. UNC treatment significantly reduced 
global levels of H3K9me2 by 12.5-fold (Figure 5.2 A, B). Consistent with how UNC affects mouse 
VSMCs, the reduced level of H3K9me2 did not directly affect IL6 or MMP gene expression, but 
significantly potentiated IL-1α-mediated upregulation of MMP3, MMP9 and IL6 without influencing 
the timing of their induction (Figure 5.4 A-D). Interestingly, MMP3, IL6 and CCL2 became significantly 
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upregulated following 1.5 hours of IL-1α stimulation (Figure 5.4 A, B D, E), whereas MMP9 did not 
become significantly upregulated until 6 hours post IL-1α treatment (Figure 5.4 C). Neither IL-1α nor 
UNC treatment alone, or in combination, affected the expression of MMP2 (Figure 5.4 F). To test 
whether the effect of UNC on MMP expression is due to a general upregulation of the inflammatory 
response, we analysed expression of the pro-inflammatory cytokine CCL2, that showed no H3K9me2 
enrichment (Figure 5.3 B). IL-1α treatment induced the expression of CCL2, whereas UNC alone or in 
combination with IL-1α had no effect (Figure 5.4 E) demonstrating the specific effect of UNC-
mediated reduction of H3K9me2 on genes showing enrichment for this mark.  Together, these results 
suggest that in human VSMCs, H3K9me2 acts directly at the promoters of MMP3, MMP9 and IL6 to 
prevent excessive levels of expression without influencing the timing of their induction. 
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Figure 5.4: H3K9me2 regulates IL-1α-responsive genes in cultured hVSMCs. (A, C-F) RT-qPCR analysis of 
MMP3 (A), MMP9 (C), IL6 (D), CCL2 (E) and MMP2 (F) transcript levels in untreated control and IL-1α-treated 
(for 10 mins, 30 mins, 1.5 hr, 3 hr, 6 hr or 24 hr) cultured hVSMCs, without (-UNC, black bars) and with (+UNC, 
white bars) prior UNC0638 treatment. hVSMCs were treated after 8-13 passages of culture. Data are relative to 
UNC plus IL-1α (6hrs) treated hVSMCs and normalised to the average of two housekeeping genes (HMBS and 
YWHAZ). Data represent means ± SEM of 4 biological replicates using VSMCs derived from independent 
biopsies. Asterisks indicate significant differences (P<0.05) by one-way ANOVA with Bonferroni correction. (B) 
Representative western blot and densitomeric analysis of MMP3 protein levels in untreated control (-UNC -IL-
1α), UNC (+UNC -IL-1α), IL-1α (-UNC, +IL-1α) and IL-1α plus UNC (+UNC +IL-1α) treated hVSMCs. hVSMCs were 
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treated after 8-13 passages of culture. Data are relative to +UNC +IL-1α and normalised to ACTB levels. Data 
represent means ± SEM of 3 biological replicates using VSMCs derived from independent biopsies. Asterisks 
indicate significant differences (P<0.05) by one-way ANOVA with Bonferroni correction.  
 
5.2.4 SiRNA knockdown of G9A attenuates the expression of contractile VSMC genes. 
 
Reduction of H3K9me2, by pharmacological inhibition of G9A/GLP using UNC, potentiated IL-1α-
mediated upregulation of MMP gene expression in both mouse (Figure 4.2 D) and human cultured 
VSMCs (Figure 5.4). However, there is a possibility that UNC has off-target effects (Pappano et al., 
2015), which are perhaps responsible for this observation. Therefore, to validate these results I 
knocked down G9A in cultured human VSMCs using siRNA. G9A knockdown resulted in a 15.8-fold 
reduction in G9A at the protein level (Figure 5.5 A, B) and a 70% reduction of G9A at the mRNA level 
compared to control cells treated with scrambled non-targeting siRNA (Figure 5.5 D). This reduction 
in G9A led to a 3.3-fold reduction in global levels of H3K9me2 (Figure 5.5 A, C). Similar to what was 
observed using G9A/GLP inhibition, G9A knockdown attenuated the expression of a subset of VSMC 
genes, including ACTA2, TAGLN and CNN1 (Figure 5.5 D). However, in contrast to UNC treatment, 
G9A knockdown by siRNA did not influence MYOCD or G6PD expression (Figure 5.5 D). Consistent 
with the effect of UNC treatment, G9A knockdown alone did not significantly influence the 
expression of MMP3 or IL6, but further potentiated IL-1α-induced MMP3 and IL6 expression (Figure 
5.5 E). Neither IL-1α treatment nor G9A knockdown alone, or in combination, affected the expression 
of MMP2 (Figure 5.5 E). IL-1α treatment induced the expression of CCL2, whereas G9A knockdown 
alone or in combination with IL-1α had no effect (Figure 5.5 E). These results confirm that the 
functional role of H3K9me2 in blocking IL-1α-mediated induction of target gene expression is not due 
to an off-target effect of UNC. 
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Figure 5.5: SiRNA knock down of G9A reduced global H3K9me2 levels, attenuated contractile VSMC gene 
expression and potentiated IL-1α-induced MMP3 and IL6 expression in cultured hVSMCs. (A-C) 
Representative western blot (A) and densitometric analysis of G9A (B) and H3K9me2 (C) levels in mock, 
scrambled (Scr) siRNA and G9A siRNA transfected cultured hVSMCs. hVSMCs were treated after 7-11 passages 
of culture. Data are relative to mock transfected hVSMCs and normalised to ACTB. Data represent means ± 
SEM of 4 biological replicates using VSMCs derived from independent biopsies. Asterisks indicate significant 
difference (P<0.05) in protein level versus mock transfected hVSMCs by one-way ANOVA with Bonferroni 
correction. (D) RT-qPCR analysis of CNN1, TAGLN, ACTA2, MYOCD, SMTN, G6PD, G9A and YWHAZ transcript 
levels in mock, Scr siRNA and G9A siRNA transfected cultured hVSMCs. hVSMCs were transfected after 7-11 
passages of culture. Data are relative to mock (white bars) transfected hVSMCs and normalised to two 
housekeeping genes (HPRT1 and YWHAZ). Data represent means ± SEM of 4 biological replicates using VSMCs 
derived from independent biopsies. Asterisks indicate significant differences (P<0.05) versus mock transfected 
hVSMCs (white bars) by one-way ANOVA with Bonferroni correction. (E) RT-qPCR analysis of MMP2, MMP3, 
IL6, CCL2 and YWHAZ transcript levels in mock, Scr siRNA and G9A siRNA transfected cultured hVSMCs. hVSMCs 
were transfected/ treated after 7-11 passages of culture. Data are relative to G9a siRNA + IL-1α (black bars) 
treated hVSMCs and normalised to two housekeeping genes (HPRT1 and YWHAZ). Data represent means ± SEM 
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of 4 biological replicates using VSMCs derived from independent biopsies. Asterisks indicate significant 
differences (P<0.05) in expression level versus G9A siRNA +IL-1α (black bars) treated hVSMCs by one-way 
ANOVA with Bonferroni correction. 
 
5.3 Summary and Conclusions 
 
Together, the results presented in this chapter show that H3K9me2 plays a role in regulating the 
expression of human VSMC genes associated with vascular disease. Consistent with how UNC affects 
mouse VSMCs, loss of H3K9me2 by pharmacological inhibition of the associated methyltransferase 
G9A (Figure 5.2 A, B) attenuates the expression of MYOCD and MYOCD-dependent contractile 
hVSMC genes including CNN1, TAGLN, ACTA2 (Figure 5.2 C). However, in contrast to mouse, SMTN, a 
MYOCD-independent contractile VSMC gene, was not influenced by UNC treatment (Figure 5.2 C). I 
therefore hypothesised that H3K9me2 acts to inhibit a negative regulator of MYOCD and therefore 
MYOCD-dependent genes in human VSMCs. Interestingly, global loss of H3K9me2 upregulated mRNA 
levels of G6PD (Figure 5.2 C), a potent repressor of MYOCD (Chettimada et al., 2016; Dhagia et al., 
2014; Gupte et al., 2011).  
 
G6PD is the rate-limiting enzyme that commits glucose to the pentose phosphate pathway (Gupte et 
al., 2011). It is responsible for the generation of nicotinamide adenine dinucleotide phosphate 
reduced (NADPH), a key cofactor in various redox and antioxidant systems, and ribose 5-phosphate, 
an essential precursor for the de novo synthesis of RNA and DNA (Gupte et al., 2011). Researchers 
have shown that G6PD inhibition in cultured rat aortic SMCs increases the expression of MYOCD and 
MYOCD-dependent genes (Chettimada et al., 2016). Another study has also found that G6PD activity 
is increased, while expression of MYOCD and MYOCD-dependent genes is decreased, in large blood 
vessels from obese-diabetic compared to non-obese-diabetic patients and that MYOCD 
downregulation is blocked by G6PD inhibition or knockdown (Dhagia et al., 2014). Furthermore, 
compared to VSMCs from healthy aortic tissue, global levels of H3K9me2 are reduced in human 
VSMCs from atherosclerotic lesions (Greißel et al., 2015). Therefore, it is interesting that inhibition of 
H3K9me2 by UNC treatment upregulated G6PD transcript levels, whilst attenuating the expression of 
MYOCD and MYOCD-dependent contractile VSMC gene expression.  Perhaps, H3K9me2 inhibits the 
expression of G6PD to maintain the contractile VSMC state. It would be interesting to investigate 
whether levels of H3K9me2 specifically at the G6PD promoter influence the expression of MYOCD 
and MYOCD-dependent genes in human VSMCs. This could be achieved using CRISPR/dCas9 
technology to recruit the enzymatic activity of a H3K9me2 demethylase or methyltransferase 
specifically to the G6PD promoter.  
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In further agreement with our murine studies, IL-1α-responsive genes including IL6, MMP3 and 
MMP9 are enriched for H3K9me2 in cultured hVSMCs (Figure 5.3) and global loss of H3K9me2 by 
pharmacological inhibition (Figure 5.4) or siRNA mediated knock-down of G9A (Figure 5.5) 
potentiates the IL-1α-induced expression of these genes. To explore whether loss of H3K9me2 alters 
the kinetics of IL-1α-induced gene expression we analysed a number of time points after stimulating 
cultured hVSMCs with IL-1α with and without prior UNC treatment (Figure 5.4). Loss of H3K9me2 did 
not alter the timing of IL-1α-induced expression of the H3K9me2 marked genes analysed (MMP3, 
MMP9 and IL6) but did potentiate the level of their expression (Figure 5.4). In contrast to mouse, IL-
1α-induced IL6 expression was significantly higher after H3K9me2 inhibition (Figure 5.4), 
corresponding with H3K9me2 enrichment at the IL6 promoter (Figure 5.3 B). Intriguingly MMP3, IL6 
and CCL2 became significantly upregulated 1.5 hours after IL-1α stimulation, whereas MMP9 did not 
become significantly upregulated until 6 hours after IL-1α treatment (Figure 5.4) suggesting MMP9 is 
regulated by a different mechanism. In agreement with this finding, researchers have shown that 
Mmp3 expression precedes Mmp9 expression after balloon angioplasty of the rat carotid artery 
(Webb et al., 1997). Interestingly, Johnson and colleagues demonstrated that MMP3 is required to 
activate MMP9 mediated VSMC migration and neointima formation using a mouse carotid ligation 
injury model (Johnson et al., 2011b).  
 
Discrepancies in the regulation of SMTN and IL6 could be due to species-specific targeting of 
H3K9me2 in VSMCs or derived from technical or biological differences between human and murine 
VSMC cultures. Murine VSMCs were derived from young male mice while human VSMCs were 
sourced from male and female patients ranging from 20 to 78 years old. As sex and age are known to 
influence VSMC gene expression (Bennett et al., 2016; Mosca et al., 2011), this could explain the 
observed differences between species. Furthermore, human VSMCs were derived from patients 
undergoing aortic valve replacement surgery and are therefore likely to be from the aortic root, 
whereas mVSMCs were derived from the whole aorta. The difference in SMTN and IL6 regulation 
between mouse and human VSMCs could therefore be due to regional differences in VSMC 
physiology and disease response (Sinha et al., 2014). Moreover, human VSMC cultures were derived 
using the explant method, which may have selected for migratory and proliferative cells, whereas 
mouse VSMC cultures were derived from dissociated aortic medial cell layers. Therefore, technical 
differences between human and mouse VSMC cultures could also contribute to the observed 
discrepancies in the regulation of SMTN and IL6 between species.  
 
To explore whether UNC was exerting its effects independently from G9A inhibition we knocked 
down G9A in cultured human VSMCs using siRNA (Figure 5.5). G9A siRNA knock down reduced global 
levels of H3K9me2, attenuated contractile VSMC gene expression and potentiated IL-1α-induced 
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MMP3, MMP9 and IL6 expression in cultured hVSMCs but did not influence the expression of MYOCD 
and G6PD (Figure 5.5). Furthermore, although G9A siRNA knockdown (Figure 5.5) did significantly 
potentiate IL-1α-induced expression of MMP3 and IL6, it wasn't to as great an extent as 
pharmacological inhibition (Figure 5.4). G9A knockdown did not reduce global levels of H3K9me2 
(3.3-fold reduction) (Figure 5.5 A, C) to as great a level as pharmacological inhibition (9.9-fold 
reduction) (Figure 5.2 A, B), which could explain these inconsistencies.  
 
To conclude, our results show a specific, evolutionary conserved function of H3K9me2 to maintain 
contractile VSMC gene expression and block excessive expression of a subset of IL-1α-responsive 
genes. Since decreased contractile VSMC gene expression and increased MMP and IL6 activity are 
features of vascular disease, H3K9me2-regulation may be a novel target for clinical intervention. 
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CHAPTER 6 - RESULTS: Investigating the mechanism 
behind G9A/GLP -mediated regulation of IL-1α-
responsive VSMC genes 
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6.1 Introduction 
 
Pro-inflammatory cytokines activate NFkB and MAPK-AP-1 signalling pathways leading to VSMC 
inflammatory activation. Dysregulation of these pathways is often linked to vascular disease, 
including atherosclerosis (Meijer et al., 2012; Ridker et al., 2017; van der Heiden et al., 2010; Weber 
and von Hundelshausen, 2017). IL-1α activates translocation of the NFkB mediated transcription 
factor p65, which contains the transactivation domain necessary for gene induction (Bhatt and 
Ghosh, 2014; Tak and Firestein, 2001), from the cytoplasm to the nucleus (Figure 6.1 A). IL-1α also 
induces phosphorylation of MAPKs at specific residues, which ultimately leads to phosphorylation 
and binding of AP-1 transcription factors, such as cJUN, to target genes (Kim and Choi, 2015; Sun et 
al., 2015; Yang et al., 2013) (Figure 6.1 A).  
 
In the literature, p65 and cJUN are reported as necessary to induce the expression of MMP3 
(Borghaei et al., 2004; Clark et al., 2008; Fleenor et al., 2003; Huang et al., 2012; Lu et al., 2016), 
MMP9 (Chen and Chang, 2015; Clark et al., 2008), MMP12 (Clark et al., 2008; Xie et al., 2005) (Huang 
et al., 2012; Park et al., 2015) and IL6 (Faggioli et al., 2004). Furthermore, p65 and cJUN binding sites 
have been reported within 2 kb of the transcriptional start site (TSS) of MMP3 (Borghaei et al., 2004; 
Clark et al., 2008; Fanjul-Fernández et al., 2010), MMP9 (Chen and Chang, 2015; Clark et al., 2008; 
Fanjul-Fernández et al., 2010; Mishra et al., 2016), MMP12 (Clark et al., 2008) and IL6 (Faggioli et al., 
2004; Gomard et al., 2010; Ndlovu et al., 2009).  
 
Genome wide mapping has shown that H3K9me2 is broadly distributed (Wen et al., 2009) and may 
therefore influence numerous genes associated with NFkB and MAPK-mediated pathways. 
Moreover, in addition to their role as histone lysine methyltransferases, G9A/GLP also have non-
histone substrates, which may influence protein stability (Lee et al., 2015), protein-protein 
interactions (Lee et al., 2010; Ling et al., 2012) and regulate cellular signalling pathways (Biggar and 
Li, 2015; Pless et al., 2008). Therefore, G9A/GLP may influence IL-1α-induced signalling, including 
NFkB and MAPK-AP-1-mediated pathways, upstream of MMP and pro-inflammatory VSMC gene 
promoters. This chapter investigates how abolishing GLP/G9A activity affects IL-1α signalling in 
cultured hVSMCs.  
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Aims: 
 
To test whether G9A/GLP regulates inflammation-induced: 
1. NFkB activity,  
2. MAPK phosphorylation  
3. and transcription factor binding to H3K9me2-target genes 
in cultured hVSMCs by small molecule inhibition of G9A/GLP prior to IL-1α stimulation. 
 
6.2 Results 
 
6.2.1 Loss of H3K9me2, by pharmacological inhibition of G9A/GLP, does not influence the upstream 
NFkB signalling pathway.  
 
IL-1α signals via the cell surface receptor IL1R1 (Garlanda et al., 2013), therefore I first examined 
whether pharmacological inhibition of G9A/GLP directly influences the expression of IL1R1. Cultured 
hVSMCs were pre-treated with UNC, a G9A/GLP inhibitor, prior to IL-1α stimulation. UNC treatment 
significantly reduced H3K9me2 levels globally (Figure 5.2 A, B) but did not alter basal or IL-1α-
induced upregulation of IL1R1 transcript levels (Figure 6.1 B). TNFα is also known to activate the 
transcription of MMP and pro-inflammatory genes via NFkB and AP-1 signalling pathways (Figure 6.1 
A). However, TNFα signals via different membrane bound cytokine receptors (Sedger and 
McDermott, 2014). Therefore, cultured hVSMCs were pre-treated with UNC prior to TNFα treatment 
to further explore the mechanism by which G9A/GLP regulates the expression of IL-1α-responsive 
genes. Consistent with results from hVSMCs treated with IL-1α, the reduced level of H3K9me2 did 
not directly affect IL6 or MMP gene expression, but significantly potentiated TNFα-mediated 
upregulation of MMP3, MMP9 and IL6 (Figure 6.1 C). Neither TNFα nor UNC treatment alone, or in 
combination, affected the expression of MMP2 (Figure 6.1 C). Furthermore, UNC treatment did not 
alter basal or TNFα-induced upregulation of CCL2 (Figure 6.1 C). Together, these results suggest that 
pharmacological inhibition of G9A/GLP mediates a feature common to both IL-1α and TNFα signalling 
pathways in hVSMCs.  
 
116 
 
 
 
Figure 6.1: Loss of H3K9me2, by pharmacological inhibition of G9A/GLP (UNC), influences a feature common 
to both IL-1α and TNFα signalling pathways in cultured hVSMCs. (A) Schematic of IL-1α/TNFα-induced 
MAPK/NFkB signalling pathways. (B) RT-qPCR analysis of IL1R1 transcript levels in untreated control (-UNC -IL-
1α, white bars), UNC (+UNC -IL-1α, black bars), IL-1α (-UNC +IL-1α, grey bars) and IL-1α plus UNC (+UNC +IL-1α, 
red bars) treated cultured hVSMCs. hVSMCs were treated after 6-9 passages of culture. Data are relative to IL-
1α treated hVSMCs (-UNC +IL-1α, grey bars) and normalised to the average of two housekeeping genes (HPRT1 
and HMBS). Data represent means ± SEM of 3 experiments using hVSMCs from independent biopsies. Asterisks 
indicate significant differences (p<0.05) in expression level by one-way ANOVA with Bonferroni correction. (C) 
RT-qPCR analysis of MMP2, MMP3, MMP9, IL6 and CCL2 transcript levels in untreated control (-UNC -TNFα, 
white bars), UNC (+UNC -TNFα, black bars), TNFα (-UNC +TNFα, grey bars) and TNFα plus UNC (+UNC +TNFα, 
red bars) treated cultured hVSMCs. hVSMCs were treated after 6-9 passages of culture. Data are relative to 
TNFα treated hVSMCs (-UNC +TNFα, grey bars) and normalised to the average of two housekeeping genes 
(HPRT1 and HMBS). Data represent means ± SEM of 3 experiments using VSMCs isolated from independent 
biopsies. Asterisks indicate significant differences (p<0.05) in expression level by one-way ANOVA with 
Bonferroni correction.  
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IL-1α and TNFα both activate the NFkB signalling pathway. Ligand binding to a cell surface receptor 
activates the IKK complex which phosphorylates IkB and triggers ubiquitin-dependent proteosomal 
degradation of IkB. NFκB dimers are then released and translocate from the cytoplasm to the nucleus 
to bind to target gene promoters (Figure 6.1 A). The most prevalent activated form of NFkB dimer 
includes a p65 subunit, which contains the transactivation domain necessary for gene induction 
(Bhatt and Ghosh, 2014; Tak and Firestein, 2001). Binding of p65 to a number of MMP and pro-
inflammatory gene promoters, including MMP3 (Borghaei et al., 2004; Clark et al., 2008; Fleenor et 
al., 2003; Huang et al., 2012; Lu et al., 2016), MMP9 (Chen and Chang, 2015; Clark et al., 2008), 
MMP12 (Clark et al., 2008; Xie et al., 2005) (Huang et al., 2012; Park et al., 2015) and IL6 (Faggioli et 
al., 2004), has been reported as necessary to induce their expression. 
 
To investigate whether G9A/GLP regulates inflammation-induced NFkB activity, cultured VSMCs were 
pre-treated with UNC, a G9A/GLP inhibitor, prior to IL-1α or TNFα stimulation. UNC treatment 
significantly reduced global levels of H3K9me2 (Figure 5.2 A, B). G9A/GLP inhibition did not change 
IkBa levels upon IL-1α stimulation, suggesting that IkBa degradation is not affected (Figure 6.2 A, B). 
G9A/GLP inhibition also did not significantly alter the IL-1α-induced upregulation of p65 (Figure 6.2 C, 
D).  
 
 
 
Figure 6.2: Pharmacological inhibition of G9A/GLP does not influence IκBα levels upon IL-1α stimulation or 
alter IL-1α-induced upregulation of p65. (A, B) Representative western blot and densitometric analysis (B) of 
IkBα protein and ACTB (control) in untreated control (-UNC -IL-1α), IL-1α -UNC +IL-1α (for 30 mins), UNC (+UNC 
-IL-1α), and UNC plus IL-1α (+UNC +IL-1α) treated cultured hVSMCs. hVSMCs were treated after 7-12 passages 
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of culture. (B) Bar plot showing IkBα protein levels in untreated control (-UNC -IL-1α), UNC (+UNC -IL-1α), IL-1α 
(-UNC +IL-1α) and UNC plus IL-1α (+UNC +IL-1α) treated cultured hVSMCs. Data are relative to untreated 
control (-UNC -IL-1α) cultured hVSMCs and normalised to ACTB levels. Data represent means ± STDEV of 2 
experiments using VSMCs derived from independent biopsies. (C, D) Representative western blot and 
densitometric analysis (D) of p65 protein and b-TUBULIN in untreated control (-UNC -IL-1α), IL-1α (-UNC +IL-
1α), UNC (+UNC-IL-1α), and UNC plus IL-1α (+UNC +IL-1α) treated cultured hVSMCs. hVSMCs were treated after 
7-12 passages of culture. (D) Bar plot showing p65 protein levels in untreated control (-UNC -IL-1α), UNC 
(+UNC- IL-1α), IL-1α (-UNC + IL-1α) and UNC plus IL-1α (+UNC + IL-1α) treated cultured hVSMCs. Data are 
relative to IL-1α treated hVSMCs (-UNC +IL-1α) and normalised to β-TUBULIN levels. Data represent means ± 
SEM of 4 experiments using VSMCs derived from independent biopsies. n.s. = no significant difference by one-
way ANOVA with Bonferroni correction. The IL-1α treatment times are indicated in the figure (30 mins or 6 hrs). 
 
Immunofluorescence staining revealed the reduced level of G9A/GLP activity did not directly affect 
the nuclear to cytoplasmic ratio of p65 under basal conditions nor the translocation of p65 from the 
cytoplasm to the nucleus upon IL-1α (Figure 6.3 A, B) or TNFα stimulation (Figure 6.4 A, B). These 
results suggest that the potentiation of IL-1α/ TNFα-induced expression of IL6 and MMP genes by 
pharmacological inhibition of G9A/GLP is not due to increased upstream NFkB signalling. 
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Figure 6.3: Pharmacological inhibition of G9A/GLP does not influence IL-1α-mediated nuclear translocation 
of p65. (A) Immunofluorescence staining for p65 in untreated control (-UNC -IL-1α), UNC (+UNC-IL-1α), IL-1α (-
UNC +IL-1α) and UNC plus IL-1α (+UNC +IL-1α) treated cultured hVSMCs. hVSMCs were treated after 7-12 
passages of culture. Signals for p65 (Alexa Fluor 488, white) and DAPI counter-stained nuclei (blue) are shown. 
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Scale bars, 200 μm. (B) Bar plot showing the nuclear: cytoplasmic ratios of p65 staining in untreated control (-
UNC -IL-1α), UNC (+UNC -IL-1α), IL-1α (-UNC +IL-1α) and UNC plus IL-1α (+UNC +IL-1α) treated cultured 
hVSMCs. hVSMCs were treated after 7-12 passages of culture. Data represent means ± SEM of 4 experiments 
using VSMCs derived from independent biopsies. n.s. = no significant difference by one-way ANOVA with 
Bonferroni correction. 
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Figure 6.4: Pharmacological inhibition of G9A/GLP does not influence TNFα-mediated nuclear translocation 
of p65. (A) Immunofluorescence staining for p65 in untreated control (-UNC -TNFα), UNC (+UNC -TNFα), TNFα 
(-UNC +TNFα) and UNC plus TNFα (+UNC +TNFα) treated cultured hVSMCs. hVSMCs were treated after 7-12 
passages of culture. Signals for p65 (Alexa Fluor 488, white) and DAPI counter stained nuclei (blue) are shown. 
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Scale bars, 200 μm. (B) Bar plot showing the nuclear: cytoplasmic ratios of p65 staining in untreated control (-
UNC -TNFα), UNC (+UNC -TNFα), TNFα (-UNC +TNFα) and UNC plus TNFα (+UNC +TNFα) treated cultured 
hVSMCs. hVSMCs were treated after 7-12 passages of culture. Data represent means ± SEM of 4 experiments 
using VSMCs derived from independent biopsies. n.s. = no significant difference by one-way ANOVA with 
Bonferroni correction. 
 
6.2.2 Pharmacological inhibition of G9A/GLP potentiates IL-1α-induced p65 binding to the IL6 
promoter, correlating with reduced H3K9me2 levels in cultured hVSMCs. 
 
To investigate whether H3K9me2 acts directly at the IL6 and MMP3 promoter to block IL-1α-induced 
p65 binding, ChIP for p65 was performed. ChIP revealed p65 bound to the IL6 promoter in 
unstimulated and UNC treated cultured hVSMCs, however, p65 binding was greatly enriched by IL-1α 
stimulation and this was significantly enhanced by prior UNC treatment (Figure 6.5), correlating with 
reduced H3K9me2 levels (Figure 5.2 A, B). Enriched levels of p65 were also observed at the NFkB 
binding site within the CCL2 promoter in unstimulated and UNC treated cultured hVSMCs (Figure 
6.5). However, neither IL-1α or IL-1α in combination with UNC treatment enhanced p65 binding to 
the CCL2 promoter (Figure 6.5). In contrast, enrichment of p65 was not observed at reported NFkB 
sites or IL1-responsive elements within the MMP3 promoter (Borghaei et al., 2004; Clark et al., 2008) 
before or after IL-1α stimulation with or without prior UNC treatment (Figure 6.5). These findings 
suggest H3K9me2 acts directly at the IL6 promoter to block IL-1α-mediated p65 binding and that 
MMP3, IL6 and CCL2 are regulated via different mechanisms.  
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Figure 6.5: Pharmacological inhibition of G9A/GLP potentiates IL-1α-induced p65 binding to the IL6 
promoter, correlating with reduced H3K9me2 levels in cultured hVSMCs. (A) Schematic indicating the location 
of the reported p65 binding sites, cJUN binding sites and IL1-responsive elements at the promoters of MMP3 
(Borghaei et al., 2004; Clark et al., 2008; Quinones et al., 1994), IL6 (Gomard et al., 2010) and CCL2 (Sutcliffe et 
al., 2009). Red arrows indicate regions amplified in the ChIP-qPCR analysis. (B) ChIP-qPCR analysis for p65 in 
untreated control (-UNC -IL-1α, white bars), UNC (+UNC-IL-1α, black bars), IL-1α (-UNC +IL-1α, grey bars) and 
UNC plus IL-1α (+UNC +IL-1α, red bars) treated cultured hVSMCs (passage 6-15) showing levels of enrichment 
at the ACTB negative control locus and reported p65 binding sites/ IL1-responsive elements within the 
promoters of MMP3, IL6 and CCL2 compared with enrichment observed using negative control IgG. Background 
levels of p65 binding are based on enrichment at the ACTB negative control locus and are indicated by a line. 
Data represent means ± SEM of 4 experiments using VSMCs derived from independent biopsies. The Asterisk 
indicates significant difference (P<0.05) by one-way ANOVA with Bonferroni correction. 
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6.2.3 Loss of H3K9me2, by pharmacological inhibition of G9A/GLP, does not influence IL-1α-induced 
MAPK phosphorylation. 
 
The MAPK signalling-mediated transcription factor cJUN has also been reported to regulate the 
expression of MMP and pro-inflammatory genes (Clark et al., 2008; Faggioli et al., 2004; Sutcliffe et 
al., 2009). I therefore assessed the activity of MAPKs known to phosphorylate cJUN at serine (Ser) 63, 
which is thought to increase cJUN's transcription factor activity (Klein et al., 2013; Smeal et al., 1992), 
in response to IL-1α stimulation with and without prior UNC treatment. Three MAPKs have been 
identified to phosphorylate cJUN at Ser63, including cJUN N-terminal kinase (JNK), extracellular 
regulating kinase (ERK1/2) and p38 kinase (p38) (Figure 6.1A) (Kim and Choi, 2015; Sun et al., 2015; 
Yang et al., 2013). However, JNK has been reported to primarily mediate the phosphorylation of cJUN 
at Ser63 in different cell types (Morton et al., 2003). IL-1α/TNFα activate these MAPKs via 
phosphorylation of JNK at threonine (Thr) 183 and tyrosine (Tyr) 185, ERK1/2 at Thr 202 and Tyr 202 
and p38 at (Thr) 180 and (Tyr) 182 (Kim and Choi, 2015; Sun et al., 2015; Yang et al., 2013). 
 
Western blot analysis showed that prior UNC treatment did not influence the level of IL-1α-induced 
phosphorylation of p38 (Thr180, Tyr182) (Figure 6.6 A, B), ERK1/2 (Thr202, Tyr204) (Figure 6.6 A, C) 
or JNK (Thr183, Tyr185) (Figure 6.6 A, D) in cultured hVSMCs. However, UNC treatment potentiated 
the level of IL-1α-induced cJUN phosphorylation at Ser63 (Figure 6.6 A, E) without influencing total 
levels of cJUN (Figure 6.6 A, F) in cultured hVSMCs.  
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Figure 6.6: Pharmacological inhibition of G9A/GLP does not influence IL-1α-induced phosphorylation of p38, 
ERK1/2 or JNK but potentiates IL-1α-induced cJUN phosphorylation at Ser63. (A) Representative western blot 
of p38 phosphorylated at Thr183 and Tyr185 (p-p38 Thr180/Tyr182), ERK1/2 phosphorylated at Thr202 and 
Tyr204 (p-ERK1/2 Thr202, Tyr204), JNK phosphorylated at Thr183 and Tyr185 (p-JNK Thr183/Tyr185), cJUN 
phosphorylated at Ser63 (p-cJUN Ser63), total cJUN and b-TUBULIN in untreated control and IL-1α-treated (for 
10 mins, 30 mins, 1.5 hr, 3 hr or 6 hr) hVSMCs, without and with prior UNC treatment. hVSMCs were treated 
after 8-13 passages of culture (B-E) Bar plots showing levels of p-p38 (Thr180/Tyr182) (B), p-ERK1/2 
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(Thr202/Tyr204) (C), p-JNK (Thr83, Tyr185) (D), p-cJUN (Ser63) (E) and total cJUN (F) in untreated control and 
IL-1α-treated (for 10 mins, 30 mins, 1.5 hr, 3 hr or 6 hr) hVSMCs, without and with prior UNC treatment. 
hVSMCs were treated after 8-13 passages of culture. Data are relative to +UNC +IL-1α (30 mins) treated 
hVSMCs and normalised to b-TUBULIN levels. Data represent means ± SEM of 4 experiments using VSMCs 
derived from independent biopsies. Asterisks indicate significant differences (P<0.05) by one-way ANOVA with 
Bonferroni correction. 
  
Interestingly, SP600125, a selective small molecule inhibitor of JNK (Han et al., 2001), attenuated IL-
1α-induced MMP3 expression both with and without prior UNC treatment, correlating with 
substantially reduced levels of cJUN phosphorylation at Ser63 (Figure 6.7 A-C). However, JNK 
inhibition did not influence the level of IL-1α-induced IL6 or CCL2 expression (Figure 6.7 D, E). 
Together, these results suggest cJUN phosphorylation at Ser63 via JNK is necessary for IL-1α-induced 
expression of MMP3 but not for IL-1α-induced expression of IL6 or CCL2.  
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Figure 6.7: IL-1α-induced MMP3 expression, but not IL6 or CCL2 expression, is dependent on JNK-mediated 
cJUN phosphorylation at Ser63. (A) Representative western blot of cJUN phosphorylated at serine 63 (p-cJUN 
Ser63) in untreated control and IL-1α (6hrs)-treated hVSMCs, cultured to passage 8-13, without and with prior 
UNC and/ or SP600125 (48 hours)-treatment. (B) Bar plot showing p-cJUN (Ser63) levels in untreated control 
and IL-1α-treated hVSMCs, cultured to passage 8-13, without and with prior UNC and/ or SP600125 treatment. 
Data are relative to +UNC +IL-1α -SP600125 treated hVSMCs and normalised to b-TUBULIN levels. Data 
represent means ± SEM of 4 experiments using VSMCs derived from independent biopsies. Asterisks indicate 
significant differences by one-way ANOVA with Bonferroni correction. (C-F) RT-qPCR analysis of MMP3 (C), IL6 
(D), and CCL2 (E) transcript levels in untreated control and IL-1α (6hrs)-treated hVSMCs, cultured to passage 8-
13, without and with prior UNC and/ or SP600125 (48hrs)-treatment. Data are relative to +UNC +IL-1α -
SP600125 treated hVSMCs and normalised to the average of two housekeeping genes (HPRT1 and YWHAZ). 
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Data represent means ± SEM of 4 experiments using hVSMCs derived from independent biopsies. Asterisks 
indicate significant differences (P<0.05) by one-way ANOVA with Bonferroni correction. 
 
6.2.4 Pharmacological inhibition of G9A/GLP potentiates IL-1α-induced cJUN binding to the MMP3 
and IL6 promoter, correlating with reduced H3K9me2 levels in cultured hVSMCs. 
 
ChIP-qPCR revealed IL-1α stimulation induced cJUN binding to the MMP3 and IL6 promoter and that 
this was significantly increased by prior UNC treatment in cultured hVSMCs (Figure 6.8). UNC 
treatment alone did not induce cJUN binding to any of the gene promoters analysed (Figure 6.8). 
cJUN was not observed to be significantly bound to the CCL2 promoter under any condition (Figure 
6.8). 
 
Taken together, the results described in this chapter suggest H3K9me2 acts directly at the MMP3 and 
IL6 promoter to counteract IL-1α-induced upregulation by blocking NFkB (p65) and/or AP-1 (cJUN) 
transcription factor binding. The findings also suggest that G9A/GLP may regulate JNK’s ability to 
phosphorylate cJUN or cJUN’s ability to be phosphorylated by JNK. Alternatively, G9A/GLP may 
regulate the activity of a phosphatase which targets cJUN. 
 
 
 
Figure 6.8: Pharmacological inhibition of G9A/GLP potentiates IL-1α-induced cJUN binding to the IL6 
promoter, correlating with reduced H3K9me2 levels in cultured hVSMCs. ChIP-qPCR analysis for cJUN in 
untreated control (-UNC -IL-1α, white bars), UNC (+UNC-IL-1α, black bars), IL-1α (-UNC +IL-1α, grey bars) and 
UNC plus IL-1α (+UNC +IL-1α, red bars) treated cultured hVSMCs (passage 6-15) showing levels of enrichment 
at the ACTB negative control locus and regulatory elements within the promoters of MMP3, IL6 and CCL2 
(Figure 6.5 A) compared with the enrichment observed using negative control IgG. Background levels of cJUN 
are based on enrichment at the ACTB negative control locus and are indicated by a line. Data represent means 
± SEM of 3 experiments using VSMCs derived from independent biopsies. Asterisks indicate significant 
differences (P<0.05) by one-way ANOVA with Bonferroni correction. 
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6.3 Summary and Conclusions 
 
The results described in this chapter suggest that G9A/GLP do not influence IL-1α or TNFα-induced 
activation of the upstream NFkB signalling pathway in cultured hVSMCs. However, G9A/GLP 
inhibition did potentiate IL-1α-induced p65 binding to the IL6 promoter (Figure 6.5), concomitant 
with reduced levels of H3K9me2 (Figure 5.2), suggesting H3K9me2 may act directly at the IL6 
promoter to block p65 binding. No p65 binding was observed at reported p65 consensus sites within 
the MMP3 promoter under any condition (Figure 6.5). In contrast p65 was present at the CCL2 
promoter, which is not enriched for H3K9me2 (Figure 5.3 B), at the same level under all conditions 
(Figure 6.5). The findings also imply that G9A/GLP does not influence IL-1α-induced MAPK activation 
in hVSMCs (Figure 6.6). However, G9A/GLP inhibition potentiated IL-1α-induced cJUN binding to both 
the MMP3 and IL6 promoter (Figure 6.8), concomitant with reduced levels of H3K9me2 (Figure 5.2). 
No enrichment of cJUN was observed at the CCL2 promoter under any condition (Figure 6.8). Taken 
together, these results suggest that H3K9me2 may directly act at the MMP3 and IL6 promoter to 
inhibit inflammatory signal-dependent transcription factor binding. Consistent with this hypothesis, 
diabetes has been shown to decrease H3K9me2 and increase p65 at the retinal MMP9 promoter, 
resulting in increased MMP9 activity (Zhong and Kowluru, 2013b). In addition, the promoters of a 
subset of NFκB target genes in mouse macrophages display enriched levels of H3K9me2 that, prior to 
transcriptional activation, must be diminished through the action of the H3K9me2 demethylase, Aof1 
(Saccani and Natoli, 2002; van Essen et al., 2010).   
 
Interestingly, JNK inhibition attenuated the expression of MMP3 in response to IL-1α, correlating 
with reduced cJUN phosphorylation, but did not influence IL6 or CCL2 induction (Figure 6.7). These 
observations imply that MMP3, IL6 and CCL2 are regulated via different mechanisms in hVSMCs. 
Furthermore, G9A/GLP inhibition potentiated IL-1α-induced cJUN phosphorylation at Ser63 (Figure 
6.6). Recently, studies have shown that MAPKs can phosphorylate substrates once bound to 
chromatin (Klein et al., 2013). Therefore, removal of H3K9me2 at target gene promoters could lead 
to increased IL-1α-induced recruitment of transcription factor substrates of JNK, including cJUN, 
which are phosphorylated by JNK once bound to target gene promoters (Klein et al., 2013). This may 
explain why inhibition of G9A/GLP increases the global level of cJUN phosphorylation at Ser63 in 
response to IL-1α stimulation. However, increased phosphorylation of cJUN at Ser63 is known to 
potentiate its transcriptional activity, although the precise mechanism underlying this remains 
unclear (Pulverer et al., 1991; Zhu et al., 2014). Therefore, H3K9me2 may not directly act to prevent 
cJUN binding after IL-1α-treatment in VSMCs. G9A/GLP could regulate JNK’s ability to phosphorylate 
cJUN or cJUN’s ability to be phosphorylated by JNK. Alternatively, G9A/GLP inhibition may reduce the 
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activity of a phosphatase which targets cJUN. However, a phosphatase which targets phosphorylated 
cJUN has not yet been identified (Zhu et al., 2014).  
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CHAPTER 7- DISCUSSION  
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7.1 Global levels of H3K9me2 and the associated methyltransferase GLP are reduced upon VSMC 
phenotypic switching. 
 
The results described in this thesis point towards a role for H3K9me2 in the regulation of VSMC 
phenotype. Global levels of H3K9me2, and the associated methyltransferase GLP, were reduced in 
phenotypically switched VSMCs in vitro and in vivo, concomitant with decreased levels of contractile 
VSMC gene expression. Furthermore, both pharmacological inhibition and siRNA knock down of G9A 
accelerated the downregulation of contractile VSMC gene expression upon culture. This finding 
implies reduced levels of H3K9me2 may be causally related to loss of the contractile VSMC state. 
However, H3K9me2 was absent or present at low levels at contractile VSMC gene promoters 
independent of their transcriptional state, suggesting H3K9me2 does not act directly at contractile 
VSMC gene promoters to regulate their expression.  
 
Contractile VSMC genes are reduced rapidly upon vascular injury (Herring et al., 2017; Shi et al., 
2013) and are significantly downregulated one day post carotid ligation compared to non-ligated 
controls (Shi et al., 2013). Contractile VSMC genes are expressed at their lowest levels 7 days post 
carotid ligation before becoming upregulated around 9 to 28 days post surgery (Allagnat et al., 2016; 
Shi et al., 2013). Interestingly, H3K9me2 was not significantly reduced in VSMCs within LCCAs until 7 
days post carotid ligation and remained downregulated to the same level at day 28 post surgery. 
These observations further suggest that H3K9me2 does not directly influence the expression of 
contractile VSMC genes. Moreover, levels of H3K9me2 in VSMC nuclei did not fluctuate between the 
media, core or cap of atherosclerotic plaque, which are known to express different levels of 
contractile VSMC genes, providing further evidence to support the hypothesis that H3K9me2 does 
not directly regulate VSMC contractility. An alternative hypothesis is that H3K9me2 instead regulates 
the VSMC response to inflammation, which is known to repress the expression of contractile VSMC 
genes and induce phenotypic switching (Bennett et al., 2016; Yoshida et al., 2013). In support of this 
theory, H3K9me2 levels were significantly reduced in VSMCs within LCCAs 7 days post carotid ligation 
concomitant with the infiltration of pro-inflammatory cytokine secreting CD45+ cells into the vessel 
wall (Alberts-Grill et al., 2012; Tang et al., 2008a), activation of NFkB signalling in VSMCs (Song et al., 
2011) and induction of VSMC proliferation (Moura et al., 2007). 
 
Intriguingly, genes activated by identical inflammatory cytokines differ considerably among cell 
types, despite induction of these genes being dependent on the same activating transcription factors, 
including NFkB and AP-1 family members (Natoli et al, 2010). It is thought that this context-specificity 
is due to cell-type specific enhancer activity (Heinz et al., 2015; Zhu et al., 2012). Enhancers are 
primed via cell-type specific interactions with transcription factors and chromatin modifying 
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complexes (Heinz et al., 2015; Zhu et al., 2012). Signal dependent transcription factors, such as p65 
and cJUN, bind to these primed regions of the genome enabling them to regulate transcription in a 
cell-type specific manner (Heinz et al., 2015). Therefore it is possible that H3K9me2 plays a role in 
priming enhancers and therefore regulates cell-type specific gene expression patterns and 
responses to environmental stimuli. 
 
Enhancers can be located almost anywhere in relation to the gene to be influenced and often relay 
their regulatory information over vast distances (more than 100Kb and up to 1Mb) (Sanyal et al., 
2012). Such enhancer-promoter interactions are enabled by three-dimensional chromatin folding 
(Sanyal et al., 2012), which is known to be regulated by the transcription factor CTCF (Bulger and 
Groudine, 2011; de Laat and Duboule, 2013). Interestingly WIZ, a G9A/GLP binding partner, has a 
binding consensus with a high degree of overlap with that for CTCF (Isbel et al., 2016). Furthermore, 
CTCF is often detected at the boundaries of H3K9me2- LOCKS (Ciabrelli and Cavalli, 2015; Wen et al., 
2009). Based on these findings, H3K9me2 could influence three-dimensional chromatin folding and 
affect long range inflammation-induced enhancer-promoter interactions. It would therefore be 
interesting to exploit chromatin conformation capture-derived techniques (Han et al., 2018) to 
elucidate whether loss of H3K9me2 influences the 3D organisation of VSMC genomic loci containing 
inflammation-induced genes, in both basal conditions and after inflammatory stimulation. 
 
Genomic profiling has revealed that H3K9me2-decorated megabase scale domains, termed 
H3K9me2-LOCKs, occupy a great portion of the mammalian genome (Filion and van Steensel, 2010; 
Lienert et al., 2011; Wen et al., 2009). Whether cellular differentiation coincides with a global 
increase of H3K9me2-LOCKS has been a matter of debate (Filion and van Steensel, 2010; Lienert et 
al., 2011; Wen et al., 2009). Wen and colleagues found that H3K9me2 LOCKS cover 10-46% of the 
genome in differentiated cells compared to only 4% in embryonic stem cells (ESCs), can be lineage-
specific and are substantially lost in cancer cell lines (Wen et al., 2009). In agreement with these 
findings, mass spectrometry-based quantification showed increased global levels of H3K9me2 in 
mouse fibroblasts compared to pluripotent cells (Sridharan et al., 2013). Additionally, hematopoietic 
stem and progenitor cells display lower global levels of H3K9me2 compared to mature bone marrow 
cells (Li et al., 2018). Therefore, H3K9me2-LOCKs might act to repress genomic regions that are no 
longer required as a cell adopts a certain fate (Jorgensen and Fisher, 2009). In support of this theory, 
reduction of H3K9me2-LOCKS was observed in epithelial-to-mesenchymal transition (EMT), a process 
in which cells acquire a multipotent phenotype (McDonald et al., 2011) suggesting these large 
H3K9me2-decorated domains play a functional role in cell fate specification and reprogramming. 
However, Filion and van Steensel claim that there are no significant differences in H3K9me2 LOCKS in 
ESCs compared to differentiated cells and suggest that the algorithm used by Wen et al. may have 
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may have introduced a detection bias (Filion and van Steensel, 2010). In agreement with Filion and 
van Steensel, Lienert and colleagues observed no global increase in H3K9me2-LOCKS during neuronal 
differentiation of embryonic stem cells but instead observed a local gain of H3K9me2 over select 
genes (Lienert et al., 2011).  
 
Nevertheless, numerous studies report that H3K9me2 patterning is important for silencing lineage-
inappropriate genes during differentiation as well as maintaining cell identity, and it must be reset to 
specify new fates (Chen et al., 2013; Huang et al., 2016; Liu et al., 2018; Rodriguez-Madoz et al., 
2017; Wu et al., 2011; Ying et al., 2018). For instance, H3K9me2 has been identified as a barrier for 
somatic cell nuclear transfer (SCNT)-mediated embryonic genome activation (Liu et al., 2018; Wu et 
al., 2011) and removal of H3K9me2 by G9A-inhibition has been shown to significantly enhance the 
developmental competence of SCNT embryos (Huang et al., 2016). Furthermore, mutations in GLP 
that disrupt its H3K9me1-recognition domain result in reduced H3K9me2 levels, a delay in silencing 
of pluripotency genes during ESC differentiation and abnormal embryonic development in mice (Liu 
et al., 2015a). In addition, studies have shown that inhibition of G9A improves the reprogramming 
efficiency of human primary cells to induced pluripotent stem cells by heterochromatin relaxation 
and facilitating transcription factor binding (Chen et al., 2013; Rodriguez-Madoz et al., 2017; Ying et 
al., 2018). With these observations in mind, it is tempting to speculate that loss of H3K9me2 
facilitates VSMC phenotypic switching by permitting transcription which is incompatible with the 
presence of contractile VSMC-specific H3K9me2 marked chromatin territories.  
 
7.2 H3K9me2 inhibits inflammation-induced gene upregulation in VSMCs in vitro and in vivo.   
  
ChIP identified a subset of IL-1α/injury-responsive gene promoters enriched for H3K9me2, including 
MMP3, MMP9, MMP12 and IL6, in both mouse and human VSMCs. Loss of H3K9me2 significantly 
increased the expression of MMP and pro-inflammatory mVSMC genes after injury and 
inflammation, suggesting a functional role of the H3K9me2 mark in regulating the activation of these 
genes. H3K9me2-mediated regulation of IL-1α-responsive VSMC gene expression was confirmed in 
cultured hVSMCs implying the mechanism could be relevant in the context of human CVD. Together, 
these results suggest H3K9me2 functions to inhibit inflammation-induced gene upregulation in 
VSMCs via an evolutionary conserved mechanism. 
 
In agreement with my observation that H3K9me2 inhibits inflammation-induced gene upregulation in 
VSMCs, researchers have shown that VSMCs from diabetic patients display reduced levels of 
H3K9me2 compared to non-diabetic controls and suggest that dysregulation of H3K9me2 might 
underlie the vascular complications associated with diabetes (Chen et al., 2017; Villeneuve et al., 
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2008a). Chen and colleagues found that loss of H3K9me2, by over expressing the associated 
demethylase KDM3A, accelerated neointima formation following vascular injury in diabetic rats 
(Chen et al., 2017).  
 
Several studies report an inverse correlation between H3K9me2 occupancy at MMP and other 
inflammatory gene promoters and the ability of other cell types to express these genes (Fang et al., 
2012; Gesumaria et al., 2015; Liu et al., 2014; Zhong and Kowluru, 2013b). For example, H3K9me2 
depletion at the Mmp9 promoter correlates with elevated Mmp9 expression in retinal endothelial 
cells from diabetic rats compared to controls (Zhong and Kowluru, 2013b). Furthermore, solar-
stimulated ultraviolet radiation (ssUVR) induces loss of H3K9me2 at the MMP3 promoter in primary 
human dermal fibroblasts, correlating with enhanced MMP3 mRNA levels following ssUVR exposure 
(Gesumaria et al., 2015). In addition, genetic ablation or pharmacological inhibition of G9A/GLP 
stimulates the expression of inflammatory genes in mouse embryonic fibroblasts (MEFs) (Fang et al., 
2012). Also, similar to what is reported here, reduction of H3K9me2 levels in MEFs further 
potentiated poly(I:C)-induced upregulation of inflammatory genes (Fang et al., 2012). Moreover, 
G9A deficient-mutant flies are hypersensitive to RNA virus infection and succumb faster to infection 
than wild-type controls (Merkling et al., 2015). These observations suggest that G9A/GLP plays a role 
in an evolutionary conserved mechanism to control genes that are involved in processes that require 
tight and dynamic regulation and high transcriptional plasticity, including the inflammatory response, 
in a variety of cell types. 
 
7.3 H3K9me2 hinders inflammation-induced TF binding at target VSMC gene promoters 
 
In hVSMCs, G9A/GLP inhibition did not influence upstream IL-1α/TNFα-induced NFkB signalling but 
significantly increased IL-1α-induced NFkB-p65 transcription factor binding to the IL6 promoter, 
correlating with reduced H3K9me2 levels. In contrast, enrichment of p65 was not observed at 
reported NFkB sites within the MMP3 promoter after IL-1α stimulation. Interestingly, inhibition of 
G9A/GLP potentiated IL-1α-induced phosphorylation of cJUN at Ser63, a post translational 
modification which substantially enhances cJUN's transcriptional activity (Morton et al., 2003), 
without impacting activation of the primary kinases responsible for cJUN phosphorylation, including 
JNK. In contrast to IL6, MMP3 regulation after IL-1α stimulation was dependent on JNK activity, 
suggesting regulation by cJUN. G9A/GLP inhibition potentiated IL-1α-induced cJUN binding to both 
the MMP3 and the IL6 promoter. Together, these results imply that H3K9me2 prevents binding of 
both NFkB and AP1 transcription factors at specific IL-1α-regulated VSMC genes to possibly block 
spurious induction of a pro-inflammatory state. Furthermore, MMP3 and IL6 appear to be regulated 
via different mechanisms in VSMCs (Figure 7.1).  
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Figure 7.1: Proposed mechanism underlying G9A/GLP-mediated attenuation of inflammation-responsive 
VSMC gene expression. Binding of AP-1-cJUN and NFkB-p65 transcription factors at H3K9me2 target genes is 
increased upon reduction of H3K9me2 levels following G9A/GLP inhibition. Non-H3K9me2 targets such as CCL2 
display transcription factor binding at basal levels resulting in rapid induction upon stimulation. In contrast, 
H3K9me2 target gene induction is delayed in a context-specific manner, which could be dependent on both 
specific transcription factor usage and locus-specific chromatin regulation. 
 
In addition to their role as HMTs, several studies report that G9A/GLP can methylate a wide range of 
non-histone proteins (Figure 1.13) (Biggar and Li, 2015).  However, as most of the reported 
methylation sites have been derived from mass spectrometry analyses, the function of many of these 
modifications remain unknown. Nevertheless, increasing evidence suggests methylation of non-
histone proteins may influence protein stability (Lee et al., 2015), protein-protein interactions (Lee et 
al., 2010; Ling et al., 2012) and regulate cellular signalling pathways (Biggar and Li, 2015; Pless et al., 
2008). Even though binding of p65 and cJUN to many MMP and pro-inflammatory genes is necessary 
for their expression, they are often not sufficient for their induction (Fanjul-Fernández et al., 2010; 
Smale and Natoli, 2014). Numerous other transcription factors also play an important role in the 
upregulation of these inducible genes, including those activated by the JAK-STAT and Smad signalling 
pathways (Fanjul-Fernández et al., 2010; Smale and Natoli, 2014). Therefore, it is entirely possible 
that inhibition of G9A/GLP influences the binding of other transcription factors important for the 
activation of these genes at the transcriptional and/or post transcriptional level. However, if 
G9A/GLP inhibition influenced the JAK-STAT signalling pathway I would have expected the induction 
of CCL2 to be affected upon IL-1α stimulation which was not observed.  
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Interestingly, G9A/GLP inhibition potentiated IL-1α-induced cJUN phosphorylation at Ser63. Recently, 
studies have shown that MAPKs can phosphorylate substrates once bound to chromatin (Klein et al., 
2013). Therefore, removal of H3K9me2 at target gene promoters could lead to increased IL-1α-
induced recruitment of transcription factor substrates of JNK, including cJUN, which are 
phosphorylated by JNK once bound to target gene promoters (Klein et al., 2013). This may explain 
why inhibition of G9A/GLP increases the global level of cJUN phosphorylation at Ser63 in response to 
IL-1α stimulation. Therefore, it would be interesting to examine whether IL-1α induces JNK binding at 
AP1-binding motifs in VSMCs. However, increased phosphorylation of cJUN at Ser63 is known to 
potentiate its transcriptional activity, although the precise mechanism underlying this remains 
unclear (Pulverer et al., 1991; Zhu et al., 2014). Phosphorylation of cJUN has been described to alter 
cJUN's stability, affinity for DNA or protein partners, and nuclear localisation (Bhatt and Ghosh, 2014; 
Yang et al., 2013). Therefore, H3K9me2 may not directly act to prevent cJUN binding after IL-1α-
treatment in VSMCs. G9A/GLP could regulate JNK’s ability to phosphorylate cJUN or cJUN’s ability to 
be phosphorylated by JNK. Alternatively, G9A/GLP inhibition may reduce the activity of a 
phosphatase which targets cJUN. However, a phosphatase which targets phosphorylated cJUN has 
not yet been identified (Zhu et al., 2014).  
 
7.4 Limitations of study 
 
For the studies described in this thesis, I used bulk RT-qPCR analysis to examine the effect of 
G9A/GLP inhibition on VSMC gene expression. This method averages the responses of cell 
populations and therefore obscures inherent cell-cell heterogeneity restricting the ability to 
distinguish between the individual responses of different cells within a sample. Therefore, it is not 
possible to elucidate whether G9A/GLP influences the expression level of particular genes by 
individual VSMCs or the number of VSMCs expressing the gene. Single cell sequencing would be 
required to answer this question but would have been a costly preliminary experiment (Ziegenhain et 
al., 2017). FACS could also help address this problem but the number of genes this method allows 
you to analyse is limited to the availability of antibodies and the number of colours a flow cytometer 
can detect. 
 
Many of the experiments described in this thesis were based on analysis using VSMC-specific lineage 
labelling. As described in section 1.9.1, Myh11-CreER(T2) transgenic mice where the transgene had 
integrated into the Y chromosome were chosen for breeding onto the C57BL/6 background (Wirth et 
al., 2008), excluding its application in female mice. Gender has been identified as a risk factor for 
multiple vascular diseases (Mosca et al., 2011), therefore the use of only male mice in the studies 
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described in this thesis is a limitation. Furthermore, a potential caveat is that the Myh11-Cre is not 
driven by the endogenous Myh11 gene. Even though studies report that this Cre-transgene closely 
recapitulates endogenous gene expression (Nemenoff et al., 2011; Wirth et al., 2008), differences 
under certain circumstances and the extent to which it may be active in cells which express very low 
levels of Myh11 are difficult to determine. However, Dr Joel Chappell did not observe recombination 
of the reporter in the liver, skeletal muscle or lung apart from within the vasculature within each 
tissue (Chappell et al., 2016).  
 
For the in vivo study, loss of H3K9me2 was not specific to VSMCs (Chen et al., 2017).  Therefore, the 
differences observed in gene expression may have been due to the effects of G9A/GLP inhibition on 
other cell types, such as bone marrow-derived cells. Introducing the appropriate Cre-deleter 
transgene onto Flox/Flox mice would address this problem but would involve extensive breeding. I 
chose to use pharmacologic inhibition, rather than genetic deletion to reduce H3K9me2 levels to 
comply with the 3R’s of animal research. 
 
The experiments performed in this thesis do not definitively show that H3K9me2 acts directly at the 
promoter of MMP3, MMP9, MMP12 and IL6 to inhibit the inflammation-induced expression of these 
genes. To investigate whether VSMC gene de-regulation is directly caused by H3K9me2 the 
CRISPR/dCas9 system (Sander and Joung, 2014) could be used to selectively change H3K9me2 levels 
locally at specific VSMC promoters. It has been shown that nuclease-mutant Cas9 protein can, when 
fused to specific protein domains, be used to recruit enzymatic activities to selected loci by co-
expression with appropriate complementary guide RNAs (gRNA) (Sander and Joung, 2014). It is 
therefore possible to generate dCas9 fusion proteins with the enzymatic domains of G9A/GLP or 
JMJD1A, a demethylase which specifically targets H3K9me2 (Loh et al., 2007; Shinkai and Tachibana, 
2011), 2011), to respectively increase or decrease H3K9me2 levels at target VSMC promoters. This 
experiment would demonstrate whether levels of H3K9me2 at individual gene promoters are 
functionally important. I have produced VSV-G pseudotyped lentivirus expressing dCas9 fused with 
the catalytic SET domain of G9A, which is responsible for H3K9me2 activity, and have used it to 
transduce cultured hVSMCs. I have also generated gRNA expression plasmids targeting the 
promoters of MMP2, MMP3 and CCL2. I planned to screen for successful gRNAs by transient 
transfection into cultured hVSMCs but observed extremely low transfection efficiency. Due to time 
constraints I was not able to optimise the system further. 
 
7.5 Future experiments 
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Interestingly, stem cell antigen-1 (Sca1), a cell surface protein, is upregulated in cultured compared 
to ex vivo VSMCs, concomitant with reduced levels of H3K9me2 and GLP (Dobnikar et al., 2018). Sca1 
is upregulated in VSMCs upon exposure to stimuli known to induce phenotypic switching including 
culture, injury and inflammation and has been proposed to identify a more plastic VSMC state 
(Dobnikar et al., 2018). It would be worthwhile exploring if Sca1 plays a functional role in VSMC 
phenotypic switching before investigating whether the downregulation of H3K9me2 and GLP is linked 
to the induction of Sca1 expression upon VSMC phenotypic switching. It is tempting to speculate that 
Sca1+ VSMCs display low global levels of H3K9me2 and represent a more primed state, which readily 
respond to injury and inflammation.  
 
To determine the functional importance of observed differential H3K9me2-levels in ex vivo and 
cultured VSMCs, I compared H3K9me2 ChIP-seq data to genome-wide expression data (data not 
shown). However, the H3K9me2 mark was broadly distributed in both ex vivo and cultured mVSMCs, 
consistent with the high abundance of H3K9me2-LOCKs previously identified in differentiated cell 
types (Filion and van Steensel, 2010; Lienert et al., 2011; Wen et al., 2009). Therefore, using gene-set 
enrichment analysis I could not identify biological functions previously associated with vascular 
disease among H3K9me2-marked genes. However, the ChIP-seq data did validate the enriched levels 
of H3K9me2 observed at IL-1α-reponsive VSMC gene promoters and absent or low levels of 
H3K9me2 at contractile VSMC gene promoters observed by ChIP-qPCR (data not shown). 
 
Last year the Henikoff lab published a new method to analyse DNA-protein interactions, which they 
named CUT&RUN (Cleavage Under Targets and Release Using Nuclease) (Skene and Henikoff, 2017). 
In CUT&RUN, targeted DNA-protein complexes are isolated directly from the cell nucleus rather than 
following a precipitation step. To perform CUT&RUN, a specific antibody to the DNA-binding protein 
of interest and ProtA-MNase is added to permeabilised cells. MNase is tethered to the protein of 
interest through the ProtA-antibody interaction and MNase cleaves the surrounding, unprotected 
DNA to release protein-DNA complexes, which can then be isolated and sequenced (Skene and 
Henikoff, 2017). This technique is reported to give a much higher signal to noise ratio compared to 
traditional ChIP. CUT&RUN therefore requires one tenth of the sequencing depth of ChIP and permits 
genomic mapping of histone modifications and transcription factors using extremely low cell 
numbers (Hainer et al., 2018; Skene and Henikoff, 2017). CUT&RUN has been described to generate 
robust data from as little as 100 cells for the genome wide mapping of histone modifications (Hainer 
et al., 2018). Sufficient tissue was not available for genome-wide H3K9me2 mapping after carotid 
ligation using ChIP. However, CUT&RUN could potentially be used to profile functionally relevant 
H3K9me2 target genes using low numbers of phenotypically switched VSMCs derived from murine 
models of vascular disease.  
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ChIP captures DNA-protein interactions within cell populations at one fixed time point and cannot 
assess the kinetics of H3K9me2 in single, living cells. Recently, Kimura and colleagues have created 
sensitive fluorescent genetically encoded histone modification-specific intracellular antibody 
(mintbody) probes that have been used to monitor changes in histone modifications in living cells 
(Sato et al., 2013). Such a probe targeting H3K9me2 could be used to examine the dynamics of 
H3K9me2 in living VSMCs in response to inflammatory stimuli. For example, this tool could be used 
to explore whether there is a relationship between H3K9me2 levels and the timing of NFkB/AP-1 
family transcription factor binding to inflammation-induced gene promoters. 
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